University of Kentucky

UKnowledge
Plant and Soil Sciences Faculty Patents

Plant and Soil Sciences

8-20-2019

Alteration of Tobacco Alkaloid Content Through Modification of
Specific Cytochrome P450 Genes
Ralph E. Dewey
Balazs Siminszky
University of Kentucky, balazs@uky.edu

Steven W. Bowen
Lily Gavilano
University of Kentucky

Follow this and additional works at: https://uknowledge.uky.edu/pss_patents
Part of the Plant Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Dewey, Ralph E.; Siminszky, Balazs; Bowen, Steven W.; and Gavilano, Lily, "Alteration of Tobacco Alkaloid
Content Through Modification of Specific Cytochrome P450 Genes" (2019). Plant and Soil Sciences
Faculty Patents. 44.
https://uknowledge.uky.edu/pss_patents/44

This Patent is brought to you for free and open access by the Plant and Soil Sciences at UKnowledge. It has been
accepted for inclusion in Plant and Soil Sciences Faculty Patents by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

I 1111111111111111 1111111111 111111111111111 IIIII IIIII IIIII 111111111111111111
USO 103 83299B2

c12)

(54)

(71)

(72)

(73)

( *)

United States Patent

(IO)

Dewey et al.

(45)

ALTERATION OF TOBACCO ALKALOID
CONTENT THROUGH MODIFICATION OF
SPECIFIC CYTOCHROME P450 GENES

U.S. PATENT DOCUMENTS
4,693,976
4,732,856
4,762,785
4,801,540
4,940,838
4,945,050
5,004,863
5,013,658
5,034,323
5,104,310
5,107,065
5,141,131
5,149,645
5,159,135
5,177,010
5,231,019
5,302,523
5,352,605
5,378,619

Inventors: Ralph E. Dewey, Apex, NC (US);
Balazs Siminszky, Neuchatel (CH);
Steven W. Bowen, Raleigh, NC (US);
Lily Gavilano, Raleigh, NC (US)
Assignees: North Carolina State University,
Raleigh, NC (US); University of
Kentucky Research Foundation,
Lexington, KY (US)
Subject to any disclaimer, the term ofthis
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.
This patent is subject to a terminal disclaimer.

(21)

Appl. No.: 15/883,931

(22)

Filed:

(65)

10,383,299 B2
*Aug. 20, 2019

References Cited

(56)

Applicants:North Carolina State University,
Raleigh, NC (US); University of
Kentucky Research Foundation,
Lexington, KY (US)

Notice:

Patent No.:
US
Date of Patent:

A
A
A

A
A
A
A
A
A

A
A

A
A
A

A
A
A
A
A

9/1987 Schilperoort et al.
3/1988 Federoff
8/1988 Comai
1/1989 Hiatt et al.
7/1990 Schilperoort et al.
7/1990 Sanford et al.
4/1991 Umbeck
5/1991 Dooner et al.
7/1991 Jorgensen et al.
4/1992 Saltin
4/1992 Shewmaker et al.
8/1992 Miller et al.
9/1992 Hoekema et al.
10/1992 Umbeck
1/1993 Goldman et al.
7/1993 Paszkowski et al.
4/1994 Coffee et al.
10/1994 Fraley et al.
1/1995 Rogers
(Continued)

FOREIGN PATENT DOCUMENTS
EP
EP

0 120 516 A3 10/1984
0 267 159 A3
5/1988
(Continued)

Jan. 30, 2018
OTHER PUBLICATIONS

Prior Publication Data
US 2018/0160644 Al

Jun. 14, 2018

U.S. Appl. No. 60/337,684, Xu.
(Continued)

Related U.S. Application Data
(63)

(51)

(52)

(58)

Continuation of application No. 14/878,083, filed on
Oct. 8, 2015, now Pat. No. 9,913,451, which is a
continuation of application No. 12/971,801, filed on
Dec. 17, 2010, now Pat. No. 9,187,759, which is a
continuation of application No. 11/580,765, filed on
Oct. 13, 2006, now Pat. No. 7,884,263, which is a
continuation-in-part
of
application
No.
PCT/US2005/005665, filed on Feb. 23, 2005.

Int. Cl.
A0lH 5112
(2018.01)
A0lH 6182
(2018.01)
C12N 9102
(2006.01)
C12N 15182
(2006.01)
A24B 13/00
(2006.01)
A24B 15110
(2006.01)
C12Q 116895
(2018.01)
U.S. Cl.
CPC ............... A0lH 5112 (2013.01); A0lH 61823
(2018.05); A24B 13/00 (2013.01); A24B 15110
(2013.01); C12N 9/0073 (2013.01); C12N
9/0077 (2013.01); C12N 1518243 (2013.01);
C12Q 116895 (2013.01); Cl2Q 2600/13
(2013.01); Cl2Q 2600/156 (2013.01)
Field of Classification Search
CPC ........................................................ A0lH 5/12
See application file for complete search history.

Primary Examiner - Russell Kallis
(74) Attorney, Agent, or Firm -Alston & Bird LLP
(57)

ABSTRACT

Compositions and methods for reducing the level of nornicotine and N'-nitrosonomicotine (NNN) in Nicotiana plants
and plant parts thereof are provided. The compositions
comprise isolated polynucleotides and polypeptides for
cytochrome P450s that are involved in the metabolic conversion of nicotine to nornicotine in these plants. Expression
cassettes, vectors, plants, and plant parts thereof comprising
inhibitory sequences that target expression or function of the
disclosed cytochrome P450 polypeptides are also provided.
Methods for the use of these novel sequences to inhibit
expression or function of cytochrome P450 polypeptides
involved in this metabolic conversion are also provided. The
methods find use in the production of tobacco products that
have reduced levels of nomicotine and its carcinogenic
metabolite, NNN, and thus reduced carcinogenic potential
for individuals consuming these tobacco products or
exposed to secondary smoke derived from these products.
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Figure 7

CTGTCATTAAAGCAACGGTGTTTGTAAGTTCATCTGTCATTTTTCATTTATTCACTTTT
ATTTTGAGGAGCAGACATGTTAATAATAATTTGGAGCAACTGTAAAGTTATCTATGTGT
ACAGGTTCGAGCCTCAGGTGCAACCACTAATGCTTGTATTAGATTATGTTGTCTGCAT
CATACCCCTAATTGGA GTGTGGCTCTTCCCGAACCCTGCAATGCTGGATGCTGGATGC
TTTATGTATCAGACTGACCTTTTTGTTAAACTATCTAAATACTAAGGATGATTTMTAA
AAATATAGAATGGTAAACAGAAAAAGATGAGATTATTTTTGGGGCTATATGGATTCGC
CCGGGCTTTGGGAGGJMAACGGTATCTACCAGTTGAGACTTTACTCCAGAACTTTAT
CTCGAGAGCTCTGAA TAAAAATGAAATAGTATTTACC.4CTCCAAAATCTTTGATGGTAA
AAA GATGA GATATAACCTCTTATAA TTGATTGAACCACGTTGATAGAATAAAACTTCTT
TACTCCCA TTCAGCATAAGAAAAATGAAACC4AACGGAA TTCTTCTCTTTTTTAGGGGG
AAATTCCTTAA TTGCTTGTTGAATATAGATTCATGTCGTTATTCTATTTTTAATMTGAT
GAAAATCAATATAGTCAAAGTTAATACTTATGTCATTTGGTTTGCGGACAAGTTATATT
GGAACTATATAATACGTCTATTATAGMTAGTGATTATTTAGAGGATATACATTTTTTT
TGGATAAATATTTGATTTATTGGATTAAAAATAGAATATACAGGTAAGGTCTAAAACGT
GTGTTTGCTTTTACACTAAA TAAACTTGACCTCGTACAA TTCTAAGAAAATATTTGAAA
TAAATGAATTATTTTATTGTTAATCAATTAA/44.AAA TCATAGTATAGATGAGATGTGTG
CATACTTGGCAATAACTATACI:4ACTAAAACAAGGTATGTGAATAATTGATATTCCTTT
TTTAATTATTCTTTTTTCCAGAGTTTGGTCTTGGATGCAGCAGACACAGTTGCTCTTCA

CATAAATTGGGGAATGGCATTATTGATAAACAATCAAAAGGCCTTGACGAAAGCAC
AAG
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ALTERATION OF TOBACCO ALKALOID
CONTENT THROUGH MODIFICATION OF
SPECIFIC CYTOCHROME P450 GENES

"Formation of Tobacco-specific Nitrosamines in Flue-cured
Tobacco," CORESTA Meeting, Agro-Phyto Groups,
Suzhou, China). Retrofitting these curing barns with heatexchangers virtually eliminated the mixing of combustion
gases with the curing air and dramatically reduced the
formation of TSNAs in tobaccos cured in this manner
(Boyette and Hannn (2001) Rec. Adv. Tab. Sci. 27:17-22.).
In contrast, in the air-cured Burley tobaccos, TSNA formation proceeds primarily through reaction of tobacco alkaloids with nitrite, a process catalyzed by leaf-borne microbes
(Bush et al. (200l)Rec. Adv. Tab. Sci. 27:23-46). Thus far,
attempts to reduce TNSAs through modification of curing
conditions while maintaining acceptable quality standards
have not proven to be successful for the air-cured tobaccos.
In Burley tobaccos, a positive correlation has been found
between the nornicotine content of the leaf and the amount
of NNN that accumulates in the cured product (Bush et al.
(2001) Rec. Adv. Tab. Sci. 27:23-46; Shi et al. (2000) Tab.
Chem. Res. Conj 54:Abstract 27). However, keeping nornicotine levels at a minimum has been difficult because of
the conversion phenomenon that results in a continual
introduction of high nornicotine-producing plants within
commercially grown Burley populations. Minimizing the
number of Burley plants that accumulate high levels of
nornicotine has traditionally been the responsibility of plant
breeders and seed producers. Though the percentage of
converter plants that are ultimately grown in farmers' fields
can be reduced through the roguing of converter plants
during the propagation of seed stocks, this process is costly,
time-consuming, and imperfect.
Previous studies have shown that once a plant has converted, the high nornicotine trait is inherited as a single
dominant gene (Griffith et al. (1955) Science 121:343-344;
Burk and Jeffrey (1958) Tab. Sci. 2:139-141; Mann et al.
(1964) Crop Sci. 4:349-353). The nature of this gene,
however, is currently unknown. In the most simple of
scenarios, the conversion locus may represent a nonfunctional nicotine N-demethylase gene that regains its function
in converter plants, possibly through the mobilization of a
mutation-inducing transposable element. Alternatively, the
converter locus may encode a protein that initiates a cascade
of events that ultimately enables the plant to metabolize
nicotine to nornicotine, which would mean that multiple
genes may be involved.
Regardless of whether there are one or many genes
associated with the conversion process, it is clear that the
gene(s) encoding polypeptides having nicotine demethylase
activity play a pivotal role in this process. Although the
inability to purify active nicotine N-demethylase from crude
extracts has impeded the isolation and identification of this
enzyme, there is some evidence that a member of the
cytochrome P450 superfamily of monooxygenases may be
involved (Hao and Yeoman (1996) Phytochem. 41:477-482;
Hao and Yeoman (1996) Phytochem. 42:325-329; Chelvarajan et al. (1993) J. Agric. Food Chem. 41:858-862; Hao
and Yeoman (1998) J. Plant Physiol. 152:420-426). However, these studies are not conclusive, as the classic P450
inhibitors carbon monoxide and tetcylasis have failed to
lower enzyme activity at rates comparable to other reported
P450-mediated reactions (Chelvarajan et al. (1993) J. Agric.
Food Chem. 41:858-862).
Furthermore, the cytochrome P450s are ubiquitous, transmembrane proteins that participate in the metabolism of a
wide range of compounds (reviewed by Schuler (1996) Crit.
Rev. Plant Sci. 15:235-284; Schuler and Werck-Reichhart
(2003) Annu. Rev. Plant Biol. 54:629-667). Examples of
biochemical reactions mediated by cytochrome P450s
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FIELD OF THE INVENTION
The invention relates to compositions and methods for
reducing the level of nornicotine and its metabolite, N'-nitrosonornicotine, in a plant that is a member of the genus
Nicotiana, particularly compositions and methods for inhibiting expression or function of a cytochrome P450 polypeptide involved in the metabolic conversion of nicotine to
nornicotine.

30

35

BACKGROUND OF THE INVENTION
The predominant alkaloid found in commercial tobacco
varieties is nicotine, typically accounting for 90-95% of the
total alkaloid pool. The remaining alkaloid fraction is comprised primarily of three additional pyridine alkaloids: nornicotine, anabasine, and anatabine. Nornicotine is generated
directly from nicotine through the activity of the enzyme
nicotine N-demethylase (FIG. 1). Nornicotine usually represents less than 5% of the total pyridine alkaloid pool, but
through a process termed "conversion," tobacco plants that
initially produce very low amounts of nornicotine give rise
to progeny that metabolically "convert" a large percentage
of leaf nicotine to nornicotine. In tobacco plants that have
genetically converted (termed "converters"), the great
majority of nornicotine production occurs during the senescence and curing of the mature leaf (Wernsman and Matzinger (1968) Tab. Sci. 12:226-228). Burley tobaccos are
particularly prone to genetic conversion, with rates as high
as 20% per generation observed in some cultivars.
During the curing and processing of the tobacco leaf, a
portion of the nornicotine is metabolized to the compound
N'-nitrosonornicotine (NNN; FIG. 1), a tobacco-specific
nitrosamine (TSNA) that has been shown to be carcinogenic
in laboratory animals (Hecht and Hoffmann (1990) Cancer
Surveys 8:273-294; Hoffmann et al. (1994) J. Toxicol. Environ. Health 41:1-52; Hecht (1998) Chem. Res. Toxicol.
11:559-603). In flue-cured tobaccos, TSNAs were found to
be predominantly formed through the reaction of alkaloids
with the minute amounts of nitrogen oxides present in
combustion gases formed by the direct-fired heating systems
found in traditional curing barns (Peele and Gentry (1999)

40

45

50

55

60

65

US 10,383,299 B2
3

4

include hydroxylations, demethylations, and epoxidations.
In plants, the cytochrome P450 gene families are very large.
For example, total genome sequence examination has
revealed 272 predicted cytochrome P450 genes in Arabidopsis and at least 455 unique cytochrome P450 genes in
rice (see, for example, Nelson et al. (2004) Plant Physiol.
135(2):756-772). Even though cytochrome P450 has been
implicated as having a role in the metabolic conversion of
nicotine to nornicotine, identification of key participating
members of this protein family remains a challenge.
Aside from serving as a precursor for NNN, recent studies
suggest that the nornicotine found in tobacco products may
have additional undesirable health consequences. Dickerson
and Janda demonstrated that nornicotine causes aberrant
protein glycation within the cell (Dickerson and Janda
(2002) Proc. Natl. Acad. Sci. USA 99:15084-15088). Concentrations of nornicotine-modified proteins were found to
be much higher in the plasma of smokers compared to
nonsmokers. Furthermore, this same study showed that
nornicotine can covalently modify commonly prescribed
steroid drugs such as prednisone. Such modifications have
the potential of altering both the efficacy and toxicity of
these drugs.
In view of the difficulties associated with conversion and
the undesirable health effects of nornicotine accumulation,
improved methods for reducing the nornicotine content in
tobacco varieties, particularly Burley tobacco, are therefore
desirable. Such methods would not only help ameliorate the
potential negative health consequences of the nornicotine
per se as described above, but should also concomitantly
reduce NNN levels.

The methods of the invention comprise inhibiting the
expression or function of a cytochrome P450 polypeptide of
the present invention. In some embodiments, an expression
cassette comprising an inhibitory sequence that targets
expression or function of a cytochrome P450 polypeptide of
the present invention is introduced into the plant or plant part
of interest, wherein expression of the inhibitory sequence
produces a polynucleotide or polypeptide that inhibits
expression or function of a cytochrome P450 polypeptide of
the invention. In one such embodiment, the inhibitory
sequence comprises a sequence set forth in SEQ ID NO: 1,
3, 5, 7, 9, 11, 13, 14, 15, or 16, or a complement or fragment
thereof.
The methods of the invention find use in the production of
Nicotiana plants that have decreased levels of nornicotine
and its metabolite, the nitrosamine N'-nitrosonornicotine,
within the leaf and stem tissues. When harvested, the leaf
and stem tissues of these plants can be utilized to produce
tobacco products having reduced levels of nornicotine and
this tobacco-specific nitrosamine, and thus reduced carcinogenic potential for individuals consuming these products or
exposed to secondary smoke derived from these products.
Also provided are transgenic Nicotiana plants having a
nicotine to nornicotine conversion rate of less than about
2%, where the plants comprise a heterologous nucleic acid
construct comprising a promoter capable of functioning in a
plant cell operably linked to a nucleic acid sequence having
a first nucleotide sequence comprising a fragment of
between about 100 nucleotides and about 400 nucleotides of
a Nicotiana nicotine demethylase polynucleotide and a
second nucleotide sequence capable of forming a doublestranded RNA with the first nucleotide sequence, where the
transgenic Nicotiana plants are transgenic converter lines of
Nicotiana. In some embodiments, the Nicotiana nicotine
demethylase polynucleotide is a tobacco nicotine demethylase polynucleotide.
The present invention also provides a recombinant nucleic
acid construct comprising a promoter capable of functioning
in a plant cell operably linked to a nucleic acid sequence
having a first nucleotide sequence comprising a fragment of
between about 100 nucleotides and about 400 nucleotides of
a tobacco nicotine demethylase polynucleotide and a second
nucleotide sequence capable of forming a double-stranded
RNA with the first nucleotide sequence.
Also provided are methods of reducing the conversion of
nicotine to nornicotine in a Nicotiana plant comprising
transforming a Nicotiana plant with a recombinant nucleic
acid construct comprising a promoter capable of functioning
in a plant cell operably linked to a nucleic acid sequence
having a first nucleotide sequence comprising a fragment of
between about 100 nucleotides and about 400 nucleotides of
a Nicotiana nicotine demethylase polynucleotide and a
second nucleotide sequence capable of forming a doublestranded RNA with the first nucleotide sequence; and regenerating a transgenic Nicotiana plant. In some embodiments,
the Nicotiana nicotine demethylase polynucleotide is a
tobacco nicotine demethylase polynucleotide.
The present invention also provides seed obtained from
the transgenic Nicotiana plant having a nicotine to nornicotine conversion rate of less than about 2%, where the seed
comprises a heterologous nucleic acid construct comprising
a promoter capable of functioning in a plant cell operably
linked to a nucleic acid sequence having a first nucleotide
sequence comprising a fragment of between about 100
nucleotides and about 400 nucleotides of a Nicotiana nicotine demethylase polynucleotide and a second nucleotide
sequence capable of forming a double-stranded RNA with
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SUMMARY OF THE INVENTION
Compositions and methods for reducing the nornicotine
content in plants that are members of the genus Nicotiana
are provided. Compositions include isolated cytochrome
P450 polynucleotides and polypeptides that are involved in
the metabolic conversion of nicotine to nornicotine in plants,
particularly Nicotiana species. The isolated polynucleotides
comprise the nucleotide sequence set forth in SEQ ID NO: 1,
3, 5, 7, 9, or 11, a nucleotide sequence encoding a polypeptide as set forth in SEQ ID NO:2, 4, 6, 8, 10, or 12, and
fragments and variants thereof. Isolated polypeptides of the
invention comprise an amino acid sequence set forth in SEQ
ID NO:2, 4, 6, 8, 10, or 12, an amino acid sequence encoded
by the nucleotide sequence set forth in SEQ ID NO:1, 3, 5,
7, 9, or 11, and fragments and variants thereof.
The polynucleotides of the invention find use in suppressing expression of a cytochrome P450 that is involved in the
metabolic conversion of nicotine to nornicotine in a plant,
including the cytochrome P450s of the present invention. In
this manner, compositions further include expression cassettes comprising an inhibitory sequence that is capable of
inhibiting expression or function of a cytochrome P450
polypeptide of the invention, where the inhibitory sequence
is operably linked to a promoter that is functional in a plant
cell. In some embodiments, the inhibitory sequence comprises the sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11,
13, 14, 15, or 16, or a complement or fragment thereof.
Compositions also include transformed plants and plant
parts that comprise an expression cassette of the present
invention, optionally stably incorporated into the genome of
the plant. Further provided are tobacco products, including
chewing tobacco, snuff, cigarettes, pipe tobacco, and cigars,
having a reduced level of nornicotine, and its related nitrosamine, N'-nitrosonornicotine.
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the first nucleotide sequence, where the transgenic Nicotiana
plants are transgenic converter lines of Nicotiana. In some
embodiments, the Nicotiana nicotine demethylase polynucleotide is a tobacco nicotine demethylase polynucleotide.
The present invention also provides transgenic plant cells
comprising a nucleic acid molecule having a promoter
functional in a plant cell and a nucleic acid sequence
encoding a nicotine demethylase having an isoleucine residue at position 274 and a tryptophan residue at position 330.
The present invention also provides methods of screening
for a nicotine demethylase sequence comprising: obtaining
a nucleic acid sequence that has greater than about 90%
sequence identity with SEQ ID NO:5 and identifying a
codon sequence encoding for a tryptophan residue at position 330 of the encoded polypeptide.
Further provided are methods for screening for a nicotine
demethylase having an isoleucine at position 274 or a
tryptophan at position 330 comprising obtaining a nucleic
acid sequence that has greater than about 90% sequence
identity with SEQ ID NO:5 and identifying a first codon
sequence encoding for an isoleucine residue at position 274
or a second codon sequence encoding a tryptophan residue
at position 330 of the encoded polypeptide.

28S ribosomal RNA to show the relative equivalence of
RNA loading among the lanes.
FIG. 6 shows a Northern blot analysis of transgenic plants
possessing sense-orientation constructs of members of the
3D_C12 gene family. (A) Hybridization of the 3D_Cl2-7
probe to RNAs isolated from nontreated leaves of independent transgenic lines expressing 3D_Cl2-7, 3D_C12, and
7D_A06 constructs and a vector-only control (control 8).
Estimated size of hybridizing band is indicated in kilobases
(kb). (B) Ethidium bromide staining of the portion of the gel
used in (A) that contains the 28S ribosomal RNA to show the
relative equivalence of RNA loading among the lanes.
FIG. 7 shows a genomic sequence of a fragment of the
3D_Cl2-10 gene possessing an intron. Intron sequences are
indicated in bold, italicized type. Exon sequences are shown
in plain type. The sequences corresponding to the PCR
primers used to amplify the fragment from the tobacco
genomic DNA are underlined.
FIG. 8 shows a diagram of the RNAi constructs used to
silence expression of of members of the 3D_CD12 gene
family.

BRIEF DESCRIPTION OF THE DRAWINGS
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DETAILED DESCRIPTION OF THE
INVENTION
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Background and Definitions
FIG. 1 shows the structures of nicotine, nornicotine, and
N'-nitrosonornicotine (NNN).
FIG. 2 shows Northern blot analysis of converter and
nonconverter RNAs using 7D_A06 as a hybridization probe.
Lanes 1 and 2 show RNAs isolated from sodium bicarbonate-treated leaves of genotypes DH 98-325-5 (nonconverter)
and DH 98-325-6 (converter), respectively. Lanes 3 and 4
show RNAs isolated from ethephon-treated leaves of genotypes DH 98-326-3 (nonconverter) and DH 98-326-1 (converter), respectively. Estimated size of the hybridizing band
is indicated in kilobases (kb).
FIGS. 3A-3G shows a nucleotide sequence alignment of
members of the 3D_C12 gene family. Asterisks denote
positions where sequence identity is conserved among all
sequences compared. Positions where differences are found
are indicated with dashes and the corresponding residues are
shaded grey. The nucleotide sequences present in the alignment include 3D_C12 (SEQ ID NO:1), 3D_Cl2-10 (SEQ
ID NO:3); 3D_Cl2-7 (SEQ ID NO:5); 7D_A06 (SEQ ID
NO:7); 3D_Cl2-15 (SEQ ID NO:9); and 131A_A02 (SEQ
ID NO:11). The 3D_Cl2-15 and 131A_A02 entries are
partial-length cDNA sequences. The 99 bp region of
3D_C12 that was used to make the RNAi-based construct is
underlined.
FIG. 4 shows an alignment of predicted amino acid
sequences for full-length members of the 3D_C12 family of
P450 genes. The amino acid sequences present in the
aligrnnent include 3D_C12 (SEQ ID NO:2), 3D_Cl2-10
(SEQ ID NO:4); 3D_Cl2-7 (SEQ ID NO:6); and 7D_A06
(SEQ ID NO: 8). Asterisks denote positions conserved
among all four sequences. Residues that differ among the
members are shaded in grey.
FIG. 5 shows a Northern blot analysis of transgenic plants
possessing the 3D_C12/RNAi construct. (A) Hybridization
of the 3D_Cl2-7 probe to RNAs isolated from ethephontreated, cured leaves of transgenic plants displaying low
nornicotine phenotypes (3D_C12/RNAi-1, 3, and 4) and
high nornicotine phenotypes (3D_C12/RNAi-6, 7, and vector-only control plant 11 ). Estimated size of hybridizing
band is indicated in kilo bases (kb). (B) Ethidium bromide
staining of the portion of the gel used in (A) that contains the
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Before describing the present invention in detail, it is to
be understood that many modifications and other embodiments of the inventions set forth herein will come to mind
to one skilled in the art to which this invention pertains
having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is
to be understood that the invention is not to be limited to the
specific embodiments disclosed and that modifications and
other embodiments are intended to be included within the
scope of the appended claims. Rather, these embodiments
are provided so that this disclosure will satisfy applicable
legal requirements.
Although specific terms are employed herein, they are
used in a generic and descriptive sense only and not for
purposes of limitation. Like numbers refer to like elements
throughout. Further, the article "a" and "an" are used herein
to refer to one or more than one (i.e., to at least one) of the
grammatical object of the article. By way of example, "an
element" means one or more element. Throughout the
specification the word "comprising," or variations such as
"comprises" or "comprising," will be understood to imply
the inclusion of a stated element, integer or step, or group of
elements, integers or steps, but not the exclusion of any other
element, integer or step, or group of elements, integers or
steps.
The present invention is drawn to compositions and
methods for inhibiting the expression or function of
cytochrome P450 polypeptides that are involved in the
metabolic conversion of nicotine to nornicotine in a plant,
particularly plants of the Nicotiana genus, including tobacco
plants of the various commercial varieties. As used herein,
the terms "inhibit," "inhibition," and "inhibiting" are defined
as any method known in the art or described herein that
decreases the expression or function of a gene product of
interest (i.e., the target gene product). "Inhibition" can be in
the context of a comparison between two plants, for
example, a genetically altered plant versus a wild-type plant.
Alternatively, inhibition of expression or function of a target
gene product can be in the context of a comparison between
plant cells, organelles, organs, tissues, or plant parts within
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the same plant or between different plants, and includes
comparisons between developmental or temporal stages
within the same plant or plant part or between plants or plant
parts. "Inhibition" includes any relative decrement of function or production of a gene product of interest, up to and
including complete elimination of function or production of
that gene product. The term "inhibition" encompasses any
method or composition that down-regulates translation and/
or transcription of the target gene product or functional
activity of the target gene product.
The term "inhibitory sequence" encompasses any polynucleotide or polypeptide sequence capable of inhibiting the
expression or function of a cytochrome P450 polypeptide
involved in the metabolic conversion of nicotine to nornicotine in a plant, such as full-length polynucleotide or
polypeptide sequences, truncated polynucleotide or polypeptide sequences, fragments of polynucleotide or polypeptide sequences, variants of polynucleotide or polypeptide
sequences, sense-oriented nucleotide sequences, antisenseoriented nucleotide sequences, the complement of a senseor antisense-oriented nucleotide sequence, inverted regions
of nucleotide sequences, hairpins of nucleotide sequences,
double-stranded nucleotide sequences, single-stranded
nucleotide sequences, combinations thereof, and the like.
The term "polynucleotide sequence" includes sequences of
RNA, DNA, chemically modified nucleic acids, nucleic acid
analogs, combinations thereof, and the like.
Inhibitory sequences are designated herein by the name of
the target gene product. Thus, a "cytochrome P450 inhibitory sequence" refers to an inhibitory sequence that is
capable of inhibiting the expression of a cytochrome P450
polypeptide that is involved in the metabolic conversion of
nicotine to nomicotine in a plant, for example, at the level
of transcription and/or translation, or which is capable of
inhibiting the function of such a cytochrome P450 polypeptide. When the phrase "capable of inhibiting" is used in the
context of a polynucleotide inhibitory sequence, it is
intended to mean that the inhibitory sequence itself exerts
the inhibitory effect; or, where the inhibitory sequence
encodes an inhibitory nucleotide molecule (for example,
hairpin RNA, miRNA, or double-stranded RNA polynucleotides ), or encodes an inhibitory polypeptide (i.e., a polypeptide that inhibits expression or function of the target gene
product), following its transcription (for example, in the case
of an inhibitory sequence encoding a hairpin RNA, miRNA,
or double-stranded RNA polynucleotide) or its transcription
and translation (in the case of an inhibitory sequence encoding an inhibitory polypeptide), the transcribed or translated
product, respectively, exerts the inhibitory effect on the
target gene product (i.e., inhibits expression or function of
the target gene product).
By "host cell" is meant a cell that comprises a heterologous nucleic acid sequence of the invention. Though the
nucleic acid sequences of the invention, and fragments and
variants thereof, can be introduced into any cell of interest,
of particular interest are plant cells, more particularly cells
of a Nicotiana plant species, for example, the tobacco plant
species and varieties described herein below.
The use of the term "polynucleotide" is not intended to
limit the present invention to polynucleotides comprising
DNA. Those of ordinary skill in the art will recognize that
polynucleotides can comprise ribonucleotides and combinations of ribonucleotides and deoxyribonucleotides. Such
deoxyribonucleotides and ribonucleotides include both naturally occurring molecules and synthetic analogues. The
polynucleotides of the invention also encompass all forms of

sequences including, but not limited to, single-stranded
forms, double-stranded forms, hairpins, stem-and-loop
structures, and the like.
The term "variant" as used herein is intended to mean a
substantially similar sequence, and the term "native" polynucleotide or polypeptide is intended to mean a naturally
occurring nucleotide sequence or amino acid sequence,
respectively. By "fragment" is intended a portion of a
polynucleotide or a portion of an amino acid sequence and
hence protein encoded thereby.
As used herein, the term "plant part" includes plant cells,
plant protoplasts, plant cell tissue cultures from which a
whole plant can be regenerated, plant calli, plant clumps,
and plant cells that are intact in plants or parts of plants such
as embryos, pollen, anthers, ovules, seeds, leaves, flowers,
stems, branches, fruit, roots, root tips, and the like. Progeny,
variants, and mutants of regenerated plants are also included
within the scope of the invention, provided that these
comprise the introduced nucleic acid sequences of the
invention.
By "phenotypic change" is intended a measurable change
in one or more cell functions. For example, plants having a
genetic modification at the genomic locus encoding a
cytochrome P450 polypeptide of the invention can show
reduced or eliminated expression or activity of that
cytochrome P450 polypeptide.
The term "introducing" is intended to mean presenting to
the plant the polynucleotide or polypeptide in such a manner
that the sequence gains access to the interior of a cell of the
plant.
The term "operably linked" is intended to mean a functional linkage between two or more elements. For example,
an operable linkage between a polynucleotide of interest and
a regulatory sequence (i.e., a promoter) is a functional link
that allows for expression of the polynucleotide of interest.
Operably linked elements may be contiguous or non-contiguous. When used to refer to the joining of two protein
coding regions, by operably linked is intended that the
coding regions are in the same reading frame.
The term "heterologous" according to the present invention when used in reference to a sequence is intended to
mean a sequence that originates from a foreign species, or,
if from the same species, is substantially modified from its
native form in composition and/or genomic locus by deliberate human intervention. The term also is applicable to
nucleic acid constructs, also referred to herein as "polynucleotide constructs" or "nucleotide constructs." In this
manner, a "heterologous" nucleic acid construct is intended
to mean a construct that originates from a foreign species, or,
if from the same species, is substantially modified from its
native form in composition and/or genomic locus by deliberate human intervention. Heterologous nucleic acid constructs include, but are not limited to, recombinant nucleotide constructs that have been introduced into a plant or plant
part thereof, for example, via transformation methods or
subsequent breeding of a transgenic plant with another plant
of interest.
For example, a promoter operably linked to a heterologous polynucleotide is from a species different from the
species from which the polynucleotide was derived, or, if
from the same/analogous species, one or both are substantially modified from their original form and/or genomic
locus, or the promoter is not the native promoter for the
operably linked polynucleotide. Furthermore, as used herein
a chimeric gene comprises a coding sequence operably
linked to a transcription initiation region that is heterologous
to the coding sequence.
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The term "expression" as used herein refers to the biosynthesis of a gene product, including the transcription
and/or translation of said gene product. For example, for the
purposes of the present invention, an expression cassette, as
described elsewhere herein, capable of expressing a polynucleotide that inhibits the expression of at least one
cytochrome P450 polypeptide of the invention is an expression cassette capable of producing an RNA molecule that
inhibits the transcription and/or translation of at least one
cytochrome P450 polypeptide. The "expression" or "production" of a protein or polypeptide from a DNA molecule
refers to the transcription and translation of the coding
sequence to produce the protein or polypeptide, while the
"expression" or "production" of a protein or polypeptide
from an RNA molecule refers to the translation of the RNA
coding sequence to produce the protein or polypeptide.
Cytochrome 450 Polynucleotides and Polypeptides, and
Variants and Fragments Thereof
Compositions of the present invention include isolated
cytochrome P450 polynucleotides and polypeptides that are
involved in the metabolic conversion of nicotine to nornicotine in plants, including commercial varieties of tobacco
plants. In particular, compositions of the invention include
isolated polypeptides comprising the amino acid sequences
as shown in SEQ ID NOS:2, 4, 6, 8, 10, and 12, and isolated
polynucleotides comprising the nucleotide sequences as
shown in SEQ ID NOS: 1, 3, 5, 7, 9, and 11. The polynucleotides of the invention find use in inhibiting expression of
these cytochrome P450 polypeptides or variants thereof that
are involved in the metabolic conversion of nicotine to
nomicotine in plants, particularly tobacco plants.
In this manner, the invention further provides expression
cassettes comprising all or a portion of the polynucleotide
sequence set forth in SEQ ID NO:1, 3, 5, 7, 9, or 11, a
complement or fragment thereof, or a sequence having
substantial sequence identity to SEQ ID NO:1, 3, 5, 7, 9, or
11, or a complement or fragment thereof, operably linked to
a promoter that is functional in a plant cell for use in
expressing an inhibitory RNA transcript that interferes with
expression (i.e., transcription and/or translation) of
cytochrome P450 polypeptides described herein. In some
embodiments, the expression cassettes comprise the nucleotide sequence as shown in SEQ ID NO:13, 14, 15, or 16, a
complement or fragment thereof, or a sequence having
substantial sequence identity to SEQ ID NO:13, 14, 15, or
16, or a complement or fragment thereof. Introduction of
these expression cassettes into a Nicotiana plant of interest,
particularly a tobacco plant of varieties commonly known as
flue or bright varieties, Burley varieties, dark varieties, and
oriental/Turkish varieties, results in the production of
tobacco plants having reduced amounts of nornicotine and
the nitrosamine, N'-nitrosonomicotine (NNN). Leaf and
stem material from these transgenic plants can be used to
produce a variety of tobacco products having reduced levels
of nornicotine, and a concomitant reduction in this carcinogenie nitrosamine metabolite.
The cytochrome P450 polynucleotides and encoded polypeptides of the present invention represent a novel
cytochrome P450 gene family, designated the 3D_C12
cytochrome 450 gene family, that is newly identified as
having a role in the metabolic conversion of nicotine to
nomicotine in tobacco plants. Suppression of the expression
of their encoded gene products in transgenic tobacco plants
results in a significant reduction in the accumulation of
nomicotine in the leaves of these transgenic plants. While
not being bound by theory, the metabolic role of these
polypeptides may be a direct one, i.e., directly catalyzing the

N-demethylation reaction, or an indirect one, i.e., in the form
of production of a product that leads to the up-regulation of
the nicotine demethylase activity of the leaf. Regardless of
the mechanism, any means by which expression and/or
function of the polypeptides encoded by members of this
cytochrome P450 gene family are targeted for inhibition
within a Nicotiana plant will be effective in reducing nornicotine levels, and levels of its carcinogenic metabolite,
NNN, within leaves and stems of these plants.
The cytochrome P450 genes of the invention were isolated from tobacco lines of a Burley variety. The first of
these cytochrome P450 genes, designated 3D_C12, encodes
an mRNA transcript corresponding to nucleotides (nt)
1-1551 of the cDNA sequence set forth in SEQ ID NO:1,
which codes for the full-length 517-residue polypeptide set
forth in SEQ ID NO:2. The second member of this novel
cytochrome P450 family, designated 3D_Cl2-10, encodes
an mRNA transcript corresponding to nt 1-1551 of the
cDNA sequence set forth in SEQ ID NO:3, which codes for
the full-length 517-residue polypeptide set forth in SEQ ID
NO:4. The third of these cytochrome P450 genes, designated
3 D_C 12-7, encodes an mRNA transcript corresponding to nt
1-1551 of the cDNA sequence set forth in SEQ ID NO:5,
which codes for the full-length 517 residue polypeptide set
forth in SEQ ID NO:6. The fourth member of the novel
cytochrome P450 family, designated 7D_A06, encodes an
mRNA transcript corresponding to nt 1-1554 of the cDNA
sequence set forth in SEQ ID NO:7, which codes for the
full-length 518-residue polypeptide set forth in SEQ ID
NO:8.
Two partial-length P450 gene sequences sharing high
sequence identity to the full-length members of the 3D_C12
cytochrome P450 gene family were also isolated from these
Burley tobacco lines. The first of these, designated 3D_Cl215, encodes an mRNA transcript corresponding to the cDNA
sequence set forth in SEQ ID NO:9, which encodes the
partial-length polypeptide set forth in SEQ ID NO:10. The
second partial-length P450 gene sequence, designated
131A_A02, encodes an mRNA transcript corresponding to
the cDNA sequence set forth in SEQ ID NO: 11, which
encodes the partial-length polypeptide set forth in SEQ ID
NO:12.
In one aspect, the cytochrome P450 genes of the present
invention are involved in the conversion of nicotine to
nornicotine in a plant. In one aspect, the cytochrome P450
genes of the present invention have nicotine demethylase
activity.
An alignment of the members of the 3D_C12 cytochrome
P450 gene family is shown in FIGS. 3A-3G. The predicted
amino acid sequences for the four full-length clones are
aligned in FIG. 4. These sequences share high sequence
identity with each other (at least 90% at both the nucleotide
and amino acid level (see Tables 2 and 3, Example 4 herein
below).
The invention encompasses isolated or substantially purified polynucleotide or protein compositions. An "isolated"
or "purified" polynucleotide or protein, or biologically
active portion thereof, is substantially or essentially free
from components that normally accompany or interact with
the polynucleotide or protein as found in its naturally
occurring environment. Thus, an isolated or purified polynucleotide or protein is substantially free of other cellular
material, or culture medium when produced by recombinant
techniques, or substantially free of chemical precursors or
other chemicals when chemically synthesized. Optimally, an
"isolated" polynucleotide is free of sequences (optimally
protein encoding sequences) that naturally flank the poly-
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nucleotide (i.e., sequences located at the 5' and 3' ends of the
polynucleotide) in the genomic DNA of the organism from
which the polynucleotide is derived. For example, in various
embodiments, the isolated polynucleotide can contain less
than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of
nucleotide sequence that naturally flank the polynucleotide
in genomic DNA of the cell from which the polynucleotide
is derived. A protein that is substantially free of cellular
material includes preparations of protein having less than
about 30%, 20%, 10%, 5%, or 1% (by dry weight) of
contaminating protein. When the protein of the invention or
biologically active portion thereof is recombinantly produced, optimally culture medium represents less than about
30%, 20%, 10%, 5%, or 1% (by dry weight) of chemical
precursors or non-protein-of-interest chemicals.
Fragments of the disclosed cytochrome P450 polynucleotides and polypeptides encoded thereby are also encompassed by the present invention. Fragments of a polynucleotide may encode protein fragments that retain the biological
activity of the native protein and hence are involved in the
metabolic conversion of nicotine to nomicotine in a plant.
Alternatively, fragments of a polynucleotide that are useful
as hybridization probes or PCR primers using methods
described below generally do not encode fragment proteins
retaining biological activity. Furthermore, fragments of the
disclosed nucleotide sequences include those that can be
assembled within recombinant constructs for use in gene
silencing with any method known in the art, including, but
not limited to, sense suppression/cosuppression, antisense
suppression, double-stranded RNA (dsRNA) interference,
hairpin RNA interference and intron-containing hairpin
RNA interference,
amplicon-mediated interference,
ribozymes, and small interfering RNA or micro RNA, as
described herein below. Thus, fragments of a cytochrome
P450 polynucleotide sequence may range from at least about
20 nucleotides, about 50 nucleotides, about 70 nucleotides,
about 100 nucleotides, about 150 nucleotides, about 200
nucleotides, about 250 nucleotides, about 300 nucleotides,
about 350 nucleotides, about 400 nucleotides, and up to the
full-length polynucleotide encoding the proteins of the
invention, depending upon the desired outcome. In one
aspect, the fragments of a cytochrome P450 polynucleotide
sequence can be a fragment of between about 50 and about
400 nucleotides, between about 70 and about 350 nucleotides, between about 90 and about 325 nucleotides, between
about 90 and about 300 nucleotides, between about 90 and
about 275 nucleotides, between about 100 and about 400
nucleotides, between about 100 and about 350 nucleotides,
between about 100 and about 325 nucleotides, between
about 100 and about 300 nucleotides, between about 125 and
about 300 nucleotides, or between about 125 and about 275
nucleotides in length. In some embodiments, a fragment of
a cytochrome P450 polynucleotide is about 50, about 60,
about 70, about 80, about 90, about 100, about 125, about
150, about 175, about 200, about 225, about 250, about 275,
about 300, about 325, about 350, about 400 nucleotides in
length, and other such values between about 70 and about
400 nucleotides. In one such embodiment, a fragment of a
cytochrome P450 polynucleotide of the invention is about
90 bp to about 110 bp in length, including 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107,
108, 109, and 110 bp in length. In another such embodiment,
a fragment of a cytochrome P450 polynucleotide of the
invention is about 290 to about 310 bp in length, including
290,291,292,293,294,295,296,297,298,299,300,301,
302,303,304,305,306,307,308, 309, and 310 bp in length.

A fragment of a cytochrome P450 polynucleotide of the
present invention that encodes a biologically active portion
of a cytochrome P450 polypeptide of the present invention
will encode at least 15, 25, 30, 50, 75, 100, 125, 150, 175,
200, 250, 300, 350, 400, 450, or 500 contiguous amino
acids, or up to the total number of amino acids present in a
full-length cytochrome P450 polypeptide of the invention
(e.g., 517 for SEQ ID NOS: 2, 4, and 6; and 518 for SEQ ID
NO:8), or will encode at least 15, 25, 30, 50, 75, 100, 125,
150, or up to the total number of amino acids present in a
partial-length cytochrome P450 polypeptide of the invention
(e.g., 173 for SEQ ID NO:10; and 222 for SEQ ID NO:12).
In one aspect, a fragment of a cytochrome P450 polynucleotide of the invention encodes a polypeptide that comprises
position 330 of the encoded polypeptide sequence. In
another aspect, the polynucleotide fragment encodes a fragment of a cytochrome P450 polypeptide, where the polypeptide fragment comprises the amino acids from position
225 through the amino acid at about position 600 of SEQ ID
NO:6. In in one such embodiment, the polynucleotide fragment encodes a fragment of a cytochrome P450 polypeptide,
where the polypeptide fragment comprises the amino acids
from about position 239 through the amino acid at about
position 402 of SEQ ID NO: 6. A biologically active portion
of a cytochrome P450 polypeptide can be prepared by
isolating a portion of one of the cytochrome P450 polynucleotides of the present invention, expressing the encoded
portion of the cytochrome P450 polypeptide (e.g., by recombinant expression in vitro), and assessing the activity of the
encoded portion of the cytochrome P450 polypeptide, i.e.,
the ability to promote conversion of nicotine to nomicotine,
using assays known in the art and those provided herein
below.
Polynucleotides that are fragments of a cytochrome P450
nucleotide sequence of the present invention comprise at
least 16, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450,
500, 550, 600, 650, 700, 800, 900, 950, 1000, 1050, 1100,
1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550,
1600, 1650, or 1700 contiguous nucleotides, or up to the
number of nucleotides present in a full-length cytochrome
P450 polynucleotide as disclosed herein (e.g., 539 for SEQ
ID NO:9; 666 for SEQ ID NO: 11; 1733 for SEQ ID NOS: 1,
3, and 5; and 1727 for SEQ ID NO:7). Polynucleotides that
are fragments of a cytochrome P450 nucleotide sequence of
the present invention comprise fragments from about 20 to
about 1700 contiguous nucleotides, from about 50 to about
1600 contiguous nucleotides, from about 75 to about 1500
contiguous nucleotides, from about 100 to about 1400
nucleotides, from about 150 to about 1300 contiguous
nucleotides, from about 150 to about 1200 contiguous
nucleotides, from about 17 5 to about 1100 contiguous
nucleotides, or from about 200 to about 1000 contiguous
nucleotides from a cytochrome P450 polynucleotide as
disclosed herein.
In one aspect, fragments of a cytochrome P450 polynucleotide comprise a polynucleotide sequence containing the
nucleotides from about position 700 to about position 1250
of a cytochrome P450 coding sequence. In another aspect,
fragments of a cytochrome P450 polynucleotide comprise a
polynucleotide sequence containing the nucleotides from
about position 715 to about position 1210, or from about
position 717 to about position 1207 of a cytochrome P450
coding sequence disclosed herein.
In other embodiments of the invention, fragments of a
cytochrome P450 polynucleotide comprise a polynucleotide
sequence containing the nucleotides from about position 265
to about position 625 of a cytochrome P450 coding sequence
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disclosed herein, or a complement thereof. In some of these
embodiments, the fragments of a cytochrome P450 coding
sequence disclosed herein comprise the nucleotides corresponding to about position 297 to about position 594 of the
P450 coding sequence set forth in SEQ ID NO:3 or SEQ ID
NO:5, or a complement thereof.
In yet other embodiments of the invention, fragments of
a cytochrome P450 polynucleotide comprise a polynucleotide sequence containing the nucleotides from about position 1420 to about position 1580 of a cytochrome P450
coding sequence disclosed herein, or a complement thereof.
In some of these embodiments, the fragments of a
cytochrome P450 coding sequence disclosed herein comprise the nucleotides corresponding to about position 1453
to about position 1551 of the P450 coding sequence set forth
in SEQ ID NO: 1, or a complement thereof.
Variants of the disclosed polynucleotides and polypeptides encoded thereby are also encompassed by the present
invention. Such naturally occurring variants include those
variants that share substantial sequence identity to the disclosed cytochrome P450 polynucleotides and polypeptides
disclosed herein as defined herein below. The compositions
and methods of the invention can be used to target expression or function of any naturally occurring cytochrome P450
that shares substantial sequence identity to the disclosed
cytochrome P450 polypeptides and which possesses the
relevant cytochrome P450 activity, i.e., involvement in the
metabolic conversion of nicotine to nomicotine in plants.
Such variants may result from, for example, genetic polymorphism or from human manipulation as occurs with
breeding and selection. Biologically active variants of a
cytochrome P450 protein of the invention, for example,
variants of the polypeptide set forth in SEQ ID NO:2, 4, 6,
8, 10, or 12, will have at least about 40%, 45%, 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, 99% or more sequence identity
to the amino acid sequence for the native protein as determined by sequence alignment programs and parameters
described elsewhere herein, and are characterized by their
functional involvement in the metabolic conversion of nicotine to nornicotine in plants. A biologically active variant of
a protein of the invention may differ from that protein by as
few as 1-15 amino acid residues, as few as 10, as few as 9,
as few as 8, as few as 7, as few as 6, as few as 5, as few as
4, as few as 3, as few as 2, or as few as 1 amino acid residue.
Variants of a particular polynucleotide of the present
invention include those naturally occurring polynucleotides
that encode a cytochrome P450 polypeptide that is involved
in the metabolic conversion of nicotine to nomicotine in
plants. Such polynucleotide variants can comprise a deletion
and/or addition of one or more nucleotides at one or more
sites within the native polynucleotide disclosed herein and/
or a substitution of one or more nucleotides at one or more
sites in the native polynucleotide. Because of the degeneracy
of the genetic code, conservative variants for polynucleotides include those sequences that encode the amino acid
sequence of one of the cytochrome P450 polypeptides of the
invention. Naturally occurring variants such as these can be
identified with the use of well-known molecular biology
techniques, as, for example, with polymerase chain reaction
(PCR) and hybridization techniques as outlined below. Variant polynucleotides also include synthetically derived polynucleotides, such as those generated, for example, by using
site-directed mutagenesis but which still share substantial
sequence identity to the naturally occurring sequences disclosed herein, and thus can be used in the methods of the
invention to inhibit the expression or function of a

cytochrome P450 that is involved in the metabolic conversion of nicotine to nornicotine, including the cytochrome
P450 polypeptides set forth in SEQ ID NOS:2, 4, 6, and 8,
and polypeptides comprising the sequence set forth in SEQ
ID NO:10 or 12. Generally, variants of a particular polynucleotide of the invention, for example, the sequence set
forth in SEQ ID NO:1, 3, 5, 7, 9, or 11, will have at least
about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99% or more sequence identity to that particular polynucleotide as determined by sequence alignment programs and
parameters described elsewhere herein.
Variants of a particular polynucleotide of the present
invention (also referred to as the reference polynucleotide)
can also be evaluated by comparison of the percent sequence
identity between the polypeptide encoded by the reference
polynucleotide and the polypeptide encoded by a variant
polynucleotide. For example, isolated polynucleotides
encoding a polypeptide with a particular percent sequence
identity to the full-length polypeptide of SEQ ID NO:2, 4, 6,
or 8, or the partial-length polypeptide encoded by SEQ ID
NO:9 or 11 are disclosed. Such polynucleotides can be used
in the methods of the present invention to target expression
of cytochrome P450 polypeptides involved in the metabolic
conversion of nicotine to nornicotine in plants, particularly
tobacco plants, thereby inhibiting accumulation of nomicotine and its metabolite N'-nitrosonornicotine in the stems and
leaves of the genetically modified plant. Percent sequence
identity between any two polypeptides can be calculated
using sequence alignment programs and parameters
described elsewhere herein. Where any given pair of polynucleotides of the invention is evaluated by comparison of
the percent sequence identity shared by the two polypeptides
they encode, the percent sequence identity between the two
encoded polypeptides is at least about 40%, 45%, 50%,
55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence
identity. In one aspect, a variant polypeptide of the present
invention includes a polypeptide having a tryptophan at
position 330 or an isoleucine at position 274 of the
cytochrome P450 polypeptide, or both a tryptophan at
position 330 and an isoleucine at position 274.
Furthermore, the polynucleotides of the invention can be
used to isolate corresponding cytochrome P450 sequences
from other organisms, particularly other plants, more particularly other members of the Nicotiana genus. PCR,
hybridization, and other like methods can be used to identify
such sequences based on their sequence homology to the
sequences set forth herein. Sequences isolated based on their
sequence identity to the nucleotide sequences set forth
herein or to variants and fragments thereof are encompassed
by the present invention. Such sequences include sequences
that are orthologs of the disclosed sequences.
According to the present invention, "orthologs" are genes
derived from a common ancestral gene and which are found
in different species as a result of speciation. Genes found in
different species are considered orthologs when their nucleotide sequences and/or their encoded protein sequences share
at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, 99%, or greater sequence
identity. Functions of orthologs are often highly conserved
among species. Thus, isolated polynucleotides that encode
for a cytochrome P450 polypeptide that is involved in the
nicotine-to-nomicotine metabolic conversion and which
hybridize under stringent conditions to the cytochrome P450
sequences disclosed herein, or to variants or fragments
thereof, are encompassed by the present invention. Such
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sequences can be used in the methods of the present invention to inhibit expression of cytochrome P450 polypeptides
that are involved in the metabolic conversion of nicotine to
nomicotine in plants.
Using PCR, oligonucleotide primers can be designed for
use in PCR reactions to amplify corresponding DNA
sequences from cDNA or genomic DNA extracted from any
plant of interest. Methods for designing PCR primers and
PCR cloning are generally known in the art and are disclosed
in Sambrook et al. (1989) Molecular Cloning: A Laboratory
Manual (2d ed., Cold Spring Harbor Laboratory Press,
Plainview, N.Y.). Innis et al., eds. (1990) PCR Protocols: A
Guide to Methods and Applications (Academic Press, New
York); Innis and Gelfand, eds. (1995) PCR Strategies (Academic Press, New York); and Innis and Gelfand, eds. (1999)
PCR Methods Manual (Academic Press, New York). Known
methods of PCR include, but are not limited to, methods
using paired primers, nested primers, single specific primers,
degenerate primers, gene-specific primers, vector-specific
primers, partially mismatched primers, and the like.
Hybridization techniques involve the use of all or part of
a known polynucleotide as a probe that selectively hybridizes to other corresponding polynucleotides present in a
population of cloned genomic DNA fragments or cDNA
fragments (i.e., genomic or cDNA libraries) from a chosen
organism.
Hybridization may be carried out under stringent conditions. By "stringent conditions" or "stringent hybridization
conditions" is intended conditions under which a probe will
hybridize to its target sequence to a detectably greater degree
than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and
will be different in different circumstances. By controlling
the stringency of the hybridization and/or washing conditions, target sequences that are 100% complementary to the
probe can be identified (homologous probing). Alternatively,
stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are
detected (heterologous probing). Generally, a probe is less
than about 1000 nucleotides in length, optimally less than
500 nucleotides in length.
Typically, stringent conditions will be those in which the
salt concentration is less than about 1.5 M Na ion, typically
about 0.01 to 1.0 M Na ion concentration (or other salts) at
pH 7.0 to 8.3 and the temperature is at least about 30° C.
Stringent conditions may also be achieved with the addition
of destabilizing agents such as formamide. Exemplary low
stringency conditions include hybridization with a buffer
solution of 30 to 35% formamide, 1 M NaCl, 1% SDS
(sodium dodecyl sulphate) at 37° C., and a wash in lx to
2xSSC (20xSSC=3.0 M NaCl/0.3 M trisodium citrate) at 50
to 55° C. Exemplary moderate stringency conditions include
hybridization in 40 to 45% formamide, 1.0 M NaCl, 1%
SDS at 37° C., and a wash in 0.5x to lxSSC at 55 to 60° C.
Exemplary high stringency conditions include hybridization
in 50% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash
in 0.lxSSC at 60 to 65° C. Optionally, wash buffers may
comprise about 0.1 % to about 1% SDS. Duration of hybridization is generally less than about 24 hours, usually about
4 to about 12 hours. The duration of the wash time will be
at least a length of time sufficient to reach equilibrium.
In a specific embodiment, stringency conditions include
hybridization in a solution containing 5xSSC, 0.5% SDS,
5xDenhardt's, 0.45 µg/µl Poly A RNA, 0.45 µg/µl calf
thymus DNA and 50% formamide at 42° C., and at least one
post-hybridization wash in a solution comprising from about

0.0lxSSC to about lxSSC. The duration of hybridization is
from about 14 to about 16 hours.
Specificity is typically the function of post-hybridization
washes, the critical factors being the ionic strength and
temperature of the final wash solution. For DNA-DNA
hybrids, the Tm can be approximated from the equation of
Meinkoth and Wahl (1984) Anal. Biochem. 138:267-284:
Tm=81.5° C.+16.6 (log M)+0.41 (% GC)-0.61 (% form)500/L; where M is the molarity of monovalent cations, %
GC is the percentage of guanosine and cytosine nucleotides
in the DNA, % form is the percentage of formamide in the
hybridization solution, and L is the length of the hybrid in
base pairs. The Tm is the temperature (under defined ionic
strength and pH) at which 50% of a complementary target
sequence hybridizes to a perfectly matched probe. Tm is
reduced by about 1° C. for each 1% of mismatching; thus,
Tm, hybridization, and/or wash conditions can be adjusted to
hybridize to sequences of the desired identity. For example,
if sequences with 2:90% identity are sought, the Tm can be
decreased 10° C. Generally, stringent conditions are selected
to be about 5° C. lower than the thermal melting point (Tm)
for the specific sequence and its complement at a defined
ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4°
C. lower than the thermal melting point (Tm); moderately
stringent conditions can utilize a hybridization and/or wash
at 6, 7, 8, 9, or 10° C. lower than the thermal melting point
(Tm); low stringency conditions can utilize a hybridization
and/or wash at 11, 12, 13, 14, 15, or 20° C. lower than the
thermal melting point (Tm). Using the equation, hybridization and wash compositions, and desired Tm, those of
ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently
described. If the desired degree of mismatching results in a
Tm of less than 45° C. (aqueous solution) or 32° C. (formamide solution), it is optimal to increase the SSC concentration so that a higher temperature can be used. An extensive
guide to the hybridization of nucleic acids is found in Tij ssen
(1993) Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, Part 1,
Chapter 2 (Elsevier, New York); and Ausubel et al., eds.
(1995) Current Protocols in Molecular Biology, Chapter 2
(Greene Publishing and Wiley-Interscience, New York). See
Sambrook et al. (1989) Molecular Cloning: A Laboratory
Manual (2d ed., Cold Spring Harbor Laboratory Press,
Plainview, N.Y.).
Hybridization probes may be genomic DNA fragments,
cDNA fragments, RNA fragments, or other oligonucleotides, and may be labeled with a detectable group such as
32
P, or any other detectable marker. For example, probes for
hybridization can be made by labeling synthetic oligonucleotides based on the cytochrome P450 polynucleotides
sequences of the present invention. Methods for preparation
of probes for hybridization and for construction of cDNA
and genomic libraries are generally known in the art and are
disclosed in Sambrook et al. (1989) Molecular Cloning: A
Laboratory Manual (2d ed., Cold Spring Harbor Laboratory
Press, Plainview, N.Y.).
For example, the cytochrome P450 polynucleotide
sequences disclosed herein, or one or more portions thereof,
may be used as probes capable of specifically hybridizing to
corresponding cytochrome P450 polynucleotides and messenger RNAs. To achieve specific hybridization under a
variety of conditions, such probes include sequences that are
unique among cytochrome P450 polynucleotide sequences,
including upstream regions 5' to the coding sequence and
downstream regions 3' to the coding sequence, and are
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optimally at least about 10 nucleotides in length, and most
optimally at least about 20 nucleotides in length. Such
probes may be used to amplify corresponding cytochrome
P450 polynucleotides. This technique may be used to isolate
additional coding sequences from a desired plant or as a
diagnostic assay to determine the presence of coding
sequences in a plant. Hybridization techniques include
hybridization screening of plated DNA libraries (either
plaques or colonies; see, for example, Sambrook et al.
(1989) Molecular Cloning: A Laboratory Manual (2d ed.,
Cold Spring Harbor Laboratory Press, Plainview, N.Y.).
As used herein, with respect to the sequence relationships
between two or more polynucleotides or polypeptides, the
term "reference sequence" is a defined sequence used as a
basis for sequence comparison. A reference sequence may be
a subset or the entirety of a specified sequence; for example,
as a segment of a full-length cDNA or gene sequence, or the
complete cDNA or gene sequence.
As used herein, the term "comparison window" makes
reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence
in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which
does not comprise additions or deletions) for optimal alignment of the two polynucleotides. Generally, the comparison
window is at least 20 contiguous nucleotides in length, and
optionally can be 30, 40, 50, 100, or longer. Those of skill
in the art understand that to avoid a high similarity to a
reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced
and is subtracted from the number of matches.
Methods of alignment of sequences for comparison are
well known in the art. Thus, the determination of percent
sequence identity between any two sequences can be accomplished using a mathematical algorithm. Non-limiting
examples of such mathematical algorithms are the algorithm
of Myers and Miller (1988) CABIOS 4:11-17; the local
alignment algorithm of Smith et al. (1981) Adv. Appl. Math.
2:482; the global alignment algorithm of Needleman and
Wunsch (1970) J. Mal. Biol. 48:443-453; the search-forlocal alignment method of Pearson and Lipman (1988) Proc.
Natl. Acad. Sci. 85:2444-2448; the algorithm of Karlin and
Altschul (1990) Proc. Natl. Acad. Sci. USA 872264, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci.
USA 90:5873-5877.
The BLAST programs of Altschul et al. (1990) J. Mal.
Biol. 215:403 are based on the algorithm of Karlin and
Altschul (1990) supra. BLAST nucleotide searches can be
performed with the BLASTN program, score=l00, wordlength=12, to obtain nucleotide sequences homologous to a
nucleotide sequence encoding a protein of the invention.
BLAST protein searches can be performed with the
BLASTX program, score=50, wordlength=3, to obtain
amino acid sequences homologous to a protein or polypeptide of the invention. To obtain gapped alignments for
comparison purposes, Gapped BLAST (in BLAST 2.0) can
be utilized as described in Altschul et al. (1997) Nucleic
Acids Res. 25:3389. Alternatively, PSI-BLAST (in BLAST
2.0) can be used to perform an iterated search that detects
distant relationships between molecules. See Altschul et al.
(1997) supra. When utilizing BLAST, Gapped BLAST,
PSI-BLAST, the default parameters of the respective programs (e.g., BLASTN for nucleotide sequences, BLASTX
for proteins) can be used (See www.ncbi.nlm.nih.gov).
Alignment may also be performed manually by inspection.
The sequence identity/similarity values provided herein
were calculated using the BLASTX (Altschul et al. (1997)

supra), Clustal W (Higgins et al. (1994) Nucleic Acids Res.
22: 4673-4680), and GAP (University of Wisconsin Genetic
Computing Group software package) algorithms using
default parameters. The present invention also encompasses
the use of any equivalent program thereof for the analysis
and comparison of nucleic acid and protein sequences. By
"equivalent program" is intended any sequence comparison
program that, for any two sequences in question, generates
an alignment having identical nucleotide or amino acid
residue matches and an identical percent sequence identity
when compared to the corresponding alignment generated
by BLASTX, Clustal W, or GAP.
For purposes of the foregoing discussion of variant
nucleotide and polypeptide sequences encompassed by the
present invention, the term "sequence identity" or "identity"
in the context of two polynucleotides or polypeptide
sequences makes reference to the residues in the two
sequences that are the same when aligned for maximum
correspondence over a specified comparison window. When
percentage of sequence identity is used in reference to
proteins it is recognized that residue positions which are not
identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other
amino acid residues with similar chemical properties (e.g.,
charge or hydrophobicity) and therefore do not change the
functional properties of the molecule. When sequences differ
in conservative substitutions, the percent sequence identity
may be adjusted upwards to correct for the conservative
nature of the substitution. Sequences that differ by such
conservative substitutions are said to have "sequence similarity" or "similarity." Means for making this adjustment are
well known to those of skill in the art. Typically this involves
scoring a conservative substitution as a partial rather than a
full mismatch, thereby increasing the percentage sequence
identity. Thus, for example, where an identical amino acid is
given a score of 1 and a non-conservative substitution is
given a score of zero, a conservative substitution is given a
score between zero and 1. The scoring of conservative
substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif.).
The term "percentage of sequence identity" as used herein
means the value determined by comparing two optimally
aligned sequences over a comparison window, wherein the
portion of the polynucleotide sequence in the comparison
window may comprise additions or deletions (i.e., gaps) as
compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two
sequences. The percentage is calculated by determining the
number of positions at which the identical nucleic acid base
or amino acid residue occurs in both sequences to yield the
number of matched positions, dividing the number of
matched positions by the total number of positions in the
window of comparison, and multiplying the result by 100 to
yield the percentage of sequence identity.
When any two polypeptide sequences are optimally
aligned for comparison, it is recognized that residues appearing opposite of one another within the alignment occupy
positions within their respective polypeptides that correspond to one another. Such positions are referred to herein
as "corresponding positions" and the residues residing at
corresponding positions are referred to as "corresponding
residues" or residues that "correspond" to one another. Thus,
for example, where a polypeptide of interest is optimally
aligned to a reference polypeptide sequence having, for
example, 10 residues, the residue within the polypeptide of
interest appearing opposite residue 5 of the reference
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sequence is referred to as the "residue at the position
corresponding to residue 5" of the reference sequence.
In like manner, when any two polynucleotide sequences
are optimally aligned for comparison, it is recognized that
the nucleotides appearing opposite of one another within the
aligmnent occupy positions within their respective polynucleotide positions that correspond to one another. Such
positions are referred to herein as "corresponding positions"
and the nucleotides residing at corresponding positions are
referred to as "corresponding nucleotides" or nucleotides
that "correspond" to one another. Thus, for example, where
a polynucleotide of interest is optimally aligned to a reference polynucleotide sequence having, for example, 300
nucleotides, the nucleotide within the polynucleotide of
interest appearing opposite nucleotide 275 of the reference
sequence is referred to as the "nucleotide at the position
corresponding to nucleotide 275" of the reference sequence.
Where a region of nucleotides is being compared between
a polynucleotide of interest and a reference polynucleotide,
the nucleotides within these regions are said to "correspond"
to one another. Thus, for example, where a region of a
reference polynucleotide sequence, for example, the polynucleotide sequence set forth in SEQ ID NO:5, resides from
nucleotide position 265 to nucleotide position 625 of the
reference polynucleotide, and this region of nucleotides is
being compared to the corresponding region of nucleotides
within an optimally aligned polynucleotide sequence of
interest, the nucleotides within the corresponding region of
the polynucleotide of interest are referred to herein as "a
region" of the polynucleotide of interest that "corresponds to
nucleotide position 265 to nucleotide position 625" of the
reference sequence, in this case, SEQ ID NO:5.
Cytochrome P450 polynucleotide and polypeptide
sequences can be identified using the sequences provided
herein. Such methods include obtaining a polynucleotide or
polypeptide sequence at least 80%, 85%, 90%, 95%, 98%,
99% sequence identity with the polynucleotide sequence of
SEQ ID NO 1, 3, 5, 7, 9, or 11 or a complement or fragment
thereof, or a polypeptide sequence of SEQ ID NO:2, 4, 6, 7,
10, or 12. In one embodiment, the identified sequence
contains or encodes for a tryptophan residue at position 330
and an isoleucine residue at position 274.
In this manner, one aspect of the present invention is
directed to a method of screening for a nicotine demethylase
sequence. This method comprises obtaining a nucleic acid
sequence that has greater than about 90% sequence identity
with SEQ ID NO:3 or SEQ ID NO:5; and identifying within
this nucleic acid sequence a codon sequence encoding for a
tryptophan residue at position 330 of the polypeptide
encoded by the nucleic acid sequence. In some embodiments, this nucleic acid sequence also encodes an isoleucine
at position 274 of the encoded polypeptide. Any suitable
method known in the art can be used to identify the codon
sequence encoding the tryptophan or isoleucine residue. In
one embodiment, the codon sequence is identified by a
method selected from the group consisting of identifying a
single nucleotide polymorphism and RT-PCR. In some
embodiments of this aspect of the invention, the screening
method identifies a nicotine demethylase that converts nicotine to nomicotine at a rate that is at least about 5-fold
greater than the conversion rate of the nicotine demethylase
encoded by SEQ ID NO:3 (polypeptide set forth in SEQ ID
NO:4) or SEQ ID NO:5 (polypeptide set forth in SEQ ID
NO:6). In particular embodiments, the nicotine demethylase
identified with this screening method has a conversion rate

that is at least about 8-fold greater than the conversion rate
of the nicotine demethylase encoded by SEQ ID NO:3 or
SEQ ID NO:5.
In another aspect, the present invention provides a method
for screening for a nicotine demethylase having an isoleucine at position 274 or a tryptophan at position 329 of the
polypeptide. This method comprises obtaining a nucleic acid
sequence that has greater than about 90% sequence identity
with SEQ ID NO:3 or SEQ ID NO:5; and identifying a first
codon sequence encoding for an isoleucine residue at position 274 of the encoded polypeptide or a second codon
sequence encoding a tryptophan residue at position 330 of
the encoded polypeptide. As noted above, any suitable
method known to those of skill in the art can be used to
identify these codons. In one embodiment, either or both of
the first and second codons are identified by a method
selected from the group consisting of identifying a single
nucleotide polymorphism and RT-PCR. In some embodiments of this aspect of the invention, the screening method
identifies a nicotine demethylase that converts nicotine to
nornicotine at a rate that is at least about 5-fold greater than
the conversion rate of the nicotine demethylase encoded by
SEQ ID NO:3 (polypeptide set forth in SEQ ID NO:4) or
SEQ ID NO:5 (polypeptide set forth in SEQ ID NO:6). In
particular embodiments, the nicotine demethylase identified
with this screening method has a conversion rate that is at
least about 8-fold greater than the conversion rate of the
nicotine demethylase encoded by SEQ ID NO:3 or SEQ ID
NO:5.
The present invention also provides transgenic plant cells,
plants, and seed comprising a nucleic acid molecule having
a promoter functional in a plant cell and a nucleic acid
sequence encoding a nicotine demethylase having an isoleucine residue at position 274 and a tryptophan residue at
position 330. In some embodiments, the nucleic acid
sequence encoding this nicotine demethylase is derived from
a sequence selected from the group consisting of SEQ ID
NO:3, SEQ ID NO:5, and SEQ ID NO:7. These transgenic
plant cells, plants, and seed include, but are not limited to,
Nicotiana plant cells, Nicotiana plants, and seed of Nicotiana plants. In some embodiments, the Nicotiana plant cells,
Nicotiana plants, and seed of Nicotiana plants are from
converter Nicotiana plants.
Expression Cassettes for Use in the Methods of the Invention
Compositions of the present invention further include
expression cassettes comprising inhibitory sequences
capable of inhibiting expression or function of a cytochrome
P450 polypeptide involved in the conversion of nicotine to
nornicotine in a Nicotiana plant or plant part thereof, where
the inhibitory sequences are operably linked to a promoter
that is functional in a plant cell. In this manner, expression
cassettes comprising all or part of the sequence set forth in
SEQ ID NO:1, 3, 5, 7, 9, or 11, a complement or fragment
thereof, or sequences sharing substantial sequence identity
to SEQ ID NO:1, 3, 5, 7, 9, 11, or a complement or fragment
thereof, operably linked to a promoter that is functional in a
plant cell are constructed for use in the gene-silencing
methods of the present invention described herein below.
Such sequences are referred to herein as "inhibitory
sequences" or "inhibitory polynucleotide sequences" as they
are capable of being expressed as an RNA molecule that
inhibits expression (i.e, transcription and/or translation) of
the target cytochrome P450 polypeptide, for example, the
polypeptide set forth in SEQ ID NO:2, 4, 6, or 8 and variants
thereof, or a polypeptide comprising the sequence set forth
in SEQ ID NO:10 or 12 and variants thereof, where the
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variant polypeptides have substantial sequence identity to
these disclosed cytochrome P450 polypeptides and are
involved in the metabolic conversion of nicotine to nornicotine in a plant.
As noted above, such inhibitory sequences include fragment sequences of the target cytochrome P450 polynucleotides. For example, a fragment sequence can include any
portion of the cytochrome P450 sequence, including coding
and non-coding sequence (e.g., 5' UTR, intron, and 3' UTR
sequences), and can include fragments of between about 20
and about 400 nucleotides, between about 50 and about 400
nucleotides, between about 100 and about 400 nucleotides,
between about 125 and about 325 nucleotides, between
about 125 and about 300 nucleotides, or between about 125
and about 275 nucleotides.
In this manner, such inhibitory sequences include, but are
not limited, sequences that comprise a fragment of a
cytochrome P450 polynucleotide sequence ranging from at
least about 20 nucleotides, about 50 nucleotides, about 70
nucleotides, about 100 nucleotides, about 150 nucleotides,
about 200 nucleotides, about 250 nucleotides, about 300
nucleotides, about 350 nucleotides, and up to the full-length
polynucleotide encoding the proteins of the invention,
depending upon the desired outcome. In one aspect, the
inhibitory sequences comprise a fragment of a cytochrome
P450 polynucleotide sequence that is between about 50 and
about 400 nucleotides, between about 50 and about 350
nucleotides, between about 70 and about 350 nucleotides,
between about 90 and about 325 nucleotides, between about
90 and about 300 nucleotides, between about 90 and about
275 nucleotides, between about 100 and about 400 nucleotides, between about 100 and about 350 nucleotides,
between about 100 and about 325 nucleotides, between
about 100 and about 300 nucleotides, between about 125 and
about 300 nucleotides, or between about 125 and about 275
nucleotides in length. In some embodiments, the inhibitory
sequences comprise a fragment of a cytochrome P450
polynucleotide sequence that is about 50, about 60, about 70,
about 80, about 90, about 100, about 125, about 150, about
175, about 200, about 225, about 250, about 275, about 300,
about 325, about 350, about 400 nucleotides in length, and
other such values between about 50 and about 400 nucleotides. It is recognized that the inhibitory sequence can also
comprise a sequence that is complementary to all or a part
of the fragment of the cytochrome P450 polynucleotide
sequence.
In one such embodiment, the inhibitory sequences comprise a fragment of a cytochrome P450 polynucleotide of the
invention that is about 90 bp to about 110 bp in length,
including 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101,
102,103,104,105,106,107,108,109, and ll0bp in length,
and can also comprise a sequence that is complementary to
all or a part of the fragment sequence. In another such
embodiment, a fragment of a cytochrome P450 polynucleotide of the invention is about 290 to about 310 bp in length,
including 290, 291, 292, 293, 294, 295, 296, 297, 298, 299,
300,301,302,303,304,305,306,307,308,309, and310
bp in length, and can also comprise a sequence that is
complementary to all or a part of the fragment sequence.
In other embodiments of the invention, the inhibitory
sequence within an expression cassette of the invention
comprises a polynucleotide sequence containing the nucleotides from about position 265 to about position 625 of a
cytochrome P450 coding sequence disclosed herein and
sequence that is fully or partially complementary thereto. In
some of these embodiments, the inhibitory sequence comprises the nucleotides corresponding to about position 297 to

about position 594 of the P450 coding sequence set forth in
SEQ ID NO:3 or SEQ ID NO:5 and a sequence that is fully
or partially complementary thereto. In preferred embodiments, such inhibitory sequences are expressed as a hairpin
RNA as described herein below.
In yet other embodiments of the invention, the inhibitory
sequence within an expression cassette of the invention
comprises a polynucleotide sequence containing the nucleotides from about position 1420 to about position 1580 of a
cytochrome P450 coding sequence disclosed herein and a
sequence that is fully or partially complementary thereto. In
some of these embodiments, the inhibitory sequence comprises the nucleotides corresponding to about position 1453
to about position 1551 of the P450 coding sequence set forth
in SEQ ID NO: 1 and a sequence that is fully or partially
complementary thereto. In preferred embodiments, such
inhibitory sequences are expressed as a hairpin RNA as
described herein below.
It is recognized that expression cassettes of the present
invention encompass constructs in which a desired nucleic
acid sequence is operably linked to a promoter that is
functional in a plant cell, particularly in the cell of a
Nicotiana plant. By "promoter" is intended a regulatory
region of DNA usually comprising a TATA box capable of
directing RNA polymerase II to initiate RNA synthesis at the
appropriate transcription initiation site for a particular polynucleotide sequence. A promoter may additionally comprise
other recognition sequences generally positioned upstream
or 5' to the TATA box, referred to as upstream promoter
elements, which influence the transcription initiation rate. It
is also recognized that expression cassettes of the present
invention encompass additional domains that modulate the
level of expression, the developmental timing of expression,
or tissue type that expression occurs in (e.g., Australian
Patent No. AU-A-77751/94 and U.S. Pat. Nos. 5,466,785
and 5,635,618). By "functional" is intended the promoter,
when operably linked to an inhibitory sequence encoding an
inhibitory nucleotide molecule (for example, a hairpin RNA,
double-stranded RNA, miRNA polynucleotide, and the
like), the promoter is capable of initiating transcription of
the operably linked inhibitory sequence such that the inhibitory nucleotide molecule is expressed. The promoters can be
selected based on the desired outcome. The nucleic acids can
be combined with constitutive, tissue-preferred, or other
promoters for expression in plants.
An expression cassette of the present invention may also
contain at least one additional gene to be cotransformed into
the plant. Alternatively, the additional gene(s) can be provided on multiple expression cassettes. Such an expression
cassette is provided with a plurality of restriction sites and/or
recombination sites for insertion of the cytochrome P450
inhibitory polynucleotide sequence to be under the transcriptional regulation of the regulatory regions. The expression
cassette may additionally contain selectable marker genes.
In this manner, an expression cassette of the present
invention includes a transcriptional and translational initiation region (i.e., a promoter) in the 5'-3' direction of transcription, an inhibitory sequence as described elsewhere
herein, and a transcriptional and translational termination
region (i.e., termination region) functional in a plant cell.
The regulatory regions (i.e., promoters, transcriptional regulatory regions, and translational termination regions) and/or
the inhibitory sequence of the invention may be native/
analogous to the host cell or to each other. Alternatively, the
regulatory regions and/or the inhibitory sequence of the
invention may be heterologous to the host cell or to each
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other. While heterologous promoters can be used to express
the inhibitory sequences of the invention, native promoter
sequences may also be used.
The termination region may be native with the transcriptional initiation region, may be native with the operably
linked inhibitory sequence of the invention, may be native
with the plant host, or may be derived from another source
(i.e., foreign or heterologous to the promoter, the inhibitory
sequence of interest, the plant host, or any combination
thereof). Convenient termination regions are available from
the Ti-plasmid of A. tumefaciens, such as the octopine
synthase and nopaline synthase termination regions. See
also Guerineau et al. (1991) Mal. Gen. Genet. 262:141-144;
Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991)
Genes Dev. 5:141-149; Magen et al. (1990) Plant Cell
2:1261-1272; Munroe et al. (1990) Gene 91:151-158; Ballas
et al. (1989) Nucleic Acids Res. 17:7891-7903; and Joshi et
al. (1987) Nucleic Acids Res. 15:9627-9639.
Expression cassettes of the present invention may additionally contain 5' leader sequences that can act to enhance
translation. Translation leaders are known in the art and
include: picornavirus leaders, for example, EMCV leader
(Encephalomyocarditis 5' noncoding region) (Elroy-Stein et
al. (1989) Proc. Natl. Acad. Sci. USA 86:6126-6130); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus)
(Gallie et al. (1995) Gene 165(2): 233-238), MDMV leader
(Maize Dwarf Mosaic Virus) (Virology 154:9-20), and
human immunoglobulin heavy-chain binding protein (BiP)
(Macejak et al. (1991) Nature 353:90-94); untranslated
leader from the coat protein mRNA of alfalfa mosaic virus
(AMY RNA 4) (Jobling et al. (1987) Nature 325:622-625);
tobacco mosaic virus leader (TMV) (Gallie et al. (1989) in
Molecular Biology of RNA, ed. Cech (Liss, New York), pp.
237-256); and maize chlorotic mottle virus leader (MCMV)
(Lommel et al. (1991) Virology 81:382-385). See also,
Della-Cioppa et al. (1987) Plant Physiol. 84:965-968. Other
methods known to enhance translation can also be utilized.
In preparing the expression cassette, DNA fragments of
the invention may be manipulated so as to provide for the
DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Adapters or linkers may be
employed to join the DNA fragments or other manipulations
may be involved to provide for convenient restriction sites,
removal of superfluous DNA, removal of restriction sites, or
the like. For this purpose, in vitro mutagenesis, primer
repair, restriction, annealing, resubstitutions, e.g., transitions
and transversions, may be involved.
The expression cassettes of the present invention can also
comprise a selectable marker gene for the selection of
transformed cells. Selectable marker genes are utilized for
the selection of transformed cells or tissues. Marker genes
include genes encoding antibiotic resistance, such as those
encoding neomycin phosphotransferase II (NEO) and
hygromycin phosphotransferase (HPT), as well as genes
conferring resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4dichlorophenoxyacetate (2,4-D). Additional selectable
markers include phenotypic markers such as ~-galactosidase
and fluorescent proteins such as green fluorescent protein
(GFP) (Rouwendal et al. (1997) Plant Mo. Biol. 33:989-999;
Su et al. (2004) Biotechnol Bioeng 85:610-9 and Fetter et al.
(2004) Plant Cell 16:215-28), cyan florescent protein (CYP)
(Bolte et al. (2004) J. Cell Science 117:943-54 and Kato et
al. (2002) Plant Physiol 129:913-42), and yellow fluorescent
protein (PhiYFP™ from Evrogen, see, Bolte et al. (2004) J.
Cell Science 117:943-954). For additional selectable markers, see generally, Yarranton (1992) Curr. Opin. Biotech.

3:506-511; Christopherson et al. (1992) Proc. Natl. Acad.
Sci. USA 89:6314-6318; Yao et al. (1992) Cell 71:63-72;
Reznikoff (1992) Mal. Microbial. 6:2419-2422; Barkley et
al. (1980) in The Operon, pp. 177-220; Hu et al. (1987) Cell
48:555-566; Brown et al. (1987) Cell 49:603-612; Figge et
al. (1988) Cell 52:713-722; Deuschle et al. (1989) Proc.
Natl. Acad. Aci. USA 86:5400-5404; Fuerst et al. (1989)
Proc. Natl. Acad. Sci. USA 86:2549-2553; Deuschle et al.
(1990) Science 248:480-483; Gossen (1993) Ph.D. Thesis,
University of Heidelberg; Reines et al. (1993) Proc. Natl.
Acad. Sci. USA 90:1917-1921; Labow et al. (1990) Mal.
Cell. Biol. 10:3343-3356; Zambretti et al. (1992) Proc. Natl.
Acad. Sci. USA 89:3952-3956; Baim et al. (1991) Proc. Natl.
Acad. Sci. USA 88:5072-5076; Wyborski et al. (1991)
Nucleic Acids Res. 19:4647-4653; Hillenand-Wissman
(1989) Topics Mal. Struc. Biol. 10:143-162; Degenkolb et al.
(1991) Antimicrob. Agents Chemother. 35:1591-1595;
Kleinschnidt et al. (1988) Biochemistry 27:1094-1104;
Bonin (1993) Ph.D. Thesis, University of Heidelberg; Gossen et al. (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551;
Oliva et al. (1992) Antimicrob. Agents Chemother. 36:913919; Hlavka et al. (1985) Handbook of Experimental Pharmacology, Vol. 78 (Springer-Verlag, Berlin); Gill et al.
(1988) Nature 334:721-724. Such disclosures are herein
incorporated by reference. The above list of selectable
marker genes is not meant to be limiting. Any selectable
marker gene can be used in the present invention.
A number of promoters can be used in the practice of the
invention. Of particular interest are constitutive promoters,
inducible promoters, particularly chemical-inducible promoters, and tissue-preferred promoters, particularly leafpreferred promoters.
Chemical-inducible promoters can be used to inhibit the
expression of a cytochrome P450 that is involved in the
metabolic conversion of nicotine to nomicotine in a plant
through the application of an exogenous chemical regulator.
Chemical-inducible promoters are known in the art and
include, but are not limited to, the tobacco PR-la promoter,
which is activated by salicylic acid. Other chemical-inducible promoters of interest include steroid-responsive promoters (see, for example, the glucocorticoid-inducible promoter in Schena et al. (1991) Proc. Natl. Acad. Sci. USA
88:10421-10425 and McNellis et al. (1998) Plant J. 14(2):
247-257) and tetracycline-inducible promoters (see, for
example, Gatz et al. (1991) Mal. Gen. Genet. 227:229-237,
and U.S. Pat. Nos. 5,814,618 and 5,789,156), herein incorporated by reference.
Constitutive promoters include, for example, the core
promoter of the Rsyn7 promoter and other constitutive
promoters disclosed in U.S. Pat. No. 6,072,050; the core
CaMV 35S promoter (Odell et al. (1985) Nature 313:810812); ubiquitin (Christensen et al. (1989) Plant Mal. Biol.
12:619-632 and Christensen et al. (1992) Plant Mal. Biol.
18:675-689); pEMU (Last et al. (1991) Theor. Appl. Genet.
81:581-588); MAS (Velten et al. (1984) EMBO J. 3:27232730); ALS promoter (U.S. Pat. No. 5,659,026), and the
like. Other constitutive promoters include, for example, U.S.
Pat. Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597;
5,466,785; 5,399,680; 5,268,463; 5,608,142; and 6,177,611.
Tissue-preferred promoters can be utilized to target
expression of an inhibitory polynucleotide sequence of the
present invention within a particular plant tissue. Tissuepreferred promoters include Yamamoto et al. (1997) Plant J.
12(2):255-265; Kawamata et al. (1997) Plant Cell Physiol.
38(7):792-803; Hansen et al. (1997) Mal. Gen Genet. 254
(3):337-343; Russell et al. (1997) Transgenic Res. 6(2):157168; Rinehart et al. (1996) Plant Physiol. 112(3): 1331-1341;

5

10

15

20

25

30

35

40

45

50

55

60

65

US 10,383,299 B2

25

26

Van Camp et al. (1996) Plant Physiol. 112(2):525-535;
Canevascini et al. (1996) Plant Physiol. 112(2):513-524;
Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778;
Lam (1994) Results Prob!. Cell Differ. 20:181-196; Orozco
et al. (1993) Plant Mal Biol. 23(6):1129-1138; Matsuoka et
al. (1993) Proc Natl. Acad. Sci. USA 90(20):9586-9590; and
Guevara-Garcia et al. (1993) Plant J. 4(3):495-505.
Of particular interest are leaf-preferred promoters that
provide for expression predominately in leaf tissues. See, for
example, Yamamoto et al. (1997) Plant J. 12(2):255-265;
Kwon et al. (1994) Plant Physiol. 105:357-67; Yamamoto et
al. (1994) Plant Cell Physiol. 35(5):773-778; Gator et al.
(1993) Plant J. 3:509-18; Orozco et al. (1993) Plant Mal.
Biol. 23(6): 1129-1138; Baszczynski et al. (1988) Nucl. Acid
Res. 16:4732; Mitra et al. (1994) Plant Molecular Biology
26:35-93; Kayaya et al. (1995) Molecular and General
Genetics 248:668-674; and Matsuoka et al. (1993) Proc.
Natl. Acad. Sci. USA 90(20):9586-9590. Senecence-regulated promoters are also of use, such as SAM22 (Crowell et
al. (1992) Plant Mal. Biol. 18:459-466); SAG 12 (Lohman et
al. (1994) Physiol. Plant. 92:322-328; Wingler et al. (1998)
Plant Physiol. 116:329-335); SAG 13 (Gan and Amasino
(1997) Plant Physiol. 113:313-319; SAG15 (Gan (1995)
"Molecular Characterization and Genetic Manipulation of
Plant Senescence," Ph.D. Thesis, University of Wisconsin,
Madison); SENl (Oh et al. (1996) Plant Mal. Biol. 30:739754; promoter of a senescence-specific gene for expression
ofIPT (Gan andAmasino 91995) Science 270:1986-1988);
and the like (see, for example, Or: et al. (1999) Plant Cell
11:1073-1080 and McCabe et al. (2001) Plant Physiol.
127:505-516).
Methods for Inhibiting Expression or Function of a
Cytochrome P450 Involved in the Conversion of Nicotine to
Nornicotine
Methods of reducing the concentration, content, and/or
activity of a cytochrome P450 polypeptide of the present
invention in a Nicotiana plant or plant part, particularly the
leaf tissue, are provided. Many methods may be used, alone
or in combination, to reduce or eliminate the activity of a
cytochrome P450 polypeptide of the present invention. In
addition, combinations of methods may be employed to
reduce or eliminate the activity of two or more different
cytochrome P450 polypeptides.
In accordance with the present invention, the expression
of a cytochrome P450 polypeptide of the present invention
is inhibited if the protein level of the cytochrome P450
polypeptide is statistically lower than the protein level of the
same cytochrome P450 polypeptide in a plant that has not
been genetically modified or mutagenized to inhibit the
expression of that cytochrome P450 polypeptide, and where
these plants have been cultured and harvested using the
same protocols. In particular embodiments of the invention,
the protein level of the cytochrome P450 polypeptide in a
modified plant according to the invention is less than 95%,
less than 90%, less than 80%, less than 70%, less than 60%,
less than 50%, less than 40%, less than 30%, less than 20%,
less than 10%, less than 5%, less than 4%, less than 3%, less
than 2%, or less than 1% of the protein level of the same
cytochrome P450 polypeptide in a plant that is not a mutant
or that has not been genetically modified to inhibit the
expression of that cytochrome P450 polypeptide and which
has been cultured and harvested using the same protocols.
The expression level of the cytochrome P450 polypeptide
may be measured directly, for example, by assaying for the
level of the cytochrome P450 transcript or cytochrome P450
polypeptide expressed in the Nicotiana plant or plant part, or
indirectly, for example, by measuring the conversion of

nicotine to nornicotine in the Nicotiana plant or plant part.
Methods for monitoring the expression level of a protein are
known in the art, and include, but are not limited to,
Northern blot analysis as discussed in the examples herein
below. Methods for determining the activity of the targeted
cytochrome P450 polypeptide in converting nicotine to
nornicotine are described elsewhere herein below, and
include, but are not limited to, alkaloid analysis using gas
chromatography, for example the procedures described in
the examples herein below.
In other embodiments of the invention, the activity of one
or more cytochrome P450 polypeptides is reduced or eliminated by transforming a plant or plant part with an expression cassette comprising a polynucleotide encoding a polypeptide that inhibits the activity of one or more cytochrome
P450 polypeptides of the present invention. The activity of
a cytochrome P450 polypeptide in converting nicotine to
nornicotine in a Nicotiana plant or plant part is inhibited
according to the present invention if this conversion activity
is statistically lower than conversion activity of the same
cytochrome P450 polypeptide in a Nicotiana plant or plant
part that has not been genetically modified to inhibit the
conversion activity of that cytochrome P450 polypeptide
and which has been cultured and harvested using the same
protocols. In particular embodiments, activity of a
cytochrome P450 polypeptide in converting nicotine to
nornicotine in a modified Nicotiana plant or plant part
according to the invention is inhibited if the activity is less
than 95%, less than 90%, less than 80%, less than 70%, less
than 60%, less than 50%, less than 40%, less than 30%, less
than 20%, less than 10%, less than 5%, less than 4%, less
than 3%, less than 2%, or less than 1% of the conversion
activity of the same cytochrome P450 polypeptide in a
Nicotiana plant that that has not been genetically modified
to inhibit the expression of that cytochrome P450 polypeptide and which has been cultured and harvested using the
same protocols. The activity of a cytochrome P450 polypeptide in converting nicotine to nornicotine in a Nicotiana
plant or plant part is eliminated according to the invention
when it is not detectable by the assay methods described
elsewhere herein. Methods of determining the activity of a
cytochrome P450 polypeptide in converting nicotine to
nornicotine in a Nicotiana plant or plant part are described
elsewhere herein, and include the alkaloid analyses using
gas chromatography disclosed in the examples herein below.
In specific embodiments, a cytochrome P450 inhibitory
polynucleotide sequence described herein is introduced into
a Nicotiana plant or plant part. Subsequently, a Nicotiana
plant or plant part having the introduced inhibitory polynucleotide sequence of the invention is selected using methods known to those of skill in the art such as, but not limited
to, Southern blot analysis, DNA sequencing, PCR analysis,
or phenotypic analysis. A plant or plant part altered or
modified by the foregoing embodiments is grown under
plant forming conditions for a time sufficient to modulate the
concentration and/or activity of polypeptides of the present
invention in the plant. Plant forming conditions are well
known in the art and discussed briefly elsewhere herein.
In some embodiments, a transformed tobacco plant containing a cytochrome P450 inhibitory polynucleotide
sequence described herein has a reduced level of conversion
of nicotine to nornicotine. In particular embodiments, conversion of nicotine to nornicotine in a transformed tobacco
plant or plant part according to the invention is less than
95%, less than 90%, less than 80% less than 70%, less than
60%, less than 50%, less than 40%, less than 30%, less than
20% less than 10%, less than 5%, less than 4%, less than 3%,
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less than 2%, or less than 1% of the conversion in a tobacco
plant that that has not been genetically modified to inhibit
the expression of that cytochrome P450 polypeptide and
which has been cultured and harvested using the same
protocols. In some embodiments, the transformed tobacco
plant is a converter tobacco plant. In some embodiments, the
transformed tobacco plant has a conversion rate lower than
the rate observed in commercial nonconverter tobacco
plants.
It is also recognized that the level and/or activity of the
polypeptide may be modulated by employing a polynucleotide that is not capable of directing, in a transformed plant,
the expression of a protein or an RNA. For example, the
polynucleotides of the invention may be used to design
polynucleotide constructs that can be employed in methods
for altering or mutating a genomic nucleotide sequence in an
organism. Such polynucleotide constructs include, but are
not limited to, RNA:DNA vectors, RNA:DNA mutational
vectors, RNA:DNA repair vectors, mixed-duplex oligonucleotides, self-complementary RNA:DNA oligonucleotides, and recombinogenic oligonucleobases. Such nucleotide constructs and methods of use are known in the art. See,
U.S. Pat. Nos. 5,565,350; 5,731,181; 5,756,325; 5,760,012;
5,795,972; and 5,871,984; all of which are herein incorporated by reference. See also, WO 98/49350, WO 99/07865,
WO 99/25821, and Beetham et al. (1999) Proc. Natl. Acad.
Sci. USA 96:8774-8778; herein incorporated by reference.
It is therefore recognized that methods of the present
invention do not depend on the incorporation of the entire
cytochrome P450 inhibitory polynucleotide into the
genome, only that the Nicotiana plant or plant part thereof
is altered as a result of the introduction of this inhibitory
polynucleotide into a cell. In one embodiment of the invention, the genome may be altered following the introduction
of the cytochrome P450 inhibitory polynucleotide into a
cell. For example, the inhibitory polynucleotide, or any part
thereof, may incorporate into the genome of the plant.
Alterations to the genome include, but are not limited to,
additions, deletions, and substitutions of nucleotides into the
genome. While the methods of the present invention do not
depend on additions, deletions, and substitutions of any
particular number of nucleotides, it is recognized that such
additions, deletions, or substitutions comprise at least one
nucleotide.
It is further recognized that reducing the level and/or
activity of a cytochrome P450 sequence of the present
invention can be performed to elicit the effects of the
sequence only during certain developmental stages and to
switch the effect off in other stages where expression is no
longer desirable. Control of cytochrome P450 expression
can be obtained via the use of inducible or tissue-preferred
promoters. Alternatively, the gene could be inverted or
deleted using site-specific recombinases, transposons or
recombination systems, which would also turn on or off
expression of the cytochrome P450 sequence.
According to the present invention, changes in levels,
ratios, activity, or distribution of cytochrome P450 polypeptides of the present invention, or changes in Nicotiana plant
or plant part phenotype, particularly reduced accumulation
of nornicotine and its carcinogenic metabolite, NNN, could
be measured by comparing a subject plant or plant part to a
control plant or plant part, where the subject plant or plant
part and the control plant or plant part have been cultured
and/or harvested using the same protocols. As used herein,
a subject plant or plant part is one in which genetic alteration, such as transformation, has been affected as to the
cytochrome P450 polypeptide of interest, or is a Nicotiana

plant or plant part that is descended from a Nicotiana plant
or plant part so altered and which comprises the alteration.
A control plant or plant part provides a reference point for
measuring changes in phenotype of the subject plant or plant
part.
The measurement of changes in phenotype can be measured at any time in a plant or plant part, including during
plant development, senescence, or after curing. In other
embodiments, the measurement of changes in phenotype can
be measured in plants grown under any conditions, including from plants grown in a growth chamber, greenhouse, or
in a field. In one embodiment, changes in phenotype can be
measured by determining the nicotine to nornicotine conversion rate. In a preferred embodiment, conversion can be
measured by dividing the percentage of nornicotine (as a
percentage of the total tissue weight) by the sum of the
percentage nicotine and nornicotine (as percentages of the
total tissue weight) and multiplying by 100.
According to the present invention, a control plant or
plant part may comprise a wild-type Nicotiana plant or plant
part, i.e., of the same genotype as the starting material for the
genetic alteration that resulted in the subject plant or plant
part. A control plant or plant part may also comprise a
Nicotiana plant or plant part of the same genotype as the
starting material but that has been transformed with a null
construct (i.e., with a construct that has no known effect on
the trait of interest, such as a construct comprising a selectable marker gene). Alternatively, a control plant or plant part
may comprise a Nicotiana plant or plant part that is a
non-transformed segregant among progeny of a subject plant
or plant part, or a Nicotiana plant or plant part genetically
identical to the subject plant or plant part but that is not
exposed to conditions or stimuli that would induce suppression of the cytochrome P450 gene of interest. Finally, a
control plant or plant part may comprise the subject plant or
plant part itself under conditions in which the cytochrome
P450 inhibitory sequence is not expressed. In all such cases,
the subject plant or plant part and the control plant or plant
part are cultured and harvested using the same protocols.
As described elsewhere herein, methods are provided to
reduce or eliminate the activity and/or concentration of a
cytochrome P450 polypeptide of the present invention by
introducing into a Nicotiana plant or plant part a cytochrome
P450 inhibitory polynucleotide sequence that is capable of
inhibiting expression or function of a cytochrome P450
polypeptide that is involved in the metabolic conversion of
nicotine to nornicotine. In some embodiments, the inhibitory
sequence is introduced by transformation of the plant or
plant part, such as a plant cell, with an expression cassette
that expresses a polynucleotide that inhibits the expression
of the cytochrome P450 polypeptide. The polynucleotide
may inhibit the expression of a cytochrome P450 polypeptide directly, by preventing translation of the cytochrome
P450 polypeptide messenger RNA, or indirectly, by encoding a polypeptide that inhibits the transcription or translation
of an cytochrome P450 polypeptide gene encoding a
cytochrome P450 polypeptide. Methods for inhibiting or
eliminating the expression of a gene product in a plant are
well known in the art, and any such method may be used in
the present invention to inhibit the expression of cytochrome
P450 polypeptides.
In other embodiments, the activity of a cytochrome P450
polypeptide of the present invention may be reduced or
eliminated by disrupting the gene encoding the cytochrome
P450 polypeptide. The invention encompasses mutagenized
plants that carry mutations in cytochrome P450 genes,
where the mutations reduce expression of the cytochrome
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P450 gene or inhibit the activity of an encoded cytochrome
P450 polypeptide of the present invention.
In some embodiments of the present invention, a Nicotiana plant or plant part is transformed with an expression
cassette that is capable of expressing a polynucleotide that
inhibits the expression of a cytochrome P450 sequence.
Such methods may include the use of sense suppression/
cosuppression, antisense suppression, double-stranded RNA
(dsRNA) interference, hairpin RNA interference and introncontaining hairpin RNA interference, amplicon-mediated
interference, ribozymes, and small interfering RNA or micro
RNA.
For cosuppression, an expression cassette is designed to
express an RNA molecule corresponding to all or part of a
messenger RNA encoding a cytochrome P450 polypeptide
of interest (for example, a cytochrome P450 polypeptide
comprising the sequence set forth in SEQ ID NO:2, 4, 6, 8,
10, or 12 or a sequence having substantial sequence identity
to SEQ ID NO:2, 4, 6, 8, 10, or 12) in the "sense"
orientation. Over expression of the RNA molecule can result
in reduced expression of the native gene. Multiple plant lines
transformed with the cosuppression expression cassette are
then screened to identify those that show the greatest inhibition of cytochrome P450 polypeptide expression.
The polynucleotide used for cosuppression may correspond to all or part of the sequence encoding a cytochrome
P450 polypeptide or the present invention, all or part of the
5' and/or 3' untranslated region of a cytochrome P450
polypeptide transcript, or all or part of both the coding
sequence and the untranslated regions of a transcript encoding a cytochrome P450 polypeptide. In some embodiments
where the polynucleotide comprises all or part of the coding
region for a cytochrome P450 polypeptide of the present
invention, the expression cassette is designed to eliminate
the start codon of the polynucleotide so that no protein
product will be transcribed.
Cosuppression may be used to inhibit the expression of
plant genes to produce plants having undetectable protein
levels for the proteins encoded by these genes or may also
be used to inhibit the expression of multiple proteins in the
same plant (e.g., Brain et al. (2002) Plant Cell 14:14171432; U.S. Pat. No. 5,942,657). Methods for using cosuppression to inhibit the expression of endogenous genes in
plants are described in Flavell et al. (1994) Proc. Natl. Acad.
Sci. USA 91:3490-3496; Jorgensen et al. (1996) Plant Mal.
Biol. 31:957-973; Johansen and Carrington (2001) Plant
Physiol. 126:930-938; Brain et al. (2002) Plant Cell
14:1417-1432; Stoutjesdijk et al (2002) Plant Physiol. 129:
1723-1731; Yu et al. (2003) Phytochemistry 63:753-763; and
U.S. Pat. Nos. 5,034,323, 5,283,184, and 5,942,657; each of
which is herein incorporated by reference. The efficiency of
cosuppression may be increased by including a poly-dT
region in the expression cassette at a position 3' to the sense
sequence and 5' of the polyadenylation signal. See, U.S.
Patent Publication No. 20020048814, herein incorporated
by reference. Typically, such a nucleotide sequence has
substantial sequence identity to the sequence of the transcript of the endogenous gene, optimally greater than about
65% sequence identity, more optimally greater than about
85% sequence identity, most optimally greater than about
95% sequence identity (e.g., U.S. Pat. Nos. 5,283,184 and
5,034,323; herein incorporated by reference).
In some embodiments of the invention, inhibition of the
expression of the cytochrome P450 polypeptide of the
present invention may be obtained by antisense suppression.
For antisense suppression, the expression cassette is
designed to express an RNA molecule complementary to all

or part of a messenger RNA encoding the cytochrome P450
polypeptide. Over expression of the antisense RNA molecule can result in reduced expression of the native gene.
Accordingly, multiple plant lines transformed with the antisense suppression expression cassette are screened to identify those that show the greatest inhibition of cytochrome
P450 polypeptide expression.
The polynucleotide for use in antisense suppression may
correspond to all or part of the complement of the sequence
encoding the cytochrome P450 polypeptide, all or part of the
complement of the 5' and/or 3' untranslated region of the
cytochrome P450 polypeptide transcript, or all or part of the
complement of both the coding sequence and the untranslated regions of a transcript encoding the cytochrome P450
polypeptide. In addition, the antisense polynucleotide may
be fully complementary (i.e., 100% identical to the complement of the target sequence) or partially complementary
(i.e., less than 100% identical to the complement of the
target sequence) to the target sequence. Antisense suppression may be used to inhibit the expression of multiple
proteins in the same plant (e.g., U.S. Pat. No. 5,942,657).
Furthermore, portions of the antisense nucleotides may be
used to disrupt the expression of the target gene. Generally,
sequences of at least 50 nucleotides, 100 nucleotides, 200
nucleotides, 300, 400, 450, 500, 550, or greater may be used.
Methods for using antisense suppression to inhibit the
expression of endogenous genes in plants are described, for
example, in Liu et al (2002) Plant Physiol. 129:1732-1743
and U.S. Pat. Nos. 5,759,829 and 5,942,657, each of which
is herein incorporated by reference. Efficiency of antisense
suppression may be increased by including a poly-dT region
in the expression cassette at a position 3' to the antisense
sequence and 5' of the polyadenylation signal. See, U.S.
Patent Publication No. 20020048814, herein incorporated
by reference.
For dsRNA interference, a sense RNA molecule like that
described above for cosuppression and an antisense RNA
molecule that is fully or partially complementary to the
sense RNA molecule are expressed in the same cell, resulting in inhibition of the expression of the corresponding
endogenous messenger RNA.
Expression of the sense and antisense molecules can be
accomplished by designing the expression cassette to comprise both a sense sequence and an antisense sequence for
the target cytochrome P450 sequence. Alternatively, separate expression cassettes may be used for the sense and
antisense sequences. Multiple plant lines transformed with
the dsRNA interference expression cassette or expression
cassettes are then screened to identify plant lines that show
the greatest inhibition of expression of the targeted
cytochrome P450 polypeptide. Methods for using dsRNA
interference to inhibit the expression of endogenous plant
genes are described in Waterhouse et al. (1998) Proc. Natl.
Acad. Sci. USA 95:13959-13964, Liu et al. (2002) Plant
Physiol. 129:1732-1743, and WO 99/49029, WO 99/53050,
WO 99/61631, and WO 00/49035; each of which is herein
incorporated by reference.
Amplicon expression cassettes comprise a plant virusderived sequence that contains all or part of the target gene
but generally not all of the genes of the native virus. The
viral sequences present in the transcription product of the
expression cassette allow the transcription product to direct
its own replication. The transcripts produced by the amplicon may be either sense or antisense relative to the target
sequence (i.e., the messenger RNA for a cytochrome P450
polypeptide that is involved in the metabolic conversion of
nicotine to nornicotine). Methods of using amplicons to
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inhibit the expression of endogenous plant genes are
described, for example, in Angell and Baulcombe (1997)
EMBO J. 16:3675-3684, Angell and Baulcombe (1999)
Plant J. 20:357-362, and U.S. Pat. No. 6,646,805, each of
which is herein incorporated by reference.
In additional embodiments of the present invention, the
polynucleotide expressed by the expression cassette of the
invention is catalytic RNA or has ribozyme activity specific
for the messenger RNA of a cytochrome P450 polypeptide
described herein. Thus, the polynucleotide causes the degradation of the endogenous messenger RNA, resulting in
reduced expression of the cytochrome P450 polypeptide.
This method is described, for example, in U.S. Pat. No.
4,987,071, herein incorporated by reference.
In further embodiments of the invention, inhibition of the
expression of one or more cytochrome P450 polypeptides
may be obtained by RNA interference (RNAi) by expression
of a gene encoding a micro RNA (miRNA). miRNAs are
regulatory agents consisting of about 22 ribonucleotides.
miRNA are highly efficient at inhibiting the expression of
endogenous genes. See, for example Javier et al. (2003)
Nature 425: 257-263, herein incorporated by reference.
For miRNA interference, the expression cassette is
designed to express an RNA molecule that is modeled on an
endogenous miRNA gene. The miRNA gene encodes an
RNA that forms a hairpin structure containing a 22-nucleotide sequence that is complementary to another endogenous
gene (target sequence). For suppression of cytochrome P450
polypeptide expression, the 22-nucleotide sequence is
selected from a cytochrome P450 polypeptide transcript
sequence and contains 22 nucleotides encoding this
cytochrome P450 polypeptide sequence in sense orientation
and 21 nucleotides of a corresponding antisense sequence
that is complementary to the sense sequence. miRNA molecules are highly efficient at inhibiting the expression of
endogenous genes, and the RNA interference they induce is
inherited by subsequent generations of plants.
In still other embodiments of the invention, inhibition of
the expression of one or more cytochrome P450 polypeptides by RNAi may be obtained by hairpin RNA (hpRNA)
interference or intron-containing hairpin RNA (ihpRNA)
interference. These methods are highly efficient at inhibiting
the expression of endogenous genes. See, Waterhouse and
Helliwell (2003) Nat. Rev. Genet. 4:29-38 and the references
cited therein.
For hpRNA interference, the expression cassette is
designed to express an RNA molecule that hybridizes with
itself to form a hairpin structure that comprises a singlestranded loop region and a base-paired stem. The basepaired stem region comprises a sense sequence corresponding to all or part of the endogenous messenger RNA
encoding the gene product whose expression is to be inhibited, in this case, a cytochrome P450 polypeptide described
herein, and an antisense sequence that is fully or partially
complementary to the sense sequence. Alternatively, the
base-paired stem region may correspond to a portion of a
promoter sequence controlling expression of the gene
encoding the cytochrome P450 polypeptide to be inhibited.
Thus, the base-paired stem region of the molecule generally
determines the specificity of the RNA interference. hpRNA
molecules are highly efficient at inhibiting the expression of
endogenous genes, and the RNA interference they induce is
inherited by subsequent generations of plants. See, for
example, Chuang and Meyerowitz (2000) Proc. Natl. Acad.
Sci. USA 97:4985-4990; Stoutjesdijk et al. (2002) Plant
Physiol. 129:1723-1731; and Waterhouse and Helliwell
(2003) Nat. Rev. Genet. 4:29-38. Methods for using hpRNA

interference to inhibit or silence the expression of genes are
described, for example, in Chuang and Meyerowitz (2000)
Proc. Natl. Acad. Sci. USA 97:4985-4990; Stoutjesdijk et al.
(2002) Plant Physiol. 129:1723-1731; Waterhouse and
Helliwell (2003) Nat. Rev. Genet. 4:29-38; Pandolfini et al.
BMC Biotechnology 3:7, and U.S. Patent Publication No.
20030175965; each of which is herein incorporated by
reference. A transient assay for the efficiency of hpRNA
constructs to silence gene expression in vivo has been
described by Panstruga et al. (2003) Mal. Biol. Rep. 30:135140, herein incorporated by reference.
For ihpRNA, the interfering molecules have the same
general structure as for hpRNA, but the RNA molecule
additionally comprises an intron that is capable of being
spliced in the cell in which the ihpRNAis expressed. The use
of an intron minimizes the size of the loop in the hairpin
RNA molecule following splicing, and this increases the
efficiency of interference. See, for example, Smith et al.
(2000) Nature 407:319-320. In fact, Smith et al. show 100%
suppression of endogenous gene expression using ihpRNAmediated interference. Methods for using ihpRNA interference to inhibit the expression of endogenous plant genes are
described, for example, in Smith et al. (2000) Nature 407:
319-320; Wesley et al. (2001) Plant J. 27:581-590; Wang
and Waterhouse (2001) Curr. Opin. Plant Biol. 5:146-150;
Waterhouse and Helliwell (2003) Nat. Rev. Genet. 4:29-38;
Helliwell and Waterhouse (2003) Methods 30:289-295, and
U.S. Patent Publication No. 20030180945, each of which is
herein incorporated by reference.
In one such embodiment, RNAi is accomplished by
expressing an inhibitory sequence that comprises a first
sequence ofa cytochrome P450 polynucleotide of the invention that is about 90 bp to about 110 bp in length, including
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103,
104, 105, 106, 107, 108, 109, and 110 bp in length, and a
second sequence that is complementary to all or a part of the
first sequence. In another such embodiment, the inhibitory
sequence comprises a first sequence of a cytochrome P450
polynucleotide of the invention that is about 290 to about
310 bp in length, including 290, 291, 292, 293, 294, 295,
296,297,298,299,300,301,302,303,304,305,306,307,
308, 309, and 310 bp in length, and a second sequence that
is complementary to all or a part of the fragment sequence.
In other embodiments of the invention, RNAi is accomplished by expressing an inhibitory sequence that comprises
a first polynucleotide sequence containing the nucleotides
from about position 265 to about position 625 of a
cytochrome P450 coding sequence disclosed herein and a
second sequence that is fully or partially complementary
thereto. In some of these embodiments, the inhibitory
sequence comprises as the first polynucleotide sequence the
nucleotides corresponding to about position 297 to about
position 594 of the P450 coding sequence set forth in SEQ
ID NO:3 or SEQ ID NO:5 and the second sequence is the
complement (i.e., antisense sequence) of this first sequence.
The inhibitory sequence can optionally comprise an intron
sequence linked between the first and second sequences.
Any intron known to those of skill in the art can be used in
this manner. In some embodiments, the intron is from the
soybean omega-6 fatty acid desaturase (FAD) (see GenBank
Accession No. DQ672337, and Example 7 herein below). In
one such embodiment, the intron comprises about 151
nucleotides that comprise nucleotides 100-247 of the soybean omega-6 fatty acid desaturase polynucleotide shown in
Genbank Accession No. DQ672337. Examples of other
intrans include, but are not limited to, the intron nucleotide
sequences of alcohol dehydrogenase (adhl) genes. Expres-
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sion of this inhibitory sequence produces an intron-containing hairpin RNA that strongly interferes with expression of
the cytochrome P450 polypeptides disclosed herein. In this
manner, Nicotiana plants that are normally converters of
nicotine to nornicotine that are transformed with an expression cassette comprising such an inhibitory sequence advantageously have a nicotine to nornicotine conversion rate that,
surprisingly, is even lower than that observed for Nicotiana
plants that are nonconverters of nicotine to nornicotine.
In yet other embodiments of the invention, RNAi is
accomplished by expressing an inhibitory sequence that
comprises a first polynucleotide sequence containing the
nucleotides from about position 1420 to about position 1580
of a cytochrome P450 coding sequence disclosed herein and
a sequence that is fully or partially complementary thereto.
In some of these embodiments, the inhibitory sequence
comprises as the first polynucleotide sequence the nucleotides corresponding to about position 1453 to about position
1551 of the P450 coding sequence set forth in SEQ ID NO: 1
and the second sequence is the complement (i.e., antisense
sequence) of this first sequence. The inhibitory sequence can
optionally comprise an intron sequence linked between the
first and second sequences. Any intron known to those of
skill in the art can be used in this manner, as noted herein
above. Expression of this inhibitory sequence produces a
hairpin RNA (or intron-containing hairpin RNA when the
intron is present) that also interferes with expression of the
cytochrome P450 polypeptides disclosed herein.
The expression cassette for hpRNA interference may also
be designed such that the sense sequence and the antisense
sequence do not correspond to an endogenous RNA. In this
embodiment, the sense and antisense sequence flank a loop
sequence that comprises a nucleotide sequence corresponding to all or part of the endogenous messenger RNA of the
target gene. Thus, it is the loop region that determines the
specificity of the RNA interference. See, for example, WO
02/00904, herein incorporated by reference.
Transcriptional gene silencing (TGS) may be accomplished through use of hpRNA constructs wherein the
inverted repeat of the hairpin shares sequence identity with
the promoter region of a gene to be silenced. Processing of
the hpRNA into short RNAs that can interact with the
homologous promoter region may trigger degradation or
methylation to result in silencing (Aufsatz et al. (2002) Proc.
Natl. Acad. Sci. 99 (Suppl. 4): 16499-16506; Mette et al.
(2000) EMBO J. 19(19):5194-5201).
In further embodiments, a polynucleotide may be utilized
that encodes a zinc finger protein that binds to a gene
encoding a cytochrome P450 polypeptide, resulting in
reduced expression of the gene. In particular embodiments,
the zinc finger protein binds to a regulatory region of a
cytochrome P450 polypeptide gene. In other embodiments,
the zinc finger protein binds to a messenger RNA encoding
a cytochrome P450 polypeptide and prevents its translation.
Methods of selecting sites for targeting by zinc finger
proteins have been described, for example, in U.S. Pat. No.
6,453,242, and methods for using zinc finger proteins to
inhibit the expression of genes in plants are described, for
example, in U.S. Patent Publication No. 20030037355; each
of which is herein incorporated by reference.
In other embodiments of the invention, the polynucleotide
encodes an antibody that binds to at least one cytochrome
P450 polypeptide, and reduces the activity of a cytochrome
P450 polypeptide of the present invention. In another
embodiment, the binding of the antibody results in increased
turnover of the antibody-cytochrome P450 polypeptide
complex by cellular quality control mechanisms. The

expression of antibodies in plant parts and the inhibition of
molecular pathways by expression and binding of antibodies
to proteins in plant parts are well known in the art. See, for
example, Conrad and Sonnewald (2003) Nature Biotech.
21:35-36, incorporated herein by reference.
In other embodiments, the activity of a cytochrome P450
polypeptide of the present invention is reduced or eliminated
by disrupting the gene encoding the cytochrome P450
polypeptide. The gene encoding the cytochrome P450 polypeptide may be disrupted by any method known in the art,
for example, by transposon tagging or by mutagenizing
plants using random or targeted mutagenesis and selecting
for plants that have reduced cytochrome P450 activity.
Transposon tagging may be used to reduce or eliminate
the activity of one or more cytochrome P450 polypeptides of
the present invention. Transposon tagging comprises inserting a transposon within an endogenous cytochrome P450
gene to reduce or eliminate expression of the cytochrome
P450 polypeptide.
In this embodiment, the expression of one or more
cytochrome P450 polypeptides is reduced or eliminated by
inserting a transposon within a regulatory region or coding
region of the gene encoding the cytochrome P450 polypeptide. A transposon that is within an exon, intron, 5' or 3'
untranslated sequence, a promoter, or any other regulatory
sequence of a cytochrome P450 polypeptide gene may be
used to reduce or eliminate the expression and/or activity of
the encoded cytochrome P450 polypeptide.
Methods for the transposon tagging of specific genes in
plants are well known in the art. See, for example, Maes et
al. (1999) Trends Plant Sci. 4:90-96; Dharmapuri and Santi
(1999) FEMS Microbial. Lett. 179:53-59; Meissner et al.
(2000) Plant J. 22:265-274; Phogat et al. (2000) J. Biosci.
25:57-63; Walbot (2000) Curr. Opin. Plant Biol. 2:103-107;
Gai et al. (2000) Nucleic Acids Res. 28:94-96; Fitzmaurice
et al. (1999) Genetics 153:1919-1928).
Additional methods for decreasing or eliminating the
expression of endogenous genes in plants are also known in
the art and can be similarly applied to the instant invention.
These methods include other forms of mutagenesis, such as
ethyl methanesulfonate-induced mutagenesis, deletion
mutagenesis, and fast neutron deletion mutagenesis used in
a reverse genetics sense (with PCR) to identify plant lines in
which the endogenous gene has been deleted. For examples
of these methods see Ohshima et al. (1998) Virology 243:
472-481; Okuhara et al. (1994) Genetics 137:867-874; and
Quesada et al. (2000) Genetics 154:421-436; each of which
is herein incorporated by reference. In addition, a fast and
automatable method for screening for chemically induced
mutations, TILLING (Targeting Induced Local Lesions In
Genomes), using denaturing HPLC or selective endonuclease digestion of selected PCR products is also applicable
to the instant invention. See McCallum et al. (2000) Nat.
Biotechnol. 18:455-457, herein incorporated by reference.
Mutations that impact gene expression or that interfere
with the function of the encoded cytochrome P450 protein
can be determined using methods that are well known in the
art. Insertional mutations in gene exons usually result in
null-mutants. Mutations in conserved residues can be particularly effective in inhibiting the metabolic function of the
encoded protein. Conserved residues of plant cytochrome
P450 polypeptides suitable for mutagenesis with the goal to
eliminate activity of a cytochrome P450 polypeptide in
converting nicotine to nornicotine in a Nicotiana plant or
plant part have been described (See, for example, FIGS. 3
and 4). Such mutants can be isolated according to wellknown procedures.
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In another embodiment of this invention, dominant
mutants can be used to trigger RNA silencing due to gene
inversion and recombination of a duplicated gene locus. See,
for example, Kusaba et al. (2003) Plant Cell 15:1455-1467.
While a number of sequences are recognized in the
practice of the invention, in particular SEQ ID NO:3 and
SEQ ID NO:5 find particular use. While not bound by any
particular mechanisms of action, it is believed that these
sequences encode a nicotine demethylase that catalyzes the
oxidative N-demethylation of nicotine to nornicotine. Thus,
methods to specifically inhibit these coding sequences and
not other P450 sequences may be beneficial to the recombinant plant. That is, strategies that would lead to inhibition
of gene function of this individual locus may prove to be
superior to those that inhibit the entire gene family. The
P450 enzymes are involved in many mechanisms in the
plant, the inhibition of which may prove deleterious or
detrimental to the growth and development of the plant or
may negatively impact factors such as the disease defense
capabilities of the plant. Likewise, because the Nicotiana
plant P450 enzymes have been implicated in plant metabolites such as phenylpropanoid, alkaloids, terpenoids, lipids,
cyanogenic glycosides, glucosinolates, and a host of other
chemical entities, disruption of p450 activity may alter
components involved in tobacco flavor, texture, or other
properties that would impact the commercial usefulness of
the plant. Therefore, the use of the methods discussed above
to inhibit expression in a manner that specifically targets the
coding sequence of SEQ ID NO:3 or SEQ ID NO:5 may be
preferred, including targeted mutational strategies, such as
chimeraplasty. See, for example, Stewart et al. (2000) Biotechniques 29( 4): 838-843; Graham et al. (2002) Biochim
Biophys Acta 1587 (1 ): 1-6, herein incorporated by reference.
The protein encoded by the cDNAdesignated 3D_Cl2-10
(SEQ ID NO:4) differs from 3D_Cl2-7 (SEQ ID NO:6) at
only two amino acid residues immediately following the
start methionine. The codons corresponding to these amino
acids were contained within the PCR primer used to generate the 3D_Cl2-7 cDNA. Thus, the original mRNA template
from which 3D_Cl2-7 was amplified may be the same as
that corresponding to the 3D_Cl2-10 gene, with the PCR
primer sequences mediating the changes observed in the
second and third amino acid sequence. Regardless, the
encoded protein products would function identically. The
location of the two amino acids that differ between the
predicted proteins is in the N-terminal signal sequence that
merely serves to anchor the protein to the endoplasmic
reticulum membrane and therefore would not be expected to
influence the catalytic properties of the enzyme.
In another embodiment of the invention, the compositions
of the invention find use in screening methods to identify
nonconverter plants for use in breeding programs. In this
manner, the nucleotide sequences of the invention can be
used to screen native germplasms for nonconverter plants
having a stable mutation in one or more p450 genes identified herein. These nonconverter plants identified by the
methods of the invention can be used to develop breeding
lines.
In addition to the nucleotide sequences encoding P450
coding sequences, compositions of the invention include an
intron sequence in the 3D_Cl2-10 sequence that can be used
in screening methods. While not bound by any mechanism
of action, the 3D_Cl2-7/3D_C12-10 gene(s) may represent
the only member(s) of the 3D_C12 family involved in the
metabolic conversion of nicotine to nornicotine (and as
stated previously there is a good likelihood that the
3D_Cl2-7 and 3D_Cl2-10 cDNAs originated from a single

unique genetic locus). For certain applications it would be
useful to have a means of diagnostically differentiating this
specific member of the 3D_C12 gene family from the rest of
the closely related sequences within this family. For
example, it is possible that within the naturally existing
tobacco germplasm (or in mutagenized populations), accessions may exist in which this gene is naturally dysfunctional
and may therefore may be valuable as a permanently nonconverter resource. A method to specifically assay for such
genotypes (e.g. deletion mutants, rearrangements, and the
like) could serve as a powerful tool. To obtain such a tool,
the sequence alignment shown in FIGS. 3A-3G was used to
design PCR primers in regions possessing polymorphisms
among the members. One primer combination (5' primer
shown in SEQ ID NO:25 and 3' primer shown in SEQ ID
NO:26) using sequences specific to 3D_Cl2-10 yields two
particularly useful results: (1) all PCR products amplified
from tobacco genomic DNA gave that same unique product
(as determined by DNA sequence analysis); and (2) the
presence of a 992 bp intron was revealed that is located
between the primer sequences (FIG. 7; intron shown in SEQ
ID NO:24).
When any cDNA corresponding to a member of the
3D_C12 family is used as a hybridization probe in a Southem blotting assay of tobacco genomic DNA, a complex
pattern is observed. This is expected, given that there are
multiple, closely related members of this gene family.
Because the intron regions of genes are typically less
conserved than exons, it is predicted that the use of an
intron-specific probe would reduce this complexity and
better enable one to distinguish the gene(s) corresponding to
the 3D_Cl2-7/3D_C12-10 gene from the other members of
the family. Indeed, the probe corresponding to the sequence
shown in FIG. 7 resulted in a Southern blotting pattern with
greatly reduced complexity. The use of a 3D_Cl2-10 intronspecific probe, and/or the PCR primers used to generate the
fragment shown in FIG. 7, therefore provide powerful tools
in assays to determine whether any naturally occuring, or
mutagenized, tobacco plants possess deletions or rearrangements that may render the gene inactive. Such a plant can
then be used in breeding programs to create tobacco lines
that are incapable of converting.
Transformed Plants, Plant Parts, and Products Having
Reduced Nornicotine and NNN Content
The cytochrome P450 polynucleotides of the invention,
and variants and fragments thereof, can be used in the
methods of the present invention to inhibit expression or
function of cytochrome P450s that are involved in the
metabolic conversion of nicotine to nornicotine in a plant. In
this manner, inhibitory sequences that target expression or
function of a cytochrome P450 polypeptide disclosed herein
are introduced into a plant or plant cell of interest. In some
embodiments the expression cassettes described herein are
introduced into a plant of interest, for example, a Nicotiana
plant as noted herein below, using any suitable transformation methods known in the art including those described
herein.
The methods of the invention do not depend on a particular method for introducing a sequence into a plant or
plant part, only that the desired sequence gains access to the
interior of at least one cell of the plant or plant part. Methods
for introducing polynucleotide sequences into plants are
known in the art and include, but are not limited to, stable
transformation methods, transient transformation methods,
and virus-mediated methods.
Transformation protocols as well as protocols for introducing heterologous polynucleotide sequences into plants

5

10

15

20

25

30

35

40

45

50

55

60

65

US 10,383,299 B2
37

38

vary depending on the type of plant or plant cell targeted for
transformation. Suitable methods of introducing polynucleotides into plant cells of the present invention include
microinjection (Crossway et al. (1986) Biotechniques 4:320334), electroporation (Shillito et al. (1987) Meth. Enzymol.
153:313-336; Riggs et al. (1986) Proc. Natl. Acad. Sci. USA
83:5602-5606), Agrobacterium-mediated transformation
(U.S. Pat. Nos. 5,104,310, 5,149,645, 5,177,010, 5,231,019,
5,463,174, 5,464,763, 5,469,976, 4,762,785, 5,004,863,
5,159,135, 5,563,055, and 5,981,840), direct gene transfer
(Paszkowski et al. (1984) EMBO J. 3:2717-2722), and
ballistic particle acceleration (see, for example, U.S. Pat.
Nos. 4,945,050, 5,141,131, 5,886,244, 5,879,918, and
5,932,782; Tomes et al. (1995) in Plant Cell, Tissue, and
Organ Culture: Fundamental Methods, ed. Gamborg and
Phillips (Springer-Verlag, Berlin); McCabe et al. (1988)
Biotechnology 6:923-926). Also see Weissinger et al. (1988)
Ann. Rev. Genet. 22:421-477; Christou et al. (1988) Plant
Physiol. 87:671-674 (soybean); McCabe et al. (1988) Biol
Technology 6:923-926 (soybean); Finer and McMullen
(1991) In Vitro Cell Dev. Biol. 27P: 175-182 (soybean);
Singh et al. (1998) Theor. Appl. Genet. 96:319-324 (soybean); De Wet et al. (1985) in The Experimental Manipulation ofOvule Tissues, ed. Chapman et al. (Longman, N.Y.),
pp. 197-209 (pollen); Kaeppler et al. (1990) Plant Cell
Reports 9:415-418 and Kaeppler et al. (1992) Theor. Appl.
Genet. 84:560-566 (whisker-mediated transformation);
D'Halluin et al. (1992) Plant Cell 4:1495-1505 (electroporation); all of which are herein incorporated by reference.
Any plant tissue that can be subsequently propagated
using clonal methods, whether by organogenesis or embryogenesis, may be transformed with a recombinant construct
comprising a cytochrome P450 inhibitory sequence, for
example, an expression cassette of the present invention. By
"organogenesis" in intended the process by which shoots
and roots are developed sequentially from meristematic
centers. By "embryogenesis" is intended the process by
which shoots and roots develop together in a concerted
fashion (not sequentially), whether from somatic cells or
gametes. Exemplary tissues that are suitable for various
transformation protocols described herein include, but are
not limited to, callus tissue, existing meristematic tissue
(e.g., apical meristems, axillary buds, and root meristems)
and induced meristem tissue (e.g., cotyledon meristem and
hypocotyl meristem), hypocotyls, cotyledons, leaf disks,
pollen, embryos, and the like.
As used herein, the term "stable transformation" is
intended to mean that the nucleotide construct of interest
introduced into a plant integrates into the genome of the
plant and is capable of being inherited by the progeny
thereof. "Transient transformation" is intended to mean that
a sequence is introduced into the plant and is only temporally expressed or is only transiently present in the plant.
In specific embodiments, the inhibitory sequences of the
invention can be provided to a plant using a variety of
transient transformation methods. The inhibitory sequences
of the invention can be transiently transformed into the plant
using techniques known in the art. Such techniques include
viral vector systems and the precipitation of the polynucleotide in a manner that precludes subsequent release of the
DNA. Thus, the transcription from the particle-bound DNA
can occur, but the frequency with which it is released to
become integrated into the genome is greatly reduced. Such
methods include the use of particles coated with polyethyenlimine (PEI; Sigma #P3143).
In other embodiments, the inhibitory sequence of the
invention may be introduced into plants by contacting plants

with a virus or viral nucleic acids. Generally, such methods
involve incorporating an expression cassette of the invention
within a viral DNA or RNA molecule. It is recognized that
promoters for use in the expression cassettes of the invention
also encompass promoters utilized for transcription by viral
RNA polymerases. Methods for introducing polynucleotides
into plants and expressing a protein encoded therein, involving viral DNA or RNA molecules, are known in the art. See,
for example, U.S. Pat. Nos. 5,889,191, 5,889,190, 5,866,
785, 5,589,367, 5,316,931, and Porta et al. (1996) Molecular
Biotechnology 5:209-221; herein incorporated by reference.
Transformed cells may be grown into Nicotiana plants in
accordance with conventional methods. See, for example,
methods disclosed in Vasil and Hildebrandt (1965) Science
150:889; Negaard and Hoffman (1989) Biotechniques 7(8):
808-812. These plants may then be grown, and either
pollinated with the same transformed line or different lines,
and the resulting progeny having expression of the desired
phenotypic characteristic identified, i.e., reduced expression
of one or more cytochrome P450s that are involved in the
metabolic conversion of nicotine to nornicotine, and thus
reduced content of nornicotine, and a concomitant reduced
content of its nitrosamine metabolite, NNN, in the plant,
particularly in the leaf tissues. Two or more generations may
be grown to ensure that expression of the desired phenotypic
characteristic is stably maintained and inherited and then
seeds harvested to ensure expression of the desired phenotypic characteristic has been achieved. In this manner, the
present invention provides transformed seed (also referred to
as "transgenic seed") having a polynucleotide of the invention, for example, an expression cassette of the invention,
stably incorporated into their genome.
The compositions and methods of the invention can be
used to reduce the nornicotine content, particularly in the
leaves and stems, of any plant of the genus Nicotiana
including, but not limited to, the following species: acuminata, aifinis, alata, attenuate, bigelovii, clevelandii, excelsior, forgetiana, glauca, glutinosa, langsdorifii, longiflora,
obtusifolia, palmeri, paniculata, plumbaginifolia, qudrivalvis, repanda, rustica, suaveolens, sylvestris, tabacum,
tomentosa, trigonophylla, and x sanderae. The present
invention also encompasses the transformation of any varieties of a plant of the genus Nicotiana, including but not
limited to Nicotiana acuminata multiflora, Nicotiana alata
grandiflora, Nicotiana bigelovii quadrivalvis, Nicotiana
bigelovii wallacei, Nicotiana obtusifolia obtusifolia, Nicotiana obtusifolia plameri, Nicotiana quadrivalvis bigelovii,
Nicotiana quadrivalvis quadrivalvis, Nicotiana quadrivalvis
wallacei, and Nicotiana trigonophylla palmeri, as well as
varieties commonly known as flue or bright varieties, Burley
varieties, dark varieties, and oriental/Turkish varieties.
The transgenic plants of the genus Nicotiana as described
herein are suitable for conventional growing and harvesting
techniques, such as cultivation in manure rich soil or without
manure, bagging the flowers or no bagging, or topping or no
topping. The harvested leaves and stems may be used in any
traditional tobacco product including, but not limited to,
pipe, cigar and cigarette tobacco, and chewing tobacco in
any form including leaf tobacco, shredded tobacco, or cut
tobacco.
Thus the present invention provides a Nicotiana plant,
particularly leaf tissues of these plants, comprising an
expression cassette of the invention and a reduced amount of
nornicotine and N'-nitrosonornicotine. As used herein, the
term "a reduced amount" or "a reduced level" is intended to
refer to an amount of nornicotine and/or N'-nitrosonornicotine in a treated or transgenic plant of the genus Nicotiana

5

10

15

20

25

30

35

40

45

50

55

60

65

US 10,383,299 B2
39

40

or a plant part or tobacco product thereof that is less than
what would be found in a plant of the genus Nicotiana or a
plant part or tobacco product from the same variety of
tobacco, processed (i.e., cultured and harvested) in the same
manner, that has not been treated or was not made transgenic
for reduced nornicotine and/or N'-nitrosonornicotine. The
amount of nornicotine may be reduced by about 10% to
greater than about 90%, including greater than about 20%,
about 30%, about 40%, about 50%, about 60%, about 70%,
and about 80%.
The term "tobacco products" as used herein include, but
are not limited to, smoking materials (e.g., cigarettes, cigars,
pipe tobacco), snuff, chewing tobacco, gum, and lozenges.
The present invention also encompasses a range of tobacco
product blends that can be made by combining conventional
tobacco with differing amounts of the low nornicotine and/or
N'-nitrosonornicotine tobacco described herein. In further
embodiments, the plant or plant part of the genus Nicotiana
as described above is cured tobacco.
In some embodiments of the present invention, the
tobacco product reduces the carcinogenic potential of
tobacco smoke that is inhaled directly with consumption of
a tobacco product such as cigars, cigarettes, or pipe tobacco,
or inhaled as secondary smoke (i.e., by an individual that
inhales the tobacco smoke generated by an individual consuming a tobacco product such as cigars, cigarettes, or pipe
tobacco). The cured tobacco described herein can be used to
prepare a tobacco product, particularly one that undergoes
chemical changes due to heat, comprising a reduced amount
of nornicotine and/or N'-nitrosonornicotine in the smoke
stream that is inhaled directly or inhaled as secondary
smoke. In the same manner, the tobacco products of the
invention may be useful in the preparation of smokeless
tobacco products such as chewing tobacco, snuff, and the
like.
The tobacco products obtained from the transgenic
tobacco plants of the present invention thus find use in
methods for reducing the carcinogenic potential of these
tobacco products, and reducing the exposure of humans to
the carcinogenic nitrosamine NNN, particularly for individuals that are users of these tobacco products.
The following examples are offered by way of illustration
and not by way of limitation.

All plants were maintained in growth chambers or greenhouses using standard potting soil and fertilizer. For the
microarray studies, the metabolism of nicotine to nornicotine was accelerated by excising individual leaves and
inserting their petioles into a solution of 0.1 % ethephon or
1% sodium bicarbonate. The leaves were then placed in a
growth chamber (27° C.) for 5 to 7 hours to facilitate the
entry of the ethephon or sodium bicarbonate solutions
throughout the transpirational stream. The treated leaves
were placed in small plastic storage bags after being lightly
sprayed with water (to maintain high humidity) and cured
for three days at 30° C. in the dark. To enhance the nicotine
to nornicotine conversion in the transgenic plants generated
in this study, detached leaves were dipped into a solution of
0.2% ethephon, dried, and cured in plastic storage bags for
seven days at room temperature in the dark.
cDNA Libraries and Expressed Sequence Tags
Total cellular RNA was isolated from senescing leaf tissue
of Burley lines DH 91-1307-46 (NC) and DH 91-1307-46
(Con) using the TRizol® reagent according to the manufacturer's protocol (Invitrogen). PolyA+ RNA was isolated
from total RNA using the MessageMaker system (Invitrogen), and cDNA was subsequently synthesized and cloned
into the lambda ZAP II phage vector using the ZAP-cDNA
Synthesis and Gigapack III Gold Cloning Kit (Stratagene).
Aliquots of the phage libraries were converted to pB!uescript-based plasmid libraries following the mass excision
protocol outlined by Stratagene.
Thousands of colonies from both the converter and nonconverter libraries were grown on selective solid media and
picked into 384-well plates containing Luria broth (with
ampicillin) in 10% glycerol to facilitate long term storage of
the clones at -80° C. Over 11,000 clones from each library
were transferred from the 384-well plates to 96-well growth
blocks and grown in selective media. Plasmids were isolated
in 96-well format using the R.E.A.L. Preparation Kit (Qiagen) with the aid of a BioRobot 3000 Workstation (Qiagen).
To generate the ESTs, the plasmid clones were sequenced
using the T3 primer (Qiagen) and BigDye® Terminator
system (Applied Biosystems) according to the BigDye®
cycle sequencing protocol. Performa® DTR 96-well plates
(Edge Biosystems) were used to remove the unincorporated
dye from the sequencing reactions prior to loading the
samples onto a Perkin Elmer Prism 3700 96-Capillary
Automated DNA Sequencer.
Preparation of DNA Chips
To obtain DNAs suitable for spotting onto glass slides, the
M13 forward and reverse sequencing primers (Qiagen) were
used as PCR primers to amplify cDNA inserts from the
plasmids containing cDNAs represented in the EST databases. Plasmid clones were subjected to PCR in 96-well
format using an Applied Biosystems Gene Amp 9700 model
thermocycler. The resulting PCR products were processed
through Millipore Multiscreen™ PCR or Montage™ PCµ96
purification systems. The resulting products were transferred
into 384-well plates containing equal volumes of DSMO.
The final DNA concentrations were estimated to be equal to
or greater than 0.1 mg/ml. The DNAs were subsequently
spotted onto amino silane-coated slides (Corning® GAPS
II) using an Affymetrix GMS 417 array printer. DNAs were
immobilized to the slide surface by UV crosslinking (-120
mJ/m2 ), followed by baking at 75° C. for two hours.
Microarray Hybridization and Analysis
The amino ally! dUTP-based indirect method of dye
incorporation described by "The Institute of Genome
Research" (http://pga.tigr.org/protocols.html) was used to
label nonconverter and converter RNAs with Cy3 and Cy3

EXPERIMENTAL
The following materials and protocols were utilized in the
experiments described herein below.
Plant Materials
All plant materials utilized in these experiments were
provided by Dr. Earl Wernsman, Department of Crop Science, North Carolina State University. DH 91-1307-46 (NC)
and DH91-1307-46 (Con) are near-isogenic doubled haploid
Burley lines (nonconverter and converter, respectively)
recovered from the same maternal haploid plant. Burley
lines DH 98-326-3 (nonconverter) and DH 98-326-1 (converter), and DH 98-325-5 (nonconverter) and DH 98-325-6
(converter) represent two additional pairs of near-isogenic
lines. SC58 is a flue-cured tobacco variety, nonconverter
individuals of which are designated SC58 (crer)- SC58
(CrCr) is a near-isogenic stable converter line that originated though the introgression of the single dominant converter locus (Cr) found in the tobacco progenitor species N.
tomentosiformis into SC58 (Mann et al. (1964) Crop Sci.
4:349-353. After eight additional backcrosses to SC58, the
near-isogenic SC58 (CrCr) line was created and subsequently maintained via self-fertilization.
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fluorescent dyes (Amersham Biosciences). Briefly, 20 µg of
total RNA was reverse transcribed in a 30 µI volume
containing 400 units of SuperScript II RT (Invitrogen), 6 ng
random hexamer primers, 0.5 mM each of dATP, dCTP, and
dGTP, 0.3 mM dTTP, and 0.2 mM amino ally! dUTP
(Sigma) in first strand synthesis buffer (Invitrogen). Reactions were incubuted for 6 to 14 hours at 42° C., followed by
hydrolysis of the RNA with NaOH. The resulting first strand
cDNA molecules were colunm purified (Qiagen) and
washed with phosphate buffer. Coupling reactions of the
NHS-ester Cy3 or Cy5 fluorescent dyes to the cDNA
occurred during incubation in 0.05 M sodium carbonate
buffer (pH 9.0) and 25% DMSO at room temperature for 1.5
hours.
Microarray slides were prehybridized in a solution of
5xSSC, 0.1 % SDS, and 1% BSA at 42° C. for 45 minutes,
rinsed gently with dH 2 O and isopropanol, and dried by low
speed centrifugation. The Cy3- and Cy5-labeled cDNAs
were colunm purified (Qiagen), combined, and hybridized to
the DNA slides in a solution containing 5xSSC, 0.5% SDS,
5xDenhardt's, 0.45 µg/µl Poly A RNA, 0.45 µg/µl calf
thymus DNA, and 50% formamide. The slides were incubated with the hybridization solution for 14 to 16 hours at
42° C. Post-hybridization washes consisted of sequential
4-minute incubations with the following solutions: lxSSC,
0.2% SDS; 0.lxSSC, 0.2% SDS; 0.lxSSC, and a final 10
second rinse with 0.OlxSSC.
The microarrays were subsequently scanned using ScanArray 2.1 (GSI Lumonics) or ScanArray Express (PerkinElmer). Sequential scanning for Cy5 and Cy3 fluorescence
was performed at a maximal resolution of 10 gm/pixel, and
laser power and PMT gain adjusted to provide reliable and
equivalent signal strengths. The acquired array images were
quantified for signal intensity with QuantArray™ analysis
software (PerkinElmer), using the histogram-based method.
Total intensities were used as quantification output fields,
and the acquired data sets were saved as Unicode, tabdelimited text files. Importation of the text files into Microsoft Excel enabled the subsequent calculation of Cy5/Cy3
and Cy3/Cy5 ratios, the statistic we employed for the
identification of candidate genes.
Cloning Full-Length andAdditional Members of the 3D C12
Gene Family
To clone the entire coding region of3D_C12 and 7D_A06
a modified 5'-RACE strategy was employed using a pB!uescript II vector-specific forward primer (BlueSK;
5'-CGCTCTAGAACTAGTGATC-3'; SEQ ID NO: 17) and a
set of gene-specific reverse primers. Two 3D_Cl2-specific
reverse primers were designed, one of which is complementary to the downstream portion of the 3' untranslated region
(5'-TTTTTGGGACAATCAGTCAA-3'; SEQ ID NO:18)
and the other complementary to a sequence within the
coding region (5'-GTTAGATTTATCGTACTCGAATT-3';
SEQ ID NO:19). For the former primer, the first five Ts are
complementary to the polyA tail of the transcript. A
7D_A06-specific reverse primer (5'-TTCATTTCAAATTATTTTATGCACCA-3'; SEQ ID NO:20) was also designed,
and is complementary to a segment in the 3' untranslated
region of this gene. PCR reactions contained 10 ng of
converter tobacco leaf cDNA library (within the pB!uescript
vector) as template, 2 µM concentration of each primer, 350
µM of each dNTP, and 1.5 mM MgCl 2 in a final reaction
volume of 50 µL. Amplification was initiated by the addition
of 2.5 units of UniPol enzyme mix using conditions
described by the manufacturer (Roche). After an initial
denaturation step at 94° C. for 4 minutes, the samples were
subjected to 30 cycles of denaturation at 94° C. for 15

seconds, annealing at 57° C. for 30 seconds, and extension
at 72° C. for 90 seconds. A final extension step at 72° C. for
10 minutes was included at the end of the 30 cycles. The
amplicons were ligated into the pGEM Easy TIA vector
(Promega), and 10 randomly selected clones from each
amplification were subjected to DNA sequence analysis.
Nucleic acid and predicted protein sequences of the various
members of the 3D_C12 gene family were analyzed and
compared using the BLAS TX (Altschul et al. (1997) Nucleic
Acids Res. 25:3389-3402), Clusta!W (Higgins et al. (1994)
Nucleic Acids Res. 22:4673-4680) and GAP (University of
Wisconsin Genetic Computing Group software package)
algorithms.
The above described strategy was effective in identifying
full-length sequence information for 3D_C12 and 7D_A06.
In addition, PCR amplifications using the PCR primer
internal to the 3D_C12 coding region gave rise to partialsequence information for the unique 3D_Cl2-15 cDNA. In
an attempt to obtain full-length sequence information for
3D_Cl2-15, a gene-specific primer complementary to the 5'
terminus of its coding region (5'-ATGGTTTTTCCCATAGAAGCC-3'; SEQ ID NO:21) was used in conjunction with
a pB!uescript-specific reverse primer (5'-TCGAGGTCGACGGTATC-3'; SEQ ID NO:22). Although a full-length
3D_Cl2-15 cDNA was not recovered, this amplification
resulted in the isolation of 3D_Cl2-7, which proved to be
another unique member of the 3D_C12 gene family.
Transgenic Plant Analysis
The RNAi-based gene silencing constructs were
assembled in a version of the pKYL80 cloning vector
(Schardl et al. (1987) Gene 61:1-11) that was engineered to
contain a 151-bp fragment of the soybean FAD3 gene intron
between the Xhol and Sad restriction sites of the polylinker
(pKYLX80I). To create a construct in which the FAD3
intron was flanked by a sense and antisense fragment of
3D_C12, a 99-bp region located immediately upstream of
the stop codon of the 3D_C12 cDNA (FIGS. 3A-3G) was
cloned between the HindIII-Xhol and Sacl-Xbal restriction
sites of pKYLX80I in its sense and antisense orientation,
respectively. The resulting HindIII-Xbal fragment containing the 3D_C12 sense arm, FAD3 intron, and 3D_C12
antisense arm was subcloned into the pKYLX71 plant
binary expression vector (Maiti et al. (1993) Proc. Natl.
Acad. Sci. USA 90:6110-6114) between the 35S CaMV
promoter and a rubisco small subunit terminator.
Overexpression constructs were created by replacing the
3-glucuronidase ORF of the plant binary expression vector
pBI121 (Clontech) with the full-length coding regions of the
3D_C12, 7D_A06, and 3D_Cl2-7 cDNAs. This placed the
tobacco P450s under the transcriptional control of the 35S
CaMV promoter. The pBI121- and pKYLX71-based constructs were transformed into Agrobacterium tumefaciens
strain LBA 4404 and introduced into tobacco cul ti vars Petite
Havana and DH98-325-6 (converter), respectively, using
established protocols (Horsch et al. (1985) Science 227:
1229-1231).
Northern Blot Analysis
Total cellular RNAs were isolated from tobacco leaves
using the TRIZOL® method as described by the manufacturer (Invitrogen). Five to ten micrograms of RNA were size
fractionated on a 1.2% agarose gel prepared in TBE buffer.
RNA immobilization, probe labeling, and signal detection
were carried out using the DIG nucleic acid labeling and
detection kits according to the manufacturer's instructions
(Roche). Alternatively, probes were synthesized using 32 PdCTP according to protocols accompanying the Random
Primed DNA Labeling kit (Roche).
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Alkaloid Analysis
Tobacco leaves were harvested and air dried in an oven at
65° C. for 2 days. A 100 mg sample of crushed, dried leaf
was added to 0.5 ml of 2 N NaOH in a 20 mL scintillation
vial. The sample was mixed and allowed to incubate for 15
minutes at room temperature. Alkaloids were extracted by
the addition of 5 mL of extraction solution [0.04% quinoline
(wt/vol) dissolved in methyl-t-butyl ether] and gently rotated
on a linear shaker for 3 hours. Following phase separation,
an aliquot of the organic phase was transferred to a sample
vial. Samples were analyzed using a PerkinElmer Autosystem XL gas chromatograph equipped with a flame ionization
detector, a 4 mm split/splitless glass liner, and a 30 mx0.53
mm ID DB-5 colunm. Chromatographic conditions were as
follows: detector temperature: 250° C.; injector temperature:
250° C.; helium flow rate at 120° C.: 20 mL/min; injection
volume: 2 µL; column conditions: 120° C., hold 1 minute,
120-280° C. at 30° C./minute ramping rate, hold at 280° C.
for 2 minutes. Alkaloid composition was determined by the
TotalChrome Navigator software using a calibration curve.

nonconverter individuals (Fannin and Bush (1992) Med. Sci.
Res. 20:867-868; Shi et al. (2003) J. Agric. Food Chem.
51:7679-7683).
To minimize the variability inherent with microarray
experiments, reciprocal experiments were conducted simultaneously. In this manner, DH 98-325-5 RNA was labeled
with Cy5 and DH 98-325-6 RNA was labeled with Cy3, and
then in a reciprocal experiment DH 98-325-5 RNA was
labeled with Cy3 and DH 98-325-6 RNA was labeled with
Cy5 (collectively referred to as Exp. 2.1). Similarly, DH
98-326-3 and DH 98-326-1 RNAs were labeled with Cy3
and Cy5, respectively, in one experiment, and then the same
RNAs were labeled with Cy5 and Cy3, respectively, in a
reciprocal experiment (collectively referred to as Exp. 2.2).
Even when conducted reciprocally, the results of any
given microarray experiment are likely to include "false
positives," representing genes that are differentially regulated between a specific genotypic pair and/or uniquely in
response to a specific treatment, as opposed to differences
directly associated with the conversion phenomenon. To
define the set of candidate genes that are most likely to be
upregulated due to the conversion process, cDNAs were
identified that met the following criteria: for any set of
reciprocal experiments (i.e., Exp. 2.1, or Exp. 2.2), the
hybridization intensity of a given cDNA had to be at least
2-fold higher with the converter probe than nonconverter
probe in at least one of the hybridizations, and not less than
1.5-fold higher in the reciprocal experiment.
Experiment 2.1Leaves from near-isogenic lines DH 98-325-5 and DH
98-325-6 were treated with ethephon and cured for 3 days at
30° C. Alkaloid analysis revealed that virtually all of the
nicotine had been metabolized to nornicotine in the DH
98-325-6 leaf during this period while minimal nornicotine
was observed in the DH 98-325-5 leaf. RNAs from the DH
98-325-5 nonconverter plant were labeled with the Cy3
fluorescent dye, and RNAs extracted from a DH 98-325-6
(converter) leaf were labeled with Cy5. The Cy3- and
Cy5-labeled cDNAs were incubated together on the same
DNA chip and allowed to hybridize overnight.
Experiment 2.2A microarray analysis similar to Exp. 2.1 was conducted
using the DH 98-326-3 (nonconverter) and DH 98-326-1
(converter) near-isogenic lines. In these experiments, leaves
from each genotype were treated with 1% sodium bicarbonate and cured for 3 days at 30° C. At the end of the treatment
period, nicotine was the predominant alkaloid in the DH
98-326-3 leaf, while nearly all of the alkaloid in the DH
98-326-1 leaf was nomicotine. As described for Exp. 2.1,
these experiments were reciprocally conducted.
Results
In both Experiment 2.1 and Experiment 2.2, the great
majority of the 4992 cDNAs spotted on the glass slides
showed no substantial differences in their hybridization
intensities to the competing Cy3- and Cy5-labeled probes.
Of the 4992 cDNAs spotted on the glass slides, only five
showed at least 2-fold higher expression in one hybridization and not less than 1.5-fold in the reciprocal hybridization
for both Exp. 2.1 and Exp. 2.2. These entries were designated 3D_C12, 7D_A06, 27C_C12, 33A_D06, and
34D_F06. BLASTX analysis of the partial sequence information for 3D_C12 and 7D_A06 found in our EST database
predicted that the cDNAs encode two closely related P450
enzymes. 27C_C12 and 33A_D06 were predicted to encode
glycine-rich cell wall proteins, displaying over 90%
sequence identity to small tobacco glycine-rich proteins
found in GenBank (e.g., Accession No. AAK57546). Clone
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Example 1: Generation of EST Databases
RNAs isolated from senescing leaves of the converter
genotype DH 91-1307-46(Con) and its near-isogenic nonconverter counterpart DH 91-1307-46(NC) were used to
generate cDNA libraries. High-throughput automated DNA
sequencers were initially used to generate single-run
sequence information (ESTs) for 11,136 randomly chosen
cDNAs from the converter library. The local alignment
search tool BLASTX (Altschul et al. (1990) J. Mal. Biol.
215:403-410) was used to compare the predicted protein
sequence of each tobacco cDNA with the nonredundant
protein database curated by the National Center for Biotechnology Information of the National Library of Medicine and
National Institutes of Health. Subsequently, a similar annotated EST database was generated by conducting sequencing
runs on 11,904 cDNAs selected from the nonconverter
library.
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Example 2: Microarray Analyses of Converter
CDNA Library
Methods
Upon completion of the EST database generated from the
converter cDNA library, the inserts from 4992 clones were
amplified by PCR and spotted onto glass slides. Given the
possibility that the nicotine demethylase enzyme may be
catalyzed by an enzyme of the P450 class of oxidative
enzymes, special attention was given to library entries that
were predicted by BLASTX analysis to encode P450s.
From visual inspection of the BLASTX results, it was
estimated that 31 unique P450 genes were represented in the
database. When selecting specific 96-well plates to be
included on the microarray, care was taken to ensure that all
unique P450 genes would be included among the 4992
cDNAs selected.
RNAs isolated from the near-isogenic Burley genotypes
DH 98-326-3 (nonconverter) and DH 98-326-1 (converter),
and DH 98-325-5 (nonconverter) and DH 98-325-6 (converter) were used to generate Cy3- and Cy5-labeled cDNAs.
To maximize the metabolic conversion of nicotine to nornicotine in converter genotypes, detached leaves were
treated with sodium bicarbonate or ethephon prior to curing,
treatments that have been shown to accelerate nornicotine
production in converter plants while having no effect in
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34D_F06 was found to contain a double cDNA insert, one
insert showing homology to serine/threonine protein
kinases, and the other showing high sequence identity to the
same glycine-rich cell wall proteins as the 27C_C12 and
33A D06 cDNAs.

6963-member unigene chip that is representative of the
closely-related P450 gene family that includes 3D_C12 and
7D_A06 (3D_C12 and 7D_A06 themselves were not spotted on the unigene slide). No other cDNAs on the array in
Example 3, which included representatives of the contigs
containing the glycine-rich protein-encoding 27C_C12 and
33A_D06 and 34D_F06 cDNAs, scored positive by the
defined criteria and also scored positive in Exp. 2.1 or Exp.
2.2 of Example 2 above, regardless of whether the results
were compared individually or collectively.

5

Example 3: Microarray Analysis of CDNA
Non-Converter Library
Upon completion of the EST database from the nonconverter library (generated from senescing leaves of genotype
DH 91-1307-46 (NC)), another set of microarray experiments was initiated. For this next generation of microarrays,
the goal was to produce glass slides containing the complete
nonredundant set of genes represented in both libraries.
To obtain an estimate of the number of unique genes that
are represented in the database, clustering analysis was
conducted to identify ESTs predicted to be represented
multiple times in the database (contigs) versus those predicted to be represented only once (singletons) (Huang and
Madan (1999) Genome Res. 9:868-877). Due to the nature of
the clustering algorithms, sequences showing high, but
imperfect, sequence identities are clustered into the same
contig. The total set of predicted unique genes, or uni genes,
within a database is calculated as the sum of the contigs and
singletons. Clustering analysis of the combined converter
and nonconverter databases predicted 2246 contigs and 4717
singletons for a total of 6,963 unigenes. Inserts from all
singletons and an individual from each contig were amplified by PCR and spotted onto glass slides, resulting in a gene
chip containing the complete 6,963 unigene set.
In addition to creating a new DNA chip, the genetic
materials used to generate hybridization probes also differed
from those used in Example 2. SC58 is a flue-cured tobacco
variety, nonconverter individuals of which are designated
SC58(crer)- SC58(CrCr) is a near-isogenic stable converter
line that originated though the introgression of the single
dominant converter locus (Cr) found in the tobacco progenitor species N. tomentosiformis into SC58 (Marni et al.
(1964) Crop Sci. 4:349-353). After eight additional backcrosses to SC58, the near-isogenic SC58(CrCr) line was
created and subsequently maintained via self-fertilization.
The conversion phenotype of SC58(CrCr) plants is unique
with respect to standard converter tobacco lines in that the
metabolism of nicotine to nomicotine in the leaf does not
require senescence or curing. Plants possessing the Cr
converter locus from N. tomentosiformis contain nornicotine
as the predominant alkaloid even in green leaf tissue (Wernsman and Matzinger (1968) Tab. Sci. 12:226-228).
RNAs isolated from green leaf tissue of SC58(CrCr) and
SC58(CrCr) were labeled with Cy3 and Cy5, respectively,
and simultaneously hybridized to a DNA chip containing the
entire 6,963 unigene set of cDNAs. The fluorescent dyes
were reversed to produce the probes for a reciprocal experiment as described in Exps. 2.1 and 2.2 of Example 2.
Results
Results were evaluated using the same criteria as in
Example 2, i.e., individual cDNAs were identified that
showed at least 2-fold enhanced hybridization to the labeled
SC58(CrCr) versus SC58(crer) cDNAs in one experiment
and at least 1.5-fold enhancement in the reciprocal assay.
Results were compared to those from Exp. 2.1 and Exp.
2.2 in Example 2 above. Enhanced hybridization of converter RNAs to cDNAs encoding members of the same
closely related P450 family was the only result shared by all
three microarray experiments using the defined criteria. 131
A_A02 is the name of the cDNA that was spotted onto the
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TABLE 1
Microarray results of members oftbe 3D_Cl2 gene family
15
Experiment 2.1
(reciprocal)

Experiment 2.1

20

cDNA
3D_Cl2
7D_A06

Cy3

Cy5

Cy5/
Cy3

Cy5

Cy5/
Cy3

ratio

Cy3
reading

reading

reading

reading

ratio

15514.14
15238.23

25928.95
37196.19

1.67
2.44

19355.85
13651.03

9507.87
8121.04

2.04
1.68

Experiment 2.2
(reciprocal)

Experiment 2.2

25

3D_Cl2
30 7D_A06

Cy3

Cy5

Cy5/
Cy3

Cy5

Cy5/
Cy3

ratio

Cy3
reading

reading

reading

reading

ratio

12756.43
7571.06

28669.28
19180.94

2.25
2.53

32198.81
42408.85

16166.13
18440.17

1.99
2.30

Example 3
(reciprocal)

Example 3
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Cy3

Cy5

Cy5/
Cy3

Cy5

Cy5/
Cy3

ratio

Cy3
reading

reading

reading

reading

ratio

11138.96

19638.82

1.76

36963.45

10085.25

3.67

Combined Results
The combined results of microarray experiments
described above defined members of a closely related P450
gene family, hereafter referred to as the 3D_C12 family, to
be the best candidates for playing a direct role in the
metabolic conversion of nicotine to nornicotine in converter
tobacco plants. The hybridization results of the members of
this P450 family in each of the three microarray experiments
are shown in Table 1. The results of the microarrays were
independently confirmed using Northern blotting assays. As
shown in FIG. 2, an approximately 2-fold higher signal was
observed in senescing, cured converter leaves compared to
their nonconverter counterparts when RNA blots were incubated with a radiolabeled 7D_A06 hybridization probe.
Example 4: Sequence Analysis of the 3D_C12
Gene Family
Once microarray experiments defined 3D_C12 and
7D_A06 as potentially being involved in the conversion
process, obtaining complete DNA sequence information for
these genes became the next step in their characterization.
The original 3D_C12 and 7D_A06 clones that were
sequenced when generating the EST database described
elsewhere herein (and spotted onto the microarrays) were
not full-length cDNAs. To obtain a full-length sequence,
primers were generated corresponding to regions in the 3'
flanking region and in the interior of the coding regions that
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were sufficiently polymorphic to distinguish between
7D_A06 and 3D_C12. These gene-specific primers were
used in combination with primers specific to the cloning site
of pB!uescript II to amplify cDNAs from the converter
cDNA library in an attempt to obtain sequence that would
include the complete 5' ends of the 3D_C12 and 7D_A06
reading frames.
This strategy led to the determination of the DNA
sequence corresponding to the complete coding regions of
3D_C12 (nt 1-1551 of SEQ ID NO:1; predicted amino acid
sequence shown in SEQ ID NO:2) and 7D_A06 (nt 1-1554
of SEQ ID NO:7; predicted amino acid sequence shown in
SEQ ID NO:8) (FIGS. 3A-3G and 4). GAP analyses of the
3D_C12 and 7D_A06 DNA and predicted protein sequences
showed that they share 93.4% DNA sequence identity and
92.3% identity at the protein level (Tables 2 and 3). Initial
BLASTX analysis against the nonredundant GenBank database revealed that 3D_C12 and 7D_A06 share greatest
sequence homology to CYP82El, a tobacco P450 gene of
unknown function that is upregulated in response to fungal
elicitors (Takemoto et al. (1999) Plant Cell Physiol.
40:1232-1242). The CYP82El protein is 66.9% and 67.5%
identical to the predicted amino acid sequences of 3D_C12
(SEQ ID NO:2) and 7D_A06 (SEQ ID NO:8), respectively,
and the CYP82El DNA sequence is 72.1 % and 73.5%
identical to the respective coding sequences for 3D_C12 (nt
1-1551 of SEQ ID NO:1) and 7D_A06 (nt 1-1554 of SEQ
ID NO:7).

corresponding DNA sequence of 3D C12 and 92.6% identical to the same region of 7D_A06 (Table 2).
Because the 3D_Cl2-15 fragment represented an additional, distinct member of the 3D_C12 gene family, an
attempt was made to obtain a full-length cDNA sequence of
this gene. A PCR primer specific to the first seven codons of
the 3D_Cl2-15 reading frame was used in combination with
a pB!uescript II-specific primer in an amplification reaction
using our converter cDNA library as template. Sequence
analysis of several independent amplification products failed
to reveal a full-length 3D_Cl2-15 gene. Instead, a new
member of this family was recovered, designated 3D_Cl2-7
(FIGS. 3A-3G; coding sequence set forth as nt 1-1551 of
SEQ ID NO:5). Across the full-length nucleotide sequence
shown in SEQ ID NO:5, 3D_Cl2-7 shares 93.7% nucleotide
sequence identity with 3D_C12 (across SEQ ID NO:1),
94.0% nucleotide sequence identity with 7D_A06 (across
SEQ ID NO:7), and 93.1% identity over the corresponding
region of fragment 3D_Cl2-15 (SEQ ID NO:9) (Table 2).
The predicted amino acid sequence of 3D_Cl2-7 (SEQ ID
NO:6) is 92.8% identical to the 3D_C12 protein (SEQ ID
NO:2), and 94.8% identical to the 7D_A06 protein (SEQ ID
NO:8) (Table 3).
Two additional members of the 3D_C12 family were also
identified. A gene designated 3D_Cl2-10 (FIGS. 3A-3G;
coding sequence set forth as nt 1-1551 of SEQ ID NO:3;
predicted amino acid sequence set forth in SEQ ID NO:4)
was recovered from an amplification reaction using a PCR
primer complementary to a sequence in the 3' flanking
region of 3D_C12 together with a Bluescript II-specific
primer (and the converter library as template). 3D_Cl2-10
differs at only five nucleotide positions from the 3D_Cl2-7
nucleotide sequence (SEQ ID NO:5) (FIGS. 3A-3G), and at
only two amino acids positions from the predicted
3D_Cl2-7 protein product (SEQ ID NO:6) (FIG. 4).
With the completion of the nonconverter EST database,
another member of the 3D_C12 gene family was revealed.
The partial DNA sequence of 131A_A02 (SEQ ID NO:11;
predicted amino acid sequence set forth in SEQ ID NO:12)
that is found in this database is 98.0% identical to the
corresponding sequence of3D_C12, and 94.0% identical to
the same region of7D_A06 (FIGS. 3A-3G and Table 2). As
described in the previous section, 131A_A02 is a member of
the 3D_C12 gene family that was represented on the comprehensive unigene chip used in microarray assays as
described elsewhere herein.
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TABLE 2
Nucleotide sequence identities between members of the 3D_Cl2 gene
famil.

7D_A06
3D_Cl2-7
3D_Cl2-10
3D_Cl215*
131A_A02*

3D_Cl2

7D_A06

3D_Cl27

3D_Cl210

93.4**
93.7
93.7
95.5

94.0
94.4
92.6

99.7
93.1

92.8

98.0

94.0

93.4

93.1

3D_Cl215*

35

40
93.1

*partial sequences
**numbers indicate percentages
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TABLE 3

Example 5: Transgenic Plant Analysis of Members
of the 3D_C12 Gene Family

Predicted amino acid sequence identities between full-length members of
the 3D C12 gene family.
50
7D_A06
3D_Cl2-7
3D_Cl2-10

3D_Cl2

7D_A06

3D_Cl2-7

92.3*
92.8
92.5

94.8
94.4

99.6

**numbers indicate percentages

In addition to enabling the acqms1t10n of full-length
sequence information for the 3D_C12 and 7D_A06 cDNAs,
the above described PCR amplifications yielded additional
products that were closely related to, yet clearly distinct
from, the 3D_C12 and 7D_A06 cDNA sequences. Using a
primer directed against a sequence interior to the 3D_C12
cDNA, in combination with a primer specific to pB!uescript
II, a unique sequence designated 3D_Cl2-15 (FIGS. 3A-3G;
SEQ ID NO:9; predicted amino acid sequence shown in
SEQ ID NO:10) was amplified in addition to the expected
3D_C12 product. 3D_Cl2-15 is 95.5% identical to the
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To determine whether members of the 3D_C12 family of
cytochrome P450 genes are involved in the metabolic conversion of nicotine to nornicotine, transgenic plants were
generated using constructs designed to either enhance or
inhibit gene expression. To test the effects of down-regulating gene activity, an RNA interference (RNAi) strategy was
employed. A 99-bp region of 3D_C12 located immediately
upstream of the stop codon (FIGS. 3A-3G), was used to
create a construct that would form a dsRNA hairpin within
the plant cell. Such dsRNA structures are known to activate
an RNAi silencing complex that leads to the degradation of
both transgene RNAs and endogenous RNAs that are identical or highly homologous to the sequence found in the
dsRNA (Wesley et al. (2001) Plant J. 27: 581-590; Waterhouse & Helliwell (2002) Nat. Gen. Rev. 4: 29-38).
Given that each member of the 3D_C12 characterized as
described herein shares over 90% DNA sequence identity, an
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RNAi construct synthesized against one member was
expected to silence the entire gene family. Specifically, the
RNAi construct generated against the 3D_C12 sequence
shares sequence identities of 90/99 and 91/99 with the
7D_A06 and 3D_Cl2-7 cDNAs, respectively, over this
region (FIGS. 3A-3G). The 3D_C12/RNAi construct (also
referred to in Example 7 as the 3D_C12Ri99 construct) was
cloned downstream of the constitutive 35S promoter of
cauliflower mosiac virus (CaMV) and introduced into the
strong converter Burley tobacco line DH 98-325-6 using
Agrobacterium-mediated transformation.
A hallmark of RNAi-mediated silencing is the marked
reduction in steady-state transcript accumulation of the gene
whose activity has been down-regulated. To confirm that
gene silencing of the 3D_C12 gene family had occurred in

conversion and would thus potentially complicate interpretation of results (e.g., assessing whether a novel phenotype
was solely attributable to the transgene as opposed to being
the result of the plant having undergone genetic conversion).
Results
Given the high degree of variability typically observed
among independent transgenic plants transformed with the
same trans gene construct, 10 independently transformed
individuals were selected to assess the effects of the
3D_C12/RNAi construct on the metabolic conversion of
nicotine to nomicotine. Leaves from each of the 10 3D_C12/
RNAi individuals, in addition to two control plants transformed with the pBI121 vector alone, were treated with
ethephon and cured for seven days. Alkaloid analysis of
these materials is shown in Table 4.
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TABLE 4
Alkaloid analysis of DH 98-325-6 plants independently transformed with the 3D_Cl2/RNAi
construct (and pBI121 vector control). Leaves were treated with ethephon and cured for
seven da s.

Sample
3D_Cl2 RNAi (1)
3D_Cl2 RNAi (2)
3D_Cl2 RNAi (3)
3D_Cl2 RNAi (4)
3D_Cl2 RNAi (5)
3D_Cl2 RNAi (6)
3D_Cl2 RNAi (7)
3D_Cl2 RNAi (8)
3D_Cl2 RNAi (9)
3D_Cl2 RNAi
(10)
vector control (3)
vector control (11)

%

%

%

%

%

Nicotine*

Nornicotine*

Anabasine*

Anatabine*

Conversion**

3.149
2.569
2.175
3.517
1.085
0.025
0.027
2.268
2.197
2.434

0.100
0.193
0.064
0.125
0.868
2.260
1.867
0.128
0.133
0.112

0.012
0.009
0.007
0.012
0.009
0.011
0.011
0.009
0.008
0.009

0.159
0.110
0.080
0.139
0.119
0.122
0.122
0.102
0.099
0.110

2.8
7.0
2.9
3.4
44.4
98.9
98.6
5.3
5.7
4.4

1.811
0.290

1.1735
2.090

0.G18
0.013

0.170
0.143

48.9
87.8

*percentage of leaf dry weight
**[% nornicotine/(% nicotine+ nornicotine)] x 100

the plants showing low nornicotine phenotypes, a Northern
blot analysis was conducted using RNAs isolated from three
of the transgenic plants possessing 3D_C12/RNAi constructs and displaying low nomicotine phenotypes, two
individuals transformed with the 3D_C12/RNAi construct
yet still showing high levels of nornicotine, and one of the
vector-only control plants.
To assess the affects of overexpression of gene activity,
the cDNAs from the three members of the 3D_C12 gene
family for which we first obtained full-length sequence
information (3D_C12, 7D_A06, and 3D_Cl2-7) were
cloned in their sense orientations downstream of the 35S
CaMV promoter. These constructs were subsequently introduced into N. tabacum cultivar Petite Havana using Agrobacterium-mediated transformation. The Petite Havana line
is commonly used by researchers because of its shorter
stature and abbreviated generation time in relation to commercial tobacco cultivars. The converter/nonconverter status
of the Petite Havana cultivar is unknown, but the alkaloid
assays of the present application clearly showed that the
plants in our possession were strong converters.
Although the host plants in these experiments were converters, the present strategy was to conduct alkaloid assays
on green, non-cured tissue, where minimal nomicotine accumulates in converter and nonconverter plants alike (and the
35S CaMV promoter is very active). In fact, a nonconverter
line was purposely chosen because tissue culturing, as
required when conducting Agrobacterium-mediated transformation, is known to enhance the frequency of genetic
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Typical of line DH 98-325-6, ethephon treatment and
curing resulted in substantial nomicotine production in the
two control plants (48.9% and 87.8% conversion of nicotine
to nomicotine ). In dramatic contrast, seven of the ten
independent transgenic plants possessing the 3D_C12/RNAi
construct displayed minimal nicotine to nomicotine conversion, with conversion percentages ranging from 2.8 to 7.0
percent. The other three 3D_C12/RNAi lines displayed
alkaloid contents similar to the vector-only control plants.
Concentrations of the minor alkaloids anabasine and anatabine did not appear to be significantly influenced by the
presence or absence of the 3D_C12/RNAi transgene (Table
4).
Although the cDNA insert of the 3D_Cl2-7 gene was
used as the specific hybridization probe, at the hybridization
and wash conditions used in this experiment, cross-hybridization to the entire 3D_C12 gene family would be expected.
As shown in FIG. 5, a strong hybridization signal was
detected in each plant showing a high nomicotine phenotype, and minimal hybridization was detected in the plants
transformed with the 3D_C12/RNAi construct that showed
a low nomicotine phenotype. We thus conclude that the
effective silencing of the 3D_C12 gene family inhibits the
metabolic conversion of nicotine to nornicotine in tobacco.
Alkaloid analysis of the Petite Havana transgenic plants is
shown in Table 5. Four independently transformed plants
containing the 35S:3D_C12 and 35S:3D_Cl2-7 constructs
were tested along with seven independent 35S:7D_A06
individuals and three plants independently transformed with
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the pBI121 control vector. As expected, the green, non-cured
leaves of the three vector-only control plants contained
minimal amounts of nornicotine. Likewise, all plants transformed with the 35S:3D_C12 and 35S:7D_A06 constructs
showed minimal metabolic conversion of nicotine to nornicotine. A very different phenotype, however, was observed
with plants transformed with 35S:3D_Cl2-7. All four plants
independently transformed with this construct contained
nornicotine as the predominant alkaloid in the green, nontreated leaf; nicotine to nornicotine conversion percentages
ranged from 94.6 to 98.6.

gene is expressed in its sense orientation (Fagard and
Vaucheret (2000) Annu. Rev. Plant Physiol. Plant Mal. Biol.
51: 167-194).
If plant 35S:3D_C12 (1) was truly displaying a cosuppression phenotype, this phenotype would be expected to be
maintained even upon ethephon treatment and curing of the
leaves, similar to the low nornicotine phenotypes conferred
by the 3D_C12/RNAi construct in the converter genotype
DH 98-325-6 as described above. To test this prediction,
alkaloid profiles were determined on ethephon treated, cured
leaves of 35S:3D_C12 (1) and two vector-only control

5

10

TABLE 5
Alkaloid analysis of individual Petite Havana plants transformed with 3D_Cl2,
3D_Cl2-7, 7D_A06 constructs or the pBI121 vector control. Green
leaves were harvested and analyzed without treatment or curing.

Sample
vector control (2)
vector control (8)
vector control (10)
35S:3D_Cl2 (1)
35S:3D_Cl2 (2)
35S:3D_Cl2 (3)
35S:3D_Cl2 (4)
35S:3D_Cl2-7 (1)
35S:3D_Cl2-7 (2)
35S:3D_Cl2-7 (3)
35S:3D_Cl2-7 (4)
35S:7D_A06 (1)
35S:7D_A06 (2)
35S:7D_A06 (4)
35S:7D_A06 (5)
35S:7D_A06 (6)
35S:7D_A06 (7)
35S:7D_A06 (8)

%

%

%

%

%

Nicotine*

Nornicotine*

Anabasine*

Anatabine*

Conversion**

0.673
0.605
0.694
0.706
0.814
0.630
0.647
0.005
0.006
0.017
0.010
0.761
0.507
0.653
0.643
0.521
0.716
0.701

0.018
0.014
0.017
0.005
0.022
0.010
0.010
0.347
0.255
0.300
0.384
0.011
0.009
0.015
0.013
0.007
0.015
0.027

0.006
0.005
0.004
0.006
0.007
0.003
0.004
0.002
0.002
0.002
0.002
0.005
0.003
0.006
0.004
0.004
0.005
0.004

0.G18
0.016
0.G18
0.020
0.017
0.012
0.011
0.012
0.009
0.010
0.G15
0.G18
0.007
0.G15
0.G18
0.014
0.020
0.G18

2.6
2.3
2.4
0.7
2.6
1.6
1.5
98.6
97.4
94.6
97.5
1.4
1.7

2.2
2.0
1.3

2.1
3.7

*percentage of leaf dry weight
**[% nornicotine/(% nicotine+ nornicotine)] x 100

Example 6: Cosuppression of the 3D_C12 Gene
Family

plants. As shown in Table 6, ethephon treatment and curing
40

In addition to the major conclusion that the 3D_Cl2-7
gene was capable of mediating nicotine to nornicotine
conversion, one additional observation stood out in the
alkaloid analyses of the Petite Havana transgenic plants. The
alkaloid results reported in Table 5 together with additional
alkaloid assays conducted independently (data not shown)
consistently showed one of the plants transformed with the
35S:3D_C12 construct (35S:3D_C12(1)) as having less nornicotine in the green, nontreated leaf than any other plant in

resulted in over 97% nicotine to nornicotine conversion in
the two control plants whereas similarly treated 35S:
3D_C12 (1) leaves displayed negligible conversion (0.6%).
Leaves from five other plants expressing either 35S:3D_C12

45

and 35S:7D_A06 transgenes were also subjected to ethephon treatment and curing. In each case a high nornicotine
phenotype was observed, similar to the vector-only control
plants (data not shown).
TABLE 6

Alkaloid analysis of 35S:3D_Cl2 (1) and pBI121 vector controls plants. Leaves were
treated with ethephon cured for seven days.

Sample
vector control (8)
vector control (10)
35S:3D_Cl2 (1)

%

%

%

%

%

Nicotine*

Nornicotine*

Anabasine*

Anatabine*

Conversion**

0.009
0.008
1.185

0.425
0.560
0.007

n.d.
n.d.
n.d.

0.011
0.025
0.020

97.9
98.6
0.6

*percentage of leaf dry weight
**[% nornicotine/(% nicotine+ nornicotine)] x 100
n.d., not detected

this study. This may be the result of cosuppression of the
3D_C12 gene family in this specific plant, a phenomenon
frequently observed in transgenic plants even when a trans-
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Finally, Northern blot assays were conducted on select
plants representing each of the Petite Havana transgenic
genotypes (FIG. 6). Using a 3D_Cl2-7 cDNA as a hybrid-
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ization probe, minimal signal was detected with RNAs
isolated from green, nontreated leaves of the vector-only
control plant. In contrast, hybridization was easily detected
in RNA samples from all four independent transgenic plants
possessing the 35S:3D_Cl2-7 construct. A strong hybridization signal was similarly observed using RNAs from all
other transgenic plants tested that were transformed with the
35S:3D_C12 and 35S:7D_A06 constructs, with the exception of the low nornicotine containing plant 35S:3D_C12
(1 ).
Overall results of the Northern blotting assays show that
the 35S CaMV promoter was generally effective in mediating a high level of gene expression for each of the three
members of the 3D_C12 gene family tested in this study.
Failure to detect a hybridization signal in plant 35S:3D_C12
(1) is consistent with the interpretation that the 3D_C12
gene family has been silenced via cosuppression in this
individual.

A calibration curve was generated with a serial dilution of
the 3D_ Cl 2-7 cDNA cloned into the pGEM®-T Easy vector
(Promega Corporation, Madison, Wis.). The RT-PCR mixture contained 2.5 mM MgC1 2 , 125 µMeach dNTP, 0.5 µM
each primer, 0.5x SYBR® Green I, 0.5 µg cDNA (or 1 µl
reference plasmid), and 1.25 U Platinum Taq polymerase
(lnvitrogen Life Technologies). The sequences of the allelespecific 3D_Cl2-7 primers (E4SyFwd and E4SyRev) were
5'-ACGTGATCCTAAACTCTGGTCTG-3'
(E4SyFwd
(SEQ ID NO:29)) and 5'-GCCTGCACCTTCCTTCATG-3'
(E4SyRev (SEQ ID NO:30)). RT-PCR was performed in a
BioRad iCycler thermocycler (BioRad Laboratories, Hercules, Calif.) set to the following protocol: 95° C. for 2 min;
35 cycles of 95° C. for 30 sec, 55° C. for 30 sec 72° C. for
50 sec, followed by final extension at 72° C. for 5 min. A
165-bp fragment of the a-tubulin gene was used as an
internal standard. 3D_Cl2-7 cDNAconcentration was determined from the transcript-specific calibration curve and
normalized to the internal standard. Fold-induction was
calculated by dividing the normalized fluorescence values of
the converter by the nonconverter samples. Melting-curve
analysis was used to confirm the purity of PCR products as
described in Ririe et al. (1997) Anal. Biochem. 245:154-160.
Two plants were sampled per treatment and amplifications
were repeated three times.
TaqMan® Chemistry
Total RNA was isolated from tobacco lines using TRizol
reagent. Purified RNA was treated with RNase-free DNase
(TURBO DNA-Free™). First strand cDNA was synthesized
using 10 µg of total RNA and the High Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, Calif.). The
RT-PCR mixture contained lx TaqMan® Universal PCR
Master Mix (Applied Biosystems, Foster City, Calif.), 400
nM of each primer (E4TmFwd and E4TmRev), 250 nM
TaqMan® minor groove binder (MGB) probe (E4MGB), 2
ng of cDNA, and nuclease-free water (Afonina et al. (2002)
Biotechniques 32:940-949). The primer and probe
sequences
were
5'-CGGTAATCGGCCATCTTTTC-3'
(E4TmFwd (SEQ ID NO:31)), 5'-CCGAGTTTTCGAGCTAATGGA-3' (E4TmRev(SEQ ID NO:32)), and
5'-CAATGACGAACGGCGACAG-3' (MGB probe(SEQ
ID NO:33)). RT-PCR was performed in anABI 7500 RealTime System (Applied Biosystems, Foster City, Calif.) set to
the following protocol: 50° C. for 2 min; 95° C. for 10 min;
40 cycles of 95° C. for 15 sec, 60° C. for 1 min. Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) was used as
the endogenous control to normalize the amount of cDNA
template in the reactions. Fold-change was determined by
dividing the normalized fluorescence values of each sample
by those obtained from a nonconverter or uncured control
sample. For each treatment, RNA was isolated from three
independent plants and amplifications were repeated 3 times
per RNA sample.
Northern and Southern Blot Analyses
Total RNA was isolated from cured tobacco leaves using
the TRizol reagent according to the manufacturer's instructions (Invitrogen, Life Technologies). Total RNA samples
were separated on 1.2% TBE agarose gel, and transferred to
positively charged nylon membranes by electroblotting with
2xTBE buffer. Membranes were UV crosslinked and washed
in 2xSSC for 5 min. Northern blot hybridization, washing,
and detection were carried out using the digoxigenin (DIG)
System as described by the manufacturer (Roche Diagnostics Corp., Indianapolis, Ind.). The 1.8 kb full-length ORF of
the 3D_Cl2-7 cDNA was labeled with DIG and used as a
probe.

Example 7: Additional Characterization and
Suppression of Additional 3D C12 Genes
A second RNAi construct was prepared using polynucleotide sequences from the 3D_Cl2-7 sequence. The assembly of the 3D_Cl2-7/RNAi expression cassette followed the
same basic steps as those outlined for 3D_C12/RNAi above.
Briefly, a 298-bp sense and antisense strand of the
3D_Cl2-7 cDNA (SEQ ID NO:5) corresponding to the
region between nucleotide positions 297 and 594 of the
coding sequence (positions 1-1551 of SEQ ID NO:5) were
ligated into the pKYLX801 vector downstream and
upstream of the 151-bp soybean omega-6 fatty acid desaturase intron (see GenBank Accession No. DQ672337),
respectively. The primers (E4SFwd and E4SRev) used for
the isolation of the 298-bp region by sense and antisense
arms were 5'-AAGCTTTGACGCCATTTTTTCCAATCG3' (SEQ ID NO:27), and 5'-CTCGAGTTTTCCAGCGATCATCTTCAC-3' (SEQ ID NO:28), respectively. The RNAi
cassette was excised from pKYL801 and placed between a
strong CaMV35S 2 promoter and a rubisco small subunit
terminator of the binary plant expression vector, pKYLX71
(see FIG. 8). In the discussions below, this RNAi construct
is referred to as the 3D_Cl2-7-Ri298 construct.
Transgenic tobacco plants were generated via Agrobacterium-mediated transformation following the procedures
provided above. Briefly, transformed burley tobacco plants
were regenerated from calli on Murashige-Skoog (MS)
medium supplemented with 100 mg/L kanamycin and plant
hormones in a growth room maintained at 25° C. under a 16
hr/8 hr light/dark cycle. Calli were transferred to fresh
selection media every 2-3 weeks until shoots appeared.
Small shoots were transferred to rooting media to allow root
development for 2 weeks. Fully regenerated plants were
transferred to a greenhouse and grown under standard conditions.
SYBR® Green I Chemistry
Total RNA was isolated from cured leaves of converter
and nonconverter burley tobacco plants using the TRizol®
reagent (Invitrogen, Life Technologies, Carlsbad, Calif.).
Purified RNA was treated with RNase-free DNase (TURBO
DNA-Free™, Ambion, Austin, Tex.). First strand cDNA was
synthesized using 5 µg of total RNA and the StrataScript®
First-Strand Synthesis System (Stratagene, Cedar Creek,
Tex.). Relative quantitative RT-PCR was employed for
determining the abundance of the 3D_Cl2-7 cDNA using
SYBR® Green I fluorescence chemistry Morrison et al.
(1998) Biotechniques 24:954-962.
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Genomic DNA was extracted with DNAzol® (Invitrogen,
Life Technologies) from green tobacco leaves according to
manufacturer's protocol. After incubation with FcoRl or
Neal restriction enzymes overnight, 15 µg of the digested
DNA was separated on 0.7% TBE agarose gel, depurinated
with 0.25 M HCl for 10 min, and denaturated with 0.5 N
NaOH for 30 minutes. DNA was blotted overnight by
capillary transfer onto positively charged nylon membranes
(Roche Diagnostics Corp.) and hybridized at 65° C. overnight with a 515-bp DIG-labeled fragment of the neomycin
phosphotransferase II (NPT II) gene. Hybridization, washing, and detection were performed according to the protocols supplied with the DIG System. The primers used for the
amplifications of the Northern and Southern hybridization
probes were E4FIFwsd (5'-ATGGTTTTTCCCATAGAAGCC-3' (SEQ ID NO:34)), E4FIRev (5'-ATGGTTTTTCCCATAGAAGCC-3' (SEQ ID NO:35)), KanFwd (5'-TGAATGAACTGCAGGACGAG-3' (SEQ ID
NO:36)), and KanRev (5'-AATATCACGGGTAGCCAACG-3' (SEQ ID NO:37)).
Alkaloid Analysis
Tobacco leaves were harvested and air dried in an oven at
50° C. for 2 days. A 100 mg sample of crushed, dried leaf
is added to 0.5 ml of 2 N Na OH in a 20 ml scintillation vial.
The sample was mixed and allowed to incubate for 15
minutes at room temperature. Alkaloids were extracted by
the addition of 5 ml of extraction solution [0.04% quinoline
(wt/vol) dissolved in methyl-t-butyl ether] and gently rotated
on a linear shaker for 3 hours. Following phase separation,
an aliquot of the organic phase was transferred to a sample
vial. Samples were analyzed using a PerkinElmer Autosystem XL (PerkinElmer, Boston, Mass.) gas chromatograph
equipped with a flame ionization detector, a 4 mm split/
splitless glass liner and a 30 mx0.53 mm ID DB-5 colunm.
Chromatographic conditions were as follows: detector temperature: 250° C.; injector temperature: 250° C.; helium flow
at 120° C.: 20 ml/min; injection volume: 2 µl; column
conditions: 120°, hold 1 min, 20-280° C. at 30° C./min
ramping rate, hold at 280° C. for 2 min. Alkaloid composition was determined by the TotalChrome Navigator software using a calibration curve. Means of the alkaloid
measurements were separated according to Fisher's Protected LSD (PROC MIXED).
Plants
Double haploid burley tobacco lines DH 98-325-5 (325-5;
nonconverter) and DH98-325-6 (325-6; converter)
described above were used in all experiments, except for the
fluorogenic 5' nuclease (TaqMan®) chemistry-based RTPCR assays where the isogenic DH 91-1307-46 (nonconverter) and DH 91-1307-46 (converter) lines were used. All
plants were grown in a controlled environment greenhouse
equipped with supplemental lighting providing, a 14 hr/10
hr light/dark cycle.
For curing, tobacco leaves were collected from converter
and nonconverter plants about 1 month before flowering and
treated by dipping each leaf twice for 10 sec, into 2%
ethephon and dried for 2 hours. Leaves were cured for up to
two weeks in plastic bags, under dark conditions, until they
turned yellow. Cured leaves were used for the Northern and
alkaloid analyses. Samples of cured leaves subjected to GC
analysis were dried at 50° C. for 2 days. For Southern
analysis, green tobacco leaves of adult plants were used. To
produce T 1 generation transgenic plants, primary transformants (T 0 ) were self-pollinated, and the harvested T 1 seed
was screened by germinating seedlings on MS-agar plates
containing 100 mg/L kanamycin for 6 weeks. Survivors
were transplanted to soil and grown in a greenhouse as

described above. Plants were fertilized with Peter's Professional All Purpose Plant Food (20-20-20; Spectrum Brands
Inc., Madison, Wis.) once a week.
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RT-PCR Analysis of3D_ Cl2-7 Expression in Converter and
Nonconverter Tobacco
To further characterize the role of3D_Cl2-7 in nicotine
N-demethylation, experiments were performed to demonstrate that the regulation of3D_Cl2-7 expression is consistent with the levels of nicotine N-demethylation activity
observed in converter versus nonconverter tobacco.
To determine the rate of3D_Cl2-7 mRNA accumulation
in converter and nonconverter tobacco, an allele-specific
real-time RT-PCR strategy was employed. Because RT-PCR
involves the detection and measurement of the amplification
products of a PCR template, the use of allele-specific
primers allows the quantification of a single isoform among
a group of highly homologous sequences. For accurate
quantification of the 3D_Cl2-7 transcript, two different
segments of the 3D_Cl2-7 coding region were amplified
and both SYBR® Green and TaqMan® chemistries were
used to generate fluorescence signals. RT-PCR analysis
using the SYBR® Green I chemistry revealed an 80-fold
increase in the levels of the 3D_Cl2-7 transcript in the cured
leaves of converter versus nonconverter tobacco. A single
peak melting curve and gel electrophoretic analyses of the
amplicons confirmed the homogeneity of the PCR products.
In the TaqMan® chemistry-based RT-PCR experiment,
3D_Cl2-7 transcript levels were quantified in untreated and
ethephon-treated converter and nonconverter tobacco leaves
that were cured for 0, 1 or 5 days. Low levels of3D_Cl2-7
transcripts were detected in the uncured leaves or following
a 1-day curing period regardless of conversion type or
ethephon treatment. Similarly, base line levels of3D_Cl2-7
transcription were observed in converter or nonconverter
leaves that were cured for 5 days without ethephon treatment. In contrast, a 7.5-fold increase in 3D_Cl2-7 transcript
accumulation was detected in the cured leaves of converter
versus nonconverter tobacco, and a 70-fold increase was
observed in the uncured versus cured leaves of a converter
tobacco variety when ethephon treatment preceded the 5-day
curing period. While not intending to be limited by any
particular theory, these results suggest that 3D_Cl2-7 is a
major contributor to nicotine N-demethylation and is
strongly inducible by ethylene in senescing tobacco leaves.
Suppression of Nicotine to Nornicotine Conversion by the
3D_Cl2-Ri99 and 3D_Cl2-7-Ri298 Constructs
To compare the extent to which 3D_C12 and 3D_Cl2-7
mediate the suppression of nomicotine production, converter and nonconverter burley tobacco plants were transformed with the two gene silencing vectors. Ten (10) transgenic plants were regenerated per RNAi construct. About
80% of tobacco plants overexpressing either the 99-bp or
298-bp inverted repeat showed reduced nornicotine levels
compared to the empty vector controls (Tables 7 and 8). In
the nonconverter genotype, 3D_Cl2-Ri99 and 3D_Cl2-7Ri298 expression reduced nicotine to nomicotine conversion by about 1.8-fold (2.0%) and 3.0-fold (1.2%), respectively, in comparison to the rate of conversion detected in the
vector controls (3.6%) (Table 7). Among the silenced nonconverter plants, the lowest conversion level of 0.9% was
achieved using the 3D_Cl2-7-Ri298 construct (Table 7).
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TABLE 7

TABLE 8-continued

Alkaloid analysis of nonconvertor burley tobacco plants
transformed witb the 3D C12-Ri99 or 3D C12-7-Ri298 construct.

Alkaloid analysis of convertor burley tobacco plants transformed witb tbe
3D C12-Ri99 or 3D C12-7-Ri298 construct.

% Nicotined

% Nornicotined

% Conversione

1.693
1.435
2.095
2.868
0.947
2.357
2.599
0.796
2.178
3.162
2.013
0.748

0.034
0.031
0.043
0.053
0.025
0.043
0.043
0.020
0.039
0.061
0.039
0.012

2.0
2.1
2.0
1.8
2.6
1.8
1.6
2.4
1.8
1.9
0.3

1.806
1.948
2.061
2.704
2.652
1.074
2.041
0.550

0.020
0.207
0.020
0.040
0.023
0.G15
0.024
0.008

1.1
1.4
1.0
1.5
0.9
1.3
1.2b
0.2

1.206
1.265
1.752
1.230
1.777
1.536
1.461
0.240

0.052
0.038
0.058
0.072
0.060
0.044
0.054
0.011

4.2
2.9
3.2
5.6
3.3
2.8

3D-C12-Ri99

2
3
4
5
6
7
8
9
10
MEAN
STE
3D_Cl2-7-Ri298
3
4
5
6
8
9
MEAN
STE
Vector ControW

2
3
4
5
6
MEAN
STE

10

Linec

% Nicotined

% Nornicotined

% Conversione

3
4
8
9
10
MEAN
STF
3D_Cl2-7-Ri298b

2.175
3.517
2.268
2.197
2.434
2.654
0.573

0.064
0.125
0.128
0.133
0.112
0.122
0.039

2.9
3.4
5.3
5.7
4.4

2.043
3.427
2.603
2.427
2.106
1.412
3.328
1.493
2.065
2.323
0.669

0.020
0.026
0.020
0.030
0.021
0.G15
0.028
0.G15
0.G18
0.021
0.005

0.126
0.330
0.060
0.114
0.119
0.150
0.093

1.550
2.604
1.419
1.267
1.303
1.628
0.498

15

2.oa

20

25

30

3.6c

2
3
5
6
7
8
9
10
MEAN
STE
Vector Controt,i

2
3
4
5
MEAN
STE

4.5a

1.6

1.0
0.8
0.8
1.2
1.0
1.1
0.8
1.0
0.8
0.9b

0.1

92.5
88.8
95.9
91.7
91.6
92.lc
2.3

1.0

aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C.
aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C.
35 bOf the plants transformed with an RNAi construct, only silenced individuals are shown.
bOf the plants transformed with an RNAi construct, only silenced individuals are shown.
'Numbers represent independently transformed individuals.
Alkaloid data represent the means of 2 measurements.
'Numbers represent independently transformed individuals.
"Percentage of leaf dry weight.
"Percentage of leaf dry weight.
e[% nornicotine/(% nicotine+% nornicotine)] x 100; values followed by different letters
are significantly different according to Fisher's Protected LSD (0.05).
e[% nornicotine/(% nicotine + % nornicotine)] x 100; values followed by different letters
are significantly different according to Fisher's Protected LSD (0.05).
fsTE, standard error
fsTE, standard error
40 gTobacco plants transformed with only pKYLX71 vector were used as controls.
gTobacco plants transformed with only pKYLX71 vector were used as controls.

Relative to nonconverter tobacco, nomicotine accumulation was suppressed even more dramatically in the silenced
individuals of the strong converter plants (Table 8). Using
3D_Cl2-Ri99 constructs, nicotine conversion was reduced
to levels as low as 4.5% in 3D_Cl2-Ri 99-transformed
325-6 tobacco plants in sharp contrast to the 325-6 control
plants exhibiting about 98% conversion rates; Table 8).
However, using the 3D_Cl2-7-Ri298 construct even greater
reductions in nicotine conversion were obtained (Table 8).
Four 3D_Cl2-7-Ri298-transformed individuals converted
as low as 0.8% of their nicotine to nomicotine, and the
arithmetic mean across the 9 silenced transformants was
0.9% conversion. All silenced plants were morphologically
indistinguishable from both the empty vector and wild-type
controls (data not shown).
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TABLE 8
Alkaloid analysis of convertor burley tobacco plants transformed witb tbe
3D C12-Ri99 or 3D C12-7-Ri298 construct.
% Nicotined

% Nornicotined

% Conversione

3.419
2.569

0.100
0.193

2.8
7.0

60

3D_Cl2-Ri99

2
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To test the heritability of nomicotine suppression in the
3D_Cl2-7-Ri298-transformed plants, a set of 3D_Cl2-7Ri298-transformed converter and nonconverter lines that
displayed the lowest levels of nicotine conversion were
advanced to the T 1 generation (Table 9). Because segregation of the transgene(s) occurs in the T 1 progeny, transgenic
individuals were identified by selecting seedlings capable of
growing on kanamycin-containing media. Nine kanamycinresistant progenies of each selected T 0 -generation 3D_Cl27-Ri298 transformant and four kanamycin-resistant individuals from each selected vector control line were analyzed
for alkaloid content. The rate of nicotine conversion did not
differ significantly between the primary 3D_Cl2-7-Ri298
transformants and their T 1 progeny, indicating high heritability of the nomicotine suppression trait (see Tables 7, 8,
and 9). However, advancing the "nonconverter" vector control line by a single generation increased the nicotine to
nornicotine conversion rate from 4.2% to an average value
of 11.6%, illustrating the high degree of instability of the
conversion locus in transgenic plants lacking the 3D_Cl27-Ri298-specific RNAi construct (Tables 7 and 9). Overall,
these results show that RNAi-mediated silencing of the
3D_C12 gene subfamily is a highly effective means of
lowering nomicotine production in both nonconverter and
strong converter tobacco plants.
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TABLE 9

6) of the 3D_Cl2-7-Ri298 construct using Southern blot
analysis of genomic DNA digested with the EcoRI restriction enzyme. Transgene copy number was confirmed using
Neal digested DNA (data not shown). These results indicate
that the integration of a single 3D_Cl2-7-Ri298 construct
into the genome of a strong converter tobacco is sufficient
for suppressing nornicotine production to very low levels.

Alkaloid analysis ofT 1-generation 3D C12-7-Ri298 transformants.
Line

% Nicotinec

% Nornicotinec

% Conversiond

5
DH98-325-5 (nonconverter)
3D_Cl2-7-Ri298#3
).4a

Mean
STE
3D_Cl2-7-Ri298#5

1.764
0.456

0.024
0.004

0.3

Mean
STE
3D_Cl2-7-Ri298#8

1.500
0.306

0.020
0.006

1.3a
0.3

Mean
STE
Vector Control#! e

1.772
0.409

0.020
0.003

1.2a
0.3

1.466
0.203
0.713
0.161
DH98-325-6 (converter)

)).6b

Mean
STE

9.7

GENERAL CONCLUSIONS
10

15

20

3D C12-7-Ri298#2
0.019
0.004

1.oa
0.3

Mean
STE
3D_Cl2-7-Ri298#8

1.970
0.536

Mean
STE
3D_Cl2-7Ri298#10

1.623
0.300

0.022
0.002

1.3a
0.2

Mean
STE
Vector Control#2e

1.419
0.515

0.017
0.004

1.3a
0.3

Mean
STE

0.028
0.006

1.170
0.234

97.6c
0.5

25

30

35

aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C.
~eans and standard errors (STE) represent 9 and 4 T 1 progenies of the 3D_C12-7-Ri298
construct and empty vector-transformed (vector control) lines, respectively.
"Percentage of leaf dry weight.
d[% nornicotine/(% nicotine+% nornicotine)] x 100; values followed by different letters
are significantly different according to Fisher's Protected LSD (0.015).
40
eTobacco plants transformed with only pKYLX71 vector were used as controls.

Furthermore, transforming tobacco with the 3D_Cl2-7298 construct conferred a 3.6-fold reduction in nicotine
conversion relative to typical nonconverter control plants
without affecting plant growth and development.
To demonstrate that the down-regulation of nornicotine
production in 3D _Cl2-7-298-transformed tobacco was concomitant with a reduction of the 3D_C12 gene subfamily
transcripts, a 3D_Cl2-7 cDNAprobe was hybridized to the
total RNA isolated from cured leaves of nonconverter and
converter plants. A weak hybridization signal was generated
by the RNA isolated from 3D_Cl2-7-Ri298 transformants
displaying low nornicotine content in contrast to the strong
signal produced by the RNA extracted from plasmid control
or wild-type plants. These results indicate that the downregulation of nicotine conversion was a result of RNAimediated gene silencing of the nicotine N-demethylase
gene(s).
Determination of Transgene Copy Number
To determine whether the integration of multiple
3D_Cl2-7-Ri298 copies were required for producing transplants displaying very low nicotine N-demethylase activity,
Southern analysis was performed on selected individuals
exhibiting <1.5% nornicotine accumulation. The number of
transgenes varied widely among these plants including individuals containing 1 copy (325-5, lines 5 & 8; 325-6, lines
2 & 8), 5 copies (325-6, line 10), and 6 copies (325-5, line

45

50

55

60

65

The analyses outlined in Examples 1-6 above resulted in
the discovery of a closely related P450 gene family, designated the 3D_C12 family, whose collective steady-state
transcript levels were significantly elevated in converter
tobacco plants that were actively metabolizing nicotine to
nornicotine in comparison to their nonconverter counterparts. Transgenic plant analysis demonstrated that the suppression of gene expression of this P450 family in converter
tobacco lines inhibited the metabolism of nicotine to nornicotine to levels similar to that observed in nonconverter
plants. Furthermore, sense expression of several individuals
of this closely related gene family identified one member,
designated 3D_Cl2-7, as playing a direct role in the metabolic conversion of nicotine to nornicotine. Overexpression
of3D_Cl2-7 using a strong constitutive promoter caused a
dramatic increase in nornicotine production and accumulation in non-cured green leaves of transgenic tobacco plants,
a tissue where nicotine is normally the predominant alkaloid
in converter and nonconverter plants alike. Given that the
cytochrome P450 family member designated 3D_Cl2-10
differs from 3D_Cl2-7 at only two amino acid residues
immediately following the start methionine and within the
N-terminal signal sequence, it is predicted that these
encoded products function identically.
The contrast in alkaloid phenotypes between the 35S:
3D_C12 (1) plant and vector-only control plants was most
dramatic in leaves that had been ethephon treated and cured
(0.6% conversion versus >97% conversion; Table 6). However, it is noteworthy that the nornicotine content of the
co-suppressed 35S:3D_C12 (1) plant was reduced even in
green, nontreated leaves where the high nornicotine phenotype is typically not manifest in converter or nonconverter
tobacco lines. The green, nontreated leaves of line 35S:
3D_C12 (1) showed only 0.7% nicotine to nornicotine
conversion, whereas every other plant in this experiment
showed conversion percentages ranging from 1.3 to 3.7
(Table 5). This result suggests that the inhibition of gene
expression of the 3D_C12 family may prove to be effective
in the further lowering of nornicotine levels even in tobacco
lines where genetic conversion isn't typically a major problem (such as flue-cured tobaccos) or in the nonconverter
individuals in lines that are prone to genetic conversion
(such as Burley tobaccos).
Southern blotting assays using members of the 3D_C12
gene family as hybridization probes gives very complex
banding patterns, suggesting that more members of this gene
family may exist even beyond those that have been identified and characterized herein (data not shown). The hypothesis that the 3D_C12 gene family is comprised of additional
members is further supported by the recent publication of75
full-length tobacco P450 cDNAs of unknown function (U.S.
Patent Application Publication 20040162420). Within this
list of P450s are additional cDNAs that would, based on the
work described herein, be placed within the 3D_C12 family
in view of their display of over 90% amino acid sequence
identity to the protein sequences shown in FIG. 4.
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With respect to the specific molecular function of the
3D_Cl2-7 gene or the nearly identical family member
3D_Cl2-10, it is possible that it encodes the actual nicotine
demethylase enzyme which catalyzes the oxidative N-demethylation of nicotine to nornicotine (FIG. 1). Alternatively,
the 3D_Cl2-7 encoded enzyme or nearly identical 3D_Cl210 encoded enzyme may produce a product that leads to the
up-regulation of the nicotine demethylase activity of the
leaf, as opposed to directly catalyzing the N-demethylation
reaction.
In addition, an allele-specific RT-PCR was employed to
compare 3D-Cl2-7 expression between converter and nonconverter plants (Example 7). An approximately 80-fold
increase in 3D-Cl2-7 expression in converter versus nonconverter plants was identified using the SYBR® Greenchemistry RT-PCR assay. A 7.5-fold up-regulation was identified by the TaqMan® chemistry-based RT-PCR
experiment. While the DH 91-1307-46 tobacco variety used
in the TaqMan® chemistry-based RT-PCR experiment
exhibits low to moderate levels of nicotine conversion, the
DH98-325-5 nonconverter plants used in the SYBR®
Green-based RT-PCR assay consistently convert a very low
percentage of their nicotine to nornicotine. Expression of the
3D-Cl2-7 gene was induced at least 7-fold by ethylene in
senescing leaves of converter tobacco plants.
An additional RNAi construct, 3D_Cl2-7-Ri298, was
prepared based on a region of the 3D_Cl2-7 polynucleotide
that corresponds to nucleotide positions 297 through 594 of
SEQ ID NO:5. Expression of this RNAi construct allows for
the suppression of nornicotine production in a strong converter tobacco line below the levels normally found in
nonconverter plants. The expression cassette of the
3D_Cl2-7-Ri298 construct encoded an intron-spliced hair-

pin RNA in which the stem region was engineered from this
298-bp fragment of the 3D_Cl2-7 cDNA inserted as an
inverted repeat. The loop of the hairpin was created by
placing a 151-bp intron of the FAD gene between the two
sides of the palindromic sequences. An arm length of298-bp
was used for the inverted repeats.
3D_Cl2-7-Ri298-transformed plants accumulated less
nornicotine than those harboring the 3D_Cl2-Ri99 construct (Tables 7 and 8). No correlation was found between
the number of copies of the 3D_Cl2-7-Ri298 construct and
nornicotine production (Tables 7 and 8). The 3D_Cl2-7Ri298 expression cassette enabled the production of tobacco
with a conversion rate as low as 0.8%, which is below the
3-5% rate detected in burley lines used by seed producers.
Such dramatic reduction in nornicotine production by targeting this particular region of the 3D_Cl2-7 polynucleotide
is an unexpected result. Also, suppression of nornicotine
production showed a high degree of heritability in the T 1
progeny of the primary transformants (Table 9). Suppression
of nornicotine production in these transgenic plants yielded
no obvious differences in growth and development when
compared to wild-type plants.
All publications and patent applications mentioned in the
specification are indicative of the level of those skilled in the
art to which this invention pertains. All publications and
patent applications are herein incorporated by reference to
the same extent as if each individual publication or patent
application was specifically and individually indicated to be
incorporated by reference.
Although the foregoing invention has been described in
some detail by way of illustration and example for purposes
of clarity of understanding, it will be obvious that certain
changes and modifications may be practiced within the
scope of the appended claims.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>
<220>
<221>
<222>

37

SEQ ID NO 1
LENGTH, 1733
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (1551)

<400> SEQUENCE,

1

atg gtt ttt CCC ata gaa gee ttt gta gga eta gta ace ttc aca ttt
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe
1

5

10

15

etc tta tac ttc eta tgg aca aaa aaa tct caa aaa ctt cca aaa CCC
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro
20

25

96

30

tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttt
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35

48

40

144

45

cac ttc aat aac gac ggc gac gac cgt cca tta get cga aaa etc gga

192

His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

gac tta get gat aaa tac ggc CCC gtt ttc act ttt egg eta ggt ctt
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65

70

75

80

ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc ttc
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe

CCC

85

90

240

95

288

us
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64

63
-continued
tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac ggc
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100

105

110

gaa tac ctt ggc tac aat aat aca atg ctt ttt eta gca aat tac gga
Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly
115

120

135

150

155

165

170

185

200

215

230

235

245

250

265

280

295

310

315

325

330

345

1056

350

ggt aag gat aga tgg gta gaa gag agt gat att aag gat tta gta tac
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
360

1104

365

etc caa get att gtt aaa aag gtg tta cga tta tat cca cca gga cct
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro
375

1152

380

ttg tta gta cca cat gaa aat gta aag gat tgt gtt gtt agt gga tat
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr
390

1008

335

aat caa aat gee ttg atg aaa gca caa gaa gag ata gac aca aaa gtt
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340

960

320

gac aca gtt get ctt cac ata aat tgg gga atg aca tta ttg ata aac
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn

385

912

300

gat act gtc att aaa gca aca gtt ttt agt ttg gtc ttg gat gca gca
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala

370

864

285

gtg ctt tea aaa ttg agt aaa gaa tat ctt gat gaa ggt tac tct cgt
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg

355

816

270

aaa atg gag gtt ggt gca gaa ggg aat gaa caa gat ttc att gat gtg
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val

305

768

255

gat tct gtt ttt cag aac tgg tta gag gaa cat att aat aaa aga gaa
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260

720

240

gat ttt caa ggt cat att aag gca atg aaa agg aca ttt aag gat ata
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile

290

672

220

gaa ttt gta tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val

275

624

205

gtg gaa aga ttt aag aat gcg ttt aag gat ttt atg gtt tta tea atg
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met

225

576

190

aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa caa
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln

210

528

175

ata aat eta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180

480

160

acg age att aag aat tta tac act cga att aat gga aat tcg agt acg
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr

195

432

140

get agt cgt etc gaa aaa ttc aaa caa gtg aga ttc ace aga att caa
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln
145

384

125

cct tac tgg cga aaa aat cgt aaa tta gtc att cag gaa gtt etc tct
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130

336

395

1200

400

cac att cct aaa gag act aga tta ttc gca aac gtc atg aaa ctg cag
His Ile Pro Lys Glu Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln

1248

us
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65

66
-continued

405

410

415

cgc gat cct aaa etc ttg tea aat cct gat aag ttc gat cca gag aga
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg
420
425
430

1296

ttc ate get ggt gat att gac ttc cgt ggt cac cac tat gag ttt ate
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile
435
440
445

1344

cca ttt ggt tct gga aga cga tct tgt ccg ggg atg act tat gca ttg
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450
455
460

1392

caa gtg gaa cac eta aca atg gca cat tta ate cag ggt ttc aat tac
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465
470
475
480

1440

aaa act cca aat gac gag gee ttg gat atg aag gaa ggt gca ggc ata
Lys Thr Pro Asn Asp Glu Ala Leu Asp Met Lys Glu Gly Ala Gly Ile
485
490
495

1488

ace ata cgt aag gta aat cca gtg gaa ttg ata ata acg cct cgc ttg
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Thr Pro Arg Leu
500
505
510

1536

gca cct gag ctt tac taaaacctaa gatctttcat cttggttgat cattgtttaa
Ala Pro Glu Leu Tyr
515

1591

tactcctaga tgggtattca tttacctttt ttcaattaat tgcatgtacg agctttttta

1651

atttggtata tttgtaacaa taagtaaaga atgattgtgc taatatataa agatttgcag

1711

aagataattg actgattgtc cc

1733

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 517
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE,

2

Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro
20
25
30
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe

35

40

45

His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly

100

105

110

Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130
135
140
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln
145
150
155
160
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr
165
170
175
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val

180

185

190
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-continued
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195
200
205
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met
210
215
220
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225
230
235
240
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245
250
255
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260
265
270
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val
275
280
285
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg
290
295
300
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala
305
310
315
320
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn
325
330
335
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val

340

345

350

Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
355
360
365
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro
370
375
380
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr
385
390
395
400
His Ile Pro Lys Glu Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln

405

410

415

Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg
420
425
430
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile
435
440
445
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450
455
460
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465
470
475
480
Lys Thr Pro Asn Asp Glu Ala Leu Asp Met Lys Glu Gly Ala Gly Ile
485
490
495
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Thr Pro Arg Leu
500
505
510
Ala Pro Glu Leu Tyr
515

<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 3
LENGTH, 1733
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (1551)

<400> SEQUENCE, 3

atg ctt tct CCC ata gaa gee att gta gga eta gta ace ttc aca ttt
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15

48

us
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70
-continued

etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa CCC
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20

25

30

tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttc
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35

96

40

144

45

cac ttc aat gac gac ggc gac gac cgt cca tta get cga aaa etc gga
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

192

gac tta get gac aaa tac ggc CCC gtt ttc act ttt egg eta ggc ctt
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu

240

65

70

75

80

ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe

CCC

85

90

95

tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100

105

120

135

150

155

165

170

185

200

215

230

235

245

250

265

280

864

285

gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg
295

912

300

gat act gtc att aaa gca acg gtg ttt agt ttg gtc ttg gat gca gca
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala
310

315

330

960

320

gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn
325

816

270

aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val

305

768

255

gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260

720

240

gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile

290

672

220

gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val

275

624

205

gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met

225

576

190

aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln

210

528

175

ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180

480

160

gcg age att aag aat tta tat act cga att gat gga aat tcg agt acg
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr

195

432

140

get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145

384

125

cct tac tgg cga aaa aat cga aaa tta gtt att cag gaa gtt etc tee
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130

336

110

gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115

288

335

1008

us
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72
-continued

aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340
345
350

1056

ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
355
360
365

1104

etc caa get att gtt aaa gaa gtg tta cga tta tat cca cca gga cct
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro
370
375
380

1152

ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr
385
390
395
400

1200

cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln
405
410
415

1248

cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg
420
425
430

1296

ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile
435
440
445

1344

ccg ttt ggt tct gga aga cga tct tgt cca ggg atg act tat gca ttg
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450
455
460

1392

caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465
470
475
480

1440

aga act cca aat gac gag CCC ttg gat atg aag gaa ggt gca ggc ata
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile
485
490
495

1488

act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu
500
505
510

1536

gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa
Ala Pro Glu Leu Tyr
515

1591

tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta

1651

atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag

1711

aagataattg actgattgtc cc

1733

<210>
<211>
<212>
<213>

SEQ ID NO 4
LENGTH, 517
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE,

4

Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe
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74

73
-continued
85

90

95

Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100

105

110

Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115

120

125

Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130

135

140

Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145

150

155

160

Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165

170

175

Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180

185

190

Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195

200

205

Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210

215

220

Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225

230

235

240

Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245

250

255

Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260

265

270

Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val
275

280

285

Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg
290

295

300

Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala
305

310

315

320

Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn
325

330

335

Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340

345

350

Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
355

360

365

Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro
370

375

380

Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr
385

390

395

400

His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln
405

410

415

Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg
420

425

430

Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile
435

440

445

Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450

455

460

Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465

470

475

480

Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile
485

490

495

Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu
500

505

510

us
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75

76
-continued

Ala Pro Glu Leu Tyr
515

<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 5
LENGTH, 1733
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (1551)

<400> SEQUENCE,

5

atg gtt ttt CCC ata gaa gee att gta gga eta gta ace ttc aca ttt
Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15

48

etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa CCC
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30

96

tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttc
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45

144

cac ttc aat gac gac ggc gac gac cgt cca tta get cga aaa etc gga
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

192

gac tta get gac aaa tac ggc CCC gtt ttc act ttt egg eta ggc ctt
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80

240

CCC

ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe
85
90
95

288

tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100
105
110

336

gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125

384

cct tac tgg cga aaa aat cga aaa tta gtt att cag gaa gtt etc tee
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130
135
140

432

get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145
150
155
160

480

gcg age att aag aat tta tat act cga att gat gga aat tcg agt acg
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165
170
175

528

ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180
185
190

576

aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195
200
205

624

gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210
215
220

672

gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225
230
235
240

720

gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245
250
255

768

us
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78
-continued

gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260
265
270

816

aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val
275
280
285

864

gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg
290
295
300

912

gat act gtc att aag gca acg gtg ttt agt ttg gtc ttg gat gca gca
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala
305
310
315
320

960

gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn
325
330
335

1008

aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340
345
350

1056

ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
355
360
365

1104

etc caa get att gtt aaa gaa gtg tta cga tta tat cca cca gga cct
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro
370
375
380

1152

ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr
385
390
395
400

1200

cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln
405
410
415

1248

cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg
420
425
430

1296

ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile
435
440
445

1344

ccg ttt ggt tct gga aga cga tct tgt cca ggg atg act tat gca ttg
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450
455
460

1392

caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465
470
475
480

1440

aga act cca aat gac gag CCC ttg gac atg aag gaa ggt gca ggc ata
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile
485
490
495

1488

act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu
500
505
510

1536

gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa
Ala Pro Glu Leu Tyr
515

1591

tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta

1651

atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag

1711

aagatgattg actgattgtc cc

1733

<210>
<211>
<212>
<213>

SEQ ID NO 6
LENGTH, 517
TYPE, PRT
ORGANISM, Nicotiana sp.
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80

79
-continued
<400> SEQUENCE, 6
Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe
85
90
95
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly

100

105

110

Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130
135
140
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145
150
155
160
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165
170
175
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180
185
190
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195
200
205
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210
215
220
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225
230
235
240
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245
250
255
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260
265
270
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val
275
280
285
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg
290
295
300
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala
305
310
315
320
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn
325
330
335
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340
345
350
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
355
360
365
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro
370
375
380
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr
385
390
395
400
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln

us
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81

82
-continued

405

410

415

Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg
420
425
430
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile
435
440
445
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450
455
460
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465
470
475
480
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile
485
490
495
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu
500
505
510
Ala Pro Glu Leu Tyr
515

<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 7
LENGTH, 1727
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (1554)

<400> SEQUENCE,

7

atg gtt ttt ccg gta gaa gee att gta ggg eta gtg ace ttc aca ttt
Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15

48

etc ttc tac ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa CCC
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30

96

tta cca ccg aaa ate ccg gga gga tgg ccg gta ate ggc cat ctt ttc
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45

144

tac ttc gat gac gac ggc gac gac cgt cca tta get cga aaa etc gga
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

192

gac tta get gac aaa tac gga CCC gtt ttc act ttt egg eta ggc ctt
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80

240

CCC

ctt gtg tta gtt gta age agt tac gaa get ata aaa gat tgt ttc
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95

288

tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac ggc
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100
105
110

336

gaa tac ctt ggc tac aaa aat gee atg eta ttt ttg gca aat tac gga
Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125

384

tct tac tgg cga aaa aat cgt aaa tta att att cag gaa gtt etc tct
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser
130
135
140

432

get agt cgt etc gaa aaa ttc aaa cac gtg aga ttc gee aga att caa
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145
150
155
160

480

acg age att aag aat tta tac act cga att gat gga aat tcg agt acg
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165
170
175

528

ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg

576

us
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-continued
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180
185
190

aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa caa
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195

200

205

gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210

215

230

235

245

250

265

280

295

310

315

325

330

345

360

375

390

395

405

410

425

1296

430

aga ttc ate get cgt gat att gac ttt cat ggt cag cac tat gag tat
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr
440

1344

445

ate ccg ttt ggt tct gga aga cgc tct tgt ccg ggg atg act tat gca
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala
455

1392

460

ttg caa gtg gaa cac eta aca atg gca cat ttg ate cag ggt ttc aat
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn
470

475

490

1440

480

tac aga act cca act gat gag CCC ttg gat atg aaa gaa ggt gca ggc
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly
485

1248

415

caa cgt gat cct aaa etc tgg tea aat cct gat aag ttc aat cca gag
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu
420

1200

400

tat cac att cct aaa gga act aga eta ttc gca aat gta atg aaa eta
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu

465

1152

380

cct ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga
Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly

450

1104

365

tac etc caa get att gtt aaa gaa gtg tta cga tta tat cca ccg gga
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly

435

1056

350

gtt ggt aag gat aga tgg gta gaa gag agt gat att aag gat ttg gta
Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val

385

1008

335

aac aat caa aat gee ttg aag aaa gca caa gaa gag ata gac aca aaa
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys
340

960

320

gca gac aca gtt get ctt cac ata aat tgc gga atg gca tta ttg ata
Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile

370

912

300

cgc gat act gtc ata aaa gca aca gta ttt agt ttg gtc ttg gat gca
Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala

355

864

285

gtg gtg ctt tea aaa atg agt aat gaa tat ctt ggc gaa ggt tac tct
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser

305

816

270

aaa ata atg gag gtt ggt aca gaa ggg aat gaa caa gat ttt ata gat
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp

290

768

255

gat tct gtt ttt cag aat tgg tta gag gaa cat att aag aaa aga gaa
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu
260

720

240

gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile

275

672

220

gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225

624

495

1488
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85

86
-continued

ata act ata cgt aag gta aat cct gtg aaa gtg ata att acg cct cgc
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg
500
505
510

1536

ttg gca cct gag ctt tat taaaatctaa gatgtttcat cttggttgat
Leu Ala Pro Glu Leu Tyr
515

1584

cattgtttaa tactcctaga tgggtattca tctacctttt ttcaattagt tgtcggtacg

1644

tattttttta atttggtaag tttgtaataa taagtaaaga aggattgtgc taatatataa

1704

tggtgcataa aataattgaa atg

1727

<210>
<211>
<212>
<213>

SEQ ID NO 8
LENGTH, 518
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE, 8
Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly

100

105

110

Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser
130
135
140
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145
150
155
160
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165
170
175
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180
185
190
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195
200
205
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210
215
220
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225
230
235
240
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245
250
255
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu
260
265
270
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp
275
280
285
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser
290
295
300

us
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-continued

Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala
305
310
315
320
Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile
325
330
335
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys
340
345
350

Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val
355
360
365
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly
370
375
380
Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly
385
390
395
400
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu
405
410
415
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu
420
425
430
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr
435
440
445
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala
450
455
460
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn
465
470
475
480
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly
485
490
495
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg
500
505
510
Leu Ala Pro Glu Leu Tyr
515

<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 9
LENGTH, 539
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (539)

<400> SEQUENCE,

9

atg gtt ttt CCC ata gaa gee ttt gta gga eta gta ace ttc aca ttt
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15

48

etc tta tac ttc eta tgg aca aaa aaa tct caa aaa ctt cca aaa CCC
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro
20
25
30

96

tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttt
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45

144

cac ttc aat aac gac ggc gac gac cgt cca tta get cga aaa etc gga
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

192

gac tta get gat aaa tac ggc CCC gtt ttc act ttt egg eta ggt ctt
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80

240

CCC

ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc ttc
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95

288

tct aca aat gat gee att ttc tee aat cgt cca get ttt ctt tat ggc
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly

336

us
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100

105

110

gaa tac ctt ggc tac agt aat gee atg eta ttt tga caa aat acg gac
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe * Gln Asn Thr Asp
115
120
125

384

ctt act ggc gaa aaa ata gaa aat tag tea ttc agg aag ttc tct gtg
Leu Thr Gly Glu Lys Ile Glu Asn * Ser Phe Arg Lys Phe Ser Val
130
135
140

432

eta gtc gtc tcg aaa aat tga age acg tga gat ttg gtg aaa ttc aga
Leu Val Val Ser Lys Asn * Ser Thr * Asp Leu Val Lys Phe Arg
145
150
155

480

cga gca tta aga att tat aca etc gaa ttg atg gaa att cga gta cga
Arg Ala Leu Arg Ile Tyr Thr Leu Glu Leu Met Glu Ile Arg Val Arg
160
165
170

528

taa ate taa ca
* Ile *

539

<210>
<211>
<212>
<213>

SEQ ID NO 10
LENGTH, 173
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE,

10

Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro
20
25
30
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe

35

40

45

His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly

100

105

110

Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Gln Asn Thr Asp Leu
115
120
125
Thr Gly Glu Lys Ile Glu Asn Ser Phe Arg Lys Phe Ser Val Leu Val
130
135
140
Val Ser Lys Asn Ser Thr Asp Leu Val Lys Phe Arg Arg Ala Leu Arg
145
150
155
160
Ile Tyr Thr Leu Glu Leu Met Glu Ile Arg Val Arg Ile
165
170

<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 11
LENGTH, 666
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... ( 666)

<400> SEQUENCE,

11

atg gtt ttt CCC ata gaa gee att gta gga gca gta ace eta att aca
Met Val Phe Pro Ile Glu Ala Ile Val Gly Ala Val Thr Leu Ile Thr
1
5
10
15

48

ttt etc tta tac ttc eta tgt aca aaa aaa tct caa aaa cat tea aag
Phe Leu Leu Tyr Phe Leu Cys Thr Lys Lys Ser Gln Lys His Ser Lys

96

us
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20

25

30

CCC

tta cca acg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt
Pro Leu Pro Thr Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu
35
40
45

144

ttc cac ttc aat aac gac ggc gac gac cgt cca ttt get cga aaa etc
Phe His Phe Asn Asn Asp Gly Asp Asp Arg Pro Phe Ala Arg Lys Leu
50
55
60

192

gga gac tta get gat aaa tac ggc CCC gtt ttc act ttt egg eta ggt
Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly
65
70
75
80

240

ctt CCC ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc
Leu Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys
85
90
95

288

ttc tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac
Phe Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr
100
105
110

336

ggc gaa tac ctt ggc tac aat aat aca atg ctt ttt eta gca aat tac
Gly Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr
115
120
125

384

gga cct tac tgg cga aaa aat cgt aaa tta gtc att cag gaa gtt etc
Gly Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu
130
135
140

432

tct get agt cgt etc gaa aaa ttc aaa caa gtg aga ttc ace aga att
Ser Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile
145
150
155
160

480

caa acg age att aag aat tta tac act cga att aat gga aat tcg agt
Gln Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser
165
170
175

528

acg ata aat eta agt gat tgg tta gaa gaa ttg aat ttt ggt ctg ate
Thr Ile Asn Leu Ser Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile
180
185
190

576

gtg aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa
Val Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu
195
200
205

624

caa gtg gaa aga ttt aag aat gcg ttt aag gat ttt atg gtt
Gln Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val
210
215
220

666

<210>
<211>
<212>
<213>

SEQ ID NO 12
LENGTH, 222
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE,

12

Met Val Phe Pro Ile Glu Ala Ile Val Gly Ala Val Thr Leu Ile Thr
1
5
10
15
Phe Leu Leu Tyr Phe Leu Cys Thr Lys Lys Ser Gln Lys His Ser Lys
20
25
30
Pro Leu Pro Thr Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu
35
40
45

Phe His Phe Asn Asn Asp Gly Asp Asp Arg Pro Phe Ala Arg Lys Leu
50
55
60
Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly
65
70
75
80
Leu Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys
85
90
95
Phe Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr
100
105
110

US 10,383,299 B2
94

93
-continued
Gly Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr
115
120
125
Gly Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu
130
135
140
Ser Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile
145
150
155
160
Gln Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser
165
170
175
Thr Ile Asn Leu Ser Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile
180
185
190
Val Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu
195
200
205
Gln Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val
210
215
220

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 13
LENGTH, 99
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Partial coding sequence selected from SEQ ID
NO,1

<400> SEQUENCE, 13
gacgaggcct tggatatgaa ggaaggtgca ggcataacca tacgtaaggt aaatccagtg

60

gaattgataa taacgcctcg cttggcacct gagctttac

99

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 14
LENGTH, 99
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Partial coding sequence selected from SEQ ID
NO,3

<400> SEQUENCE, 14
gacgagccct tggatatgaa ggaaggtgca ggcataacta tacgtaaggt aaatcctgtg

60

gaactgataa tagcgcctcg cctggcacct gagctttat

99

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 15
LENGTH, 99
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Partial coding sequence selected from SEQ ID
NO,5

<400> SEQUENCE, 15
gacgagccct tggacatgaa ggaaggtgca ggcataacta tacgtaaggt aaatcctgtg

60

gaactgataa tagcgcctcg cctggcacct gagctttat

99

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 16
LENGTH, 99
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Partial coding sequence selected from SEQ ID
NO,7

<400> SEQUENCE, 16
gatgagccct tggatatgaa agaaggtgca ggcataacta tacgtaaggt aaatcctgtg

60
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aaagtgataa ttacgcctcg cttggcacct gagctttat

<210>
<211>
<212>
<213>
<220>
<223>

99

SEQ ID NO 17
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 17
cgctctagaa ctagtgatc

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 18
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 18
tttttgggac aatcagtcaa

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 19
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 19
gttagattta tcgtactcga att

<210>
<211>
<212>
<213>
<220>
<223>

23

SEQ ID NO 20
LENGTH, 26
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 20
ttcatttcaa attattttat gcacca

<210>
<211>
<212>
<213>
<220>
<223>

26

SEQ ID NO 21
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 21
atggtttttc ccatagaagc c

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 22
LENGTH, 17
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 22
tcgaggtcga cggtatc

<210>
<211>
<212>
<213>

SEQ ID NO 23
LENGTH, 1118
TYPE, DNA
ORGANISM, Nicotiana sp.

17

us
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<400> SEQUENCE,

23

ctgtcattaa agcaacggtg tttgtaagtt catctgtcat ttttcattta ttcactttta

60

ttttgaggag cagacatgtt aataataatt tggagcaact gtaaagttat ctatgtgtac

120

aggttcgagc ctcaggtgca accactaatg cttgtattag attatgttgt ctgcatcata

180

cccctaattg gagtgtggct cttcccgaac cctgcaatgc tggatgctgg atgctttatg

240

tatcagactg acctttttgt taaactatct aaatactaag gatgatttaa taaaaatata

300

gaatggtaaa cagaaaaaga tgagattatt tttggggcta tatggattcg cccgggcttt

360

gggaggtaaa acggtatcta ccagttgaga ctttactcca gaactttatc tcgagagctc

420

tgaataaaaa tgaaatagta tttaccactc caaaatcttt gatggtaaaa agatgagata

480

taacctctta taattgattg aaccacgttg atagaataaa acttctttac tcccattcag

540

cataagaaaa atgaaaccaa acggaattct tctctttttt agggggaaat tccttaattg

600

cttgttgaat atagattcat gtcgttattc tatttttaat aatgatgaaa atcaatatag

660

tcaaagttaa tacttatgtc atttggtttg cggacaagtt atattggaac tatataatac

720

gtctattata gaatagtgat tatttagagg atatacattt tttttggata aatatttgat

780

ttattggatt aaaaatagaa tatacaggta aggtctaaaa cgtgtgtttg cttttacact

840

aaataaactt gacctcgtac aattctaaga aaatatttga aataaatgaa ttattttatt

900

gttaatcaat taaaaaaatc atagtataga tgagatgtgt gcatacttgg caataactat

960

actaactaaa acaaggtatg tgaataattg atattccttt tttaattatt cttttttcca

1020

gagtttggtc ttggatgcag cagacacagt tgctcttcac ataaattggg gaatggcatt

1080

attgataaac aatcaaaagg ccttgacgaa agcacaag

1118

<210> SEQ ID NO 24
<211> LENGTH, 998
<212> TYPE, DNA
<213> ORGANISM, Nicotiana sp.
<400> SEQUENCE,

24

gtaagttcat ctgtcatttt tcatttattc acttttattt tgaggagcag acatgttaat

60

aataatttgg agcaactgta aagttatcta tgtgtacagg ttcgagcctc aggtgcaacc

120

actaatgctt gtattagatt atgttgtctg catcataccc ctaattggag tgtggctctt

180

cccgaaccct gcaatgctgg atgctggatg ctttatgtat cagactgacc tttttgttaa

240

actatctaaa tactaaggat gatttaataa aaatatagaa tggtaaacag aaaaagatga

300

gattattttt ggggctatat ggattcgccc gggctttggg aggtaaaacg gtatctacca

360

gttgagactt tactccagaa ctttatctcg agagctctga ataaaaatga aatagtattt

420

accactccaa aatctttgat ggtaaaaaga tgagatataa cctcttataa ttgattgaac

480

cacgttgata gaataaaact tctttactcc cattcagcat aagaaaaatg aaaccaaacg

540

gaattcttct cttttttagg gggaaattcc ttaattgctt gttgaatata gattcatgtc

600

gttattctat ttttaataat gatgaaaatc aatatagtca aagttaatac ttatgtcatt

660

tggtttgcgg acaagttata ttggaactat ataatacgtc tattatagaa tagtgattat

720

ttagaggata tacatttttt ttggataaat atttgattta ttggattaaa aatagaatat

780

acaggtaagg tctaaaacgt gtgtttgctt ttacactaaa taaacttgac ctcgtacaat

840

tctaagaaaa tatttgaaat aaatgaatta ttttattgtt aatcaattaa aaaaatcata

900
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100
-continued

gtatagatga gatgtgtgca tacttggcaa taactatact aactaaaaca aggtatgtga

960

ataattgata ttcctttttt aattattctt ttttccag

998

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 25
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, PCR Primer

<400> SEQUENCE, 25
ctgtcattaa agcaacggtg

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 26
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, PCR Primer

<400> SEQUENCE, 26
ggccttgacg aaagcacaag

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 27
LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 27
aagctttgac gccatttttt ccaatcg

<210>
<211>
<212>
<213>
<220>
<223>

27

SEQ ID NO 28
LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 28
ctcgagtttt ccagcgatca tcttcac

<210>
<211>
<212>
<213>
<220>
<223>

27

SEQ ID NO 29
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 29
acgtgatcct aaactctggt ctg

<210>
<211>
<212>
<213>
<220>
<223>

23

SEQ ID NO 30
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 30
gcctgcacct tccttcatg

<210> SEQ ID NO 31
<211> LENGTH, 20

19
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<212>
<213>
<220>
<223>

TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 31
cggtaatcgg ccatcttttc

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 32
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 32
ccgagttttc gagctaatgg a

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 33
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 33
caatgacgaa cggcgacag

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 34
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 34
atggtttttc ccatagaagc c

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 35
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 35
tttttgggac aatcagtcaa t

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 36
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 36
tgaatgaact gcaggacgag

<210> SEQ ID NO 37
<211> LENGTH, 20
<212> TYPE, DNA

20
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<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 37
20

aatatcacgg gtagccaacg

10

What is claimed is:
1. A tobacco seed or a tobacco plant grown therefrom,
wherein said tobacco seed or tobacco plant comprises a
stable mutation in a wild type allele of a nicotine demethylase comprising a coding sequence having at least 98%
identity to SEQ ID NO: 3, wherein said mutation reduces or
eliminates the expression or activity of said nicotine demethylase, wherein the amount of nornicotine or N'-nitrosonomicotine in said tobacco plant is reduced by greater than
about 10% compared to a control tobacco plant comprising
said wild type allele, and wherein said tobacco plant is a
Nicotiana tabacum plant.
2. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said tobacco seed or tobacco
plant grown therefrom is homozygous for said mutation.
3. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said tobacco plant has a
non-converter phenotype and reduced nicotine demethylase
activity from said nicotine demethylase.
4. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said tobacco plant has a
non-converter phenotype and comprises less than 5% nicotine demethylation.
5. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said tobacco seed or tobacco
plant grown therefrom is selected from the group consisting
of _a Burley type, a dark type, a flue-cured type, and an
Onental type.
6. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said mutation is selected from
the group consisting of a point mutation, a deletion, and an
insertion.
7. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said wild type allele encodes
SEQ ID NO: 3.
8. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said stable mutation in a wild
type allele is a mutation in any nucleotide corresponding to
nucleotides 265 to 625 of SEQ ID NO: 3.
9. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said stable mutation in a wild
type allele is a mutation in any nucleotide corresponding to
nucleotides 700 to 1250 of SEQ ID NO: 3.
10. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein said stable mutation in a wild
type allele is a mutation in any nucleotide corresponding to
nucleotides 1420 to 1551 of SEQ ID NO: 3.
11. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein the amount of nornicotine or

15

20
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40

45
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N'-nitrosonomicotine in said tobacco plant is reduced by
greater than about 20% compared to a control tobacco plant
comprising said wild type allele.
12. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein the amount of nomicotine or
N'-nitrosonomicotine in said tobacco plant is reduced by
greater than about 60% compared to a control tobacco plant
comprising said wild type allele.
13. The tobacco seed or tobacco plant grown therefrom
according to claim 1, wherein the amount of nomicotine or
N'-nitrosonomicotine in said tobacco plant is reduced by
greater than about 90% compared to a control tobacco plant
comprising said wild type allele.
14. A method comprising preparing a tobacco product
using a cured tobacco leaf from the tobacco plant of claim
1.
15. The method of claim 14, wherein said tobacco product
is selected from the group consisting of a cigarette, a cigar,
pipe tobacco, snuff, chewing tobacco, gum, and a lozenge.
16. A tobacco product comprising cured tobacco from the
tobacco plant of claim 1, wherein said tobacco product is
selected from the group consisting of a cigarette, a cigar,
pipe tobacco, snuff, chewing tobacco, gum, and a lozenge.
17. A method comprising:
a. detecting in a tobacco plant or plant part thereof a
mutation in a polynucleotide having at least 96%
sequence identity to SEQ ID NO: 3, and wherein said
mutation is in a sequence encoding the tryptophan
residue at position 329 of SEQ ID NO: 4; and
b. producing a tobacco product from said tobacco plant or
plant part thereof comprising said mutation detected in
step a.
18. The method of claim 17, wherein said tobacco plant
is a Nicotiana tabacum plant.
. 19. The method of claim 17, wherein said tobacco plant
1s selected from the group consisting of a Burley type, a dark
type, a flue-cured type, and an Oriental type.
20. The method of claim 17, wherein said plant part is
selected from the group consisting of a cell, a protoplast, a
cell tissue culture from which a whole plant can be regenerated, a callus, an embryo, pollen, an anther, an ovule, a
seed, a leaf, a flower, a stem, a branch, a fruit, a root, and a
root tip.
21. The method of claim 17, wherein said tobacco product
is_ selected from the group consisting of a cigarette, a cigar,
pipe tobacco, snuff, chewing tobacco, gum, and a lozenge.
22. The method of claim 17, wherein said mutation
reduces or eliminates the expression of said polynucleotide.
*

*

*

*

*

